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ABSTRACT 
 
An Investigation of Public Injection Drug Use in New York City: A Mixed-Methods Study 
By 
Taeko Frost 
 
Advisor: Nancy Sohler, PhD 
 
Background: Drug use and injection-related harms are on the rise in the United States (US). As a 
result, new outbreaks of HIV and viral hepatitis C (HCV) attributed to injection drug use have 
been identified across the country. In addition to HIV and HCV, skin and soft tissue infection 
(SSTIs) that result from risky injection practices lead to preventable and costly emergency 
department (ED) visits. The concurrent opioid overdose epidemic has prompted a national 
conversation on how to effectively address drug-related harms and associated costs. International 
studies have identified that the place a person injects is related to adverse health outcomes; 
public injection drug use is associated with risky injection practices and other health harms. To 
minimize public injection drug use, eleven countries have implement supervised injection 
facilities (SIFs) to prevent both injection-related infections and opioid overdose. Despite over 30 
years of operation and 100 sites in operation around the world, the US has yet to implement a 
government-sanctioned SIF. No studies in the US have investigated public injection drug use and 
the possible association between public injection drug use and health risks.   
Objectives: To describe the prevalence of public injection drug use and associated risks among 
people who inject drugs (PWID) enrolled in syringe exchange programs (SEPs) in New York 
City (NYC) using a mixed-methods multi-phase study design including cross-sectional survey 
data and qualitative data derived from focus group sessions.   
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Methods: First, I used a grounded theory approach to create a definition of public injection drug 
through focus group sessions. I applied the PWID-informed definition of public injection drug 
use to operationalize and define public injection in the survey data. Then, I described where 
PWID inject drugs in NYC and the prevalence of public injection drug use using survey data 
from the Injection Drug User Health Alliance Citywide Study (IDUCS) from Wave 2 and Wave 
3. Next, I measured the association between public injection drug use and receptive sharing of 
injecting equipment as a proxy for HIV and HCV transmission risk using bivariate and 
multivariate logistic regression analyses. Then, I analyzed data from the focus groups identify 
characteristics of the physical and social environment where PWID inject and how they may be 
related to risk. Based on these findings, I selected variables to include in logistic regression 
models to describe socio-demographic characteristics and risk behavior associated with public 
injection drug use. Lastly, I describe the experience of public injection drug use, the relationship 
of place to risk, management of health and social risks, and initial attitudes towards SIFs.  
Results: A total of 820 participants were included in the quantitative analyses and 33 participants 
included in the focus group sessions. PWID reported that what makes a place public included 
four components: (a) physical features of a space that supported privacy, (b) sense of control 
over the space, (c) trust in the people in the space, and (d) exposure to being seen or arrested. 
Nearly two-thirds (64%) of PWID in the IDUCS study reported public injection drug in the three 
months preceding the IDUCS survey. The most frequently reported sites of injection drug use 
included one’s own home (71%), home of a friend or family member (59%), public bathroom 
(48%), or the street or park (38%). Public injectors are significantly more likely to report 
receptive sharing of injecting equipment (AOR=1.66, CI: 1.04-2.65). Public injection drug use 
was significantly associated with unstable housing (AOR=5.04, CI: 3.46-7.34), under 40 years of 
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age (AOR=2.02, CI:1.40-3.13), past 30-day heroin use (AOR=1.99, CI:1.27-3.13), past 30-day 
cocaine use (AOR=1.52, CI: 1.06-2.12), past year overdose (AOR=1.66, CI: 1.17-2.36), and 
witnessing an overdose (AOR=1.45, CI: 1.03-2.06). In the unadjusted model, public injectors 
were significantly more likely to report past year ED admission (OR=1.50, CI: 1.11-2.02) and 
less likely to have a primary care provider (PCP) (OR=0.37, CI: .23-.59) compared with non-
public injectors. Participants described fear of arrest and accidental overdose as predominant 
factors taken into consideration when identifying a place to inject drugs; other factors included 
level of withdrawal, fear of violence, and being seen by others (friends/family/public). 
Participants described complex strategies to manage risk and the impact of hiding or rushing 
injection on their ability to apply safe injection practices. The place that was perceived as the 
‘safest’ place to inject drug was in the SEP bathrooms; sterile injecting equipment and disposal 
was readily available, it is private enough to take their time and not worry about arrest but public 
enough that a staff member of a SEP could administer naloxone in the event of an overdose. In 
all focus group sessions, the response to SIFs was overwhelmingly positive; PWID believed that 
a SIF would enable them to practice safe injection and that other PWID would use it.   
Conclusions: PWID are injecting in a variety of public places in NYC. Public injection is 
associated with risky injection practices and, in turn, potential transmission of HIV and HCV. 
PWID described that injecting in public increased their risk of being arrested or rushing 
injections, but was a safer option to prevent fatal overdose. The calculated risks and trade offs 
(i.e. risking arrest by injecting in public versus fatal overdose if injecting alone) were believed to 
impede one’s ability to practice safe injection techniques. SEP bathrooms are operating as 
pseudo-SIFs but remain unsanctioned and unsupervised. SIFs are one strategy to minimize 
injection related harm and overdose and this study provide initial insight into their potential 
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acceptability among PWID. However, strategies to address drug-related harm must also 
incorporate housing, healthcare, and drug policy reform.  
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Chapter 1: Introduction 
 
1.1 Illicit drug use in the United States (US) 
One in ten Americans over the age of 12 years-old report using an illicit drug in the past 30 
days.1 Illicit drugs include marijuana, crack/cocaine, heroin, hallucinogens, inhalants, 
methamphetamine, and the non-medical use of prescription opioids, stimulants, and sedatives.  
The United States (US) has seen a steady increase in the reported use of illicit drugs in recent 
years, from 24.6 million in 20142 to 27.1 million individuals in 20151, representing a 10% 
increase. Over 20 million people report they had a substance use disorder (SUD) in the past year, 
including 7.7 million who reported illicit drug use disorder.3 In 2015, 3.8 million people reported 
current misuse of prescription opioids and 329,000 people report the use heroin.3 The number of 
people who report the misuse of prescription opioids or heroin has significantly increased every 
year since  since 2009.1 Addressing the consequences of drug use has developed into a topic of 
national conversation.  
1.1.1 US Drug Use Trends & Impact on the Health Care System 
There are several key demographic and behavioral risk trends related to the misuse of 
prescription opioids (e.g. “pain killers” such as hydrocodone) and heroin. First, prescription 
opioid misuse is highest among young adults (18-25 years of age), with 2.4% of young adults 
reporting misuse in the past 30 days.3 This is twice the rate of any other age group. In 2014, there 
were a record-breaking 28,000 opioid overdose deaths in the US.4 Deaths due to heroin use have 
tripled since 2010.5 Emergency department visits involving the misuse of prescription opioids 
increased by 153% between 2004 and 2010.6 Similarly, the use of substance use treatment 
programs due to prescription opioids misuse has increased four fold since 2002.7 However, there 
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are significant disparities in access and use of drug treatment among young adults for non-
medical use of prescription opioids; Black and Latino people who use drugs , particularly with a 
history of incarceration, were significantly less likely to access substance use treatment services.8 
In addition to the cost of lost lives, the opioid epidemic has serious financial implications. The 
economic burden of the opioid epidemic has grown from $8.1 billion in 20019 to $78.1 billion in 
2015.10 Since the establishment of the Affordable Care Act (ACA), a shift to pay-for-
performance versus fee-for-service holds providers accountable for improving quality and care 
of patients in order to reduce cost.11 In New York and several other Medicaid expansion states, 
initiatives to reduce costs by reducing preventable ED admissions have been prioritized.12 At 
least 2.5 million ED visits involve the use of an illicit drug and admissions due to opioid 
overdose have steadily increased since 2006.6 Furthermore, admissions due to injection-related 
infections result in longer and more costly hospital stays.13,14 It is more critical than ever to 
identify strategies to effectively address the opioid epidemic to save resources and lives. 
1.1.2 Initiation into Injection Drug Use 
Incidentally, efforts to minimize access to prescription opioids to prevent non-medical use may 
have contributed to a new cohort of PWID.15,16 Prescription drug monitoring programs 
(PDMPs)15 have been implemented as a state-level intervention to monitor and prevent the 
misuse of prescription opioids. PDMPs capture dispensing patterns submitted by pharmacists in 
order to provide medical providers with a snapshot of what prescriptions have been filled by 
their patients. The intention of these monitoring tools was to limit overprescribing and, in turn, 
reduce the number of prescription opioids available in the community that contribute to opioid 
overdose. The programs have been successful in minimizing over-prescribing and identifying 
patients with multiple prescriptions, but have not had an effect on preventing overdose events. 
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Studies have shown that the one reason for recent increases in injection drug use has been due to 
the increased use of heroin after prescription opioids were not as readily available.17 The 
incidence of heroin initiation was nine times higher among people who reported non-medical use 
of prescription opioids compared with those who did not report the use of non-medical use of 
prescription opioids.18 Individuals who were addicted to prescription opioids were left with a 
need for opioids; heroin is is cheaper than street-purchased prescription opioids19,20 and access to 
prescription opioids was limited due to drug monitoring programs15,21 In addition to risks 
associated with illicit drug use, the transition to using heroin may increase initiation into 
intravenous (IV) drug use.22,23 Given the steady increases in prescription opioid use and trends in 
transition to IV heroin use, understanding health risks associated with IV drug use is essential 
1.2 Injection Drug Use  
1.2.1 Overview  
In 2014, there are approximately 774,434 people in the US who reported injecting drugs in the 
past year, representing approximately 0.3% of the population.24 According to the National HIV 
Behavioral Surveillance (NHBS)25 study among people who inject drugs (PWID), the majority 
are male (71.5%), over the age of 40 years old (71%), and non-white (68.1%).26 Over half PWID 
report that they have obtained a high school diploma or equivalent (66.5%) and nearly three-
quarters (77.8%) receive an annual income at or below the federal poverty line. Over half have 
some form of health insurance (59.1%). PWID face a disproportionate level of risk compared to 
non-injectors , such as blood-borne infections27–32, overdose33,34, arrest35–37, and homelessness.38–
40 
6	
	
1.2.2 Blood-borne infections 
National increases in drug use correspond with increased viral hepatitis C (HCV) incidence.5 
Data on PWID in research is often in the context of blood-borne infections; primarily HIV and 
HCV. In the US, PWID comprise 22% of people who are living with HIV infection and 48% of 
people who report living with HCV.32,41  The mechanisms of risk for HIV and HCV include 
reusing injecting equipment that a person who is HIV or HCV positive already used, referred to 
as ‘receptive sharing’. Injecting equipment may include a syringe, a receptacle for drugs referred 
to as a “cooker”, water used for drug disintegration, and cotton filters. Sharing any injecting 
equipment with an individual who is infected with HIV or HCV generates risk of transmission42. 
Sharing syringes is the highest and most studied risk for HIV and HCV transmission, followed 
by sharing cookers and cotton filters.43 Individual socio-demographic and health factors 
associated with sharing injecting equipment include female gender44,45, younger age46, 
homelessness47, and a recent positive HCV test48. Drug use characteristics associated with 
sharing injecting equipment include the number of injection episodes per day49, any 
methamphetamine use50, and cocaine as the primary drug of choice for injection51. Social factors 
associated with sharing injecting equipment include having a concordant HCV status with an 
injecting partner52, and a close relationship53 and trust54 in the individual with whom they are 
injecting. Individuals in romantic relationships are also more likely to report sharing injecting 
equipment.55 Next, I describe the three common injection-related infections and the cost of 
treatment. 
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1.2.2.1 HIV/AIDS 
There are approximately 1.2 million people living with HIV in the US; approximately 13% are 
unaware of their status56. In 2014, there were 44,073 people diagnosed with HIV in the US.57  
HIV disproportionately affects young people ages 13 to 24, representing 16% of the population 
but accounting for 22% of all new HIV diagnoses.57 There is no vaccine for HIV but there are 
effective treatment options, including anti-retroviral therapy (ARV). The Ryan White HIV/AIDS 
Drug Assistance Program (ADAP) and the extension in 2009 (Public Law 111-87) has supported 
low-income individuals with HIV to receive treatment and other supportive services, including 
supportive housing and wrap-around services (i.e. nutritional workshops, support groups, mental 
health, dental) to engage and retain individuals in care. In 2016, the governor of New York 
committed to a vision to end the AIDS epidemic by the year 2020.58 The plan focuses on (a) 
early detection by identifying new cases of HIV, (b) connect newly infected individuals to care 
and treatment, and (c) promote pre-exposure prophylaxis (PrEP) for high-risk individuals (e.g. 
PWID) in order to keep them from contracting HIV. The latter is an up front investment to 
prevent long-term costs associated with HIV (lifetime cost approximately $379,00059). In 2014, 
PrEP initiatives and funding were integrated into syringe exchange program (SEPs) for PWID. In 
the subsequent sections of this chapter, I describe initiatives and health policies that have 
promoted HIV prevention among PWID.  
 
1.2.2.2 Viral Hepatitis C 
The burden of HCV is even larger compared to HIV. HCV causes liver disease and is transmitted 
through blood only. Injection drug use is the most common pathway for infection41. There are an 
estimated 3.2 million people living with HCV in the US.60 Of those people, 2.7 million have 
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chronic infection. In 2014, there were an estimate 30,500 new infections in the US.60  The 
incidence rate of HCV has more than doubled nationwide since 201041 and deaths associated 
with HCV have outnumbered deaths from HIV since 2007. In recent years, state-level 
surveillance reports indicate increases in HCV infection attributed to injection drug use.61,62 In 
four states in Appalachia, the number of cases of acute HCV infection among persons under 30 
years of aged increased by 364% between 2006 and 2012.2,63 Similar patterns have been 
identified in other states64,65, including New York66,67. Similar to the national sample, rates of 
HIV attributed to injection drug use have decreased over the years while HCV has increased, 
particularly in suburban and rural areas.68 Considering that more people die from hepatitis than 
all other infectious diseases combined, prevention and treatment initiatives have not been met 
with the same success as those for HIV/AIDS.69 While the lifetime cost of treating HCV is lower 
compared with HIV (~$64,490, depending on genotype70) and new non-interferon based 
treatments have been developed71, barriers to treatment still exist. Early HCV interferon-based 
treatments were painful and met with adverse side effects; PWID who were treated or knew 
friends who were treated with interferon are hesitant to initiate new treatments.72,73 Furthermore, 
HCV rapid testing and antibody tests were only recently accessible in community-based settings, 
and still required a full-blood draw for confirmatory testing. A recent study found that nearly 
three-quarters (72%) of individuals who tested positive for a confirmatory test said they were 
unsure of treatment options.74 In 2016, the National Academies of Sciences, Engineering, and 
Medicine announced a vision for eliminating hepatitis B and C by 2030, which include similar 
strategies to the End AIDS by 2020 blueprint. However, in order to implement testing and 
treatment recommendations, state-level legislation and advocacy will be required. Age 
restrictions on testing and parental consent for treatment, authorization of prevention efforts 
9	
	
including syringe exchange programs (SEPs), and coverage of treatment vary significantly by 
state. A national vision to end the epidemic will require a combination of federal mandates, 
federal funding, and community education to garner support for the implementation of 
prevention and treatment initiatives.  
 
1.2.2.3 Skin and Soft Tissue Infections (SSTIs) 
PWID are at increased risk of skin and soft-tissue infections (SSTIs). There is a wide variation in 
the number of PWID who will experience SSTI in their lifetime (6%-69%)75 but the results can 
be costly and fatal. SSTI can be caused by inadequate cleaning and care of the injection site prior 
to or after injection,76,77 repeated injection or missing veins,78 habitual practices such as licking a 
needle prior to injection,77 frequent daily injections and injection of non-powder drugs,77 and the 
sharing of injecting equipment.55 SSTI may develop into infective endocarditis, sepsis, 
thrombosis, embolism, or bone and joint infections.28,75 PWID may avoid the ED attempt to 
manage to self-manage SSTI and associated wounds, including some behaviors that were 
determined to be potentially more harmful.79 One study found that abscesses, cellulitis, and other 
SSTI accounted for the largest proportion of reasons that PWID accessed the emergency 
department (ED).80 Injection-related infections are costly to the PWID and to society. A recent 
study of just one public hospital found that the cost of treatment due to injection-related infection 
(i.e. endocarditis, bacteremia, sepsis, osteomyelitis, and other SSTIs) was $11.4 million in one 
year.13 Another study found that SSTIs tended to result in longer and more costly hospital stays, 
with an average overall cost of $4,449 per admission.14 Prioritizing the prevention of SSTIs can 
save healthcare spending and lives.   
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1.2.3 Opioid Overdose 
PWID who inject or ingest opioids are at risk of opioid overdose. Studies of PWID have found 
that factors associated with non-fatal overdose include the use of a stimulant in addition to 
opioids,81 poly-substance use,82 requiring assistance with injection,81 depression,83 and low 
tolerance due to recent incarceration84 or enrollment in drug treatment.85 Factors that are 
protective against non-fatal overdose include receiving methadone maintenance treatment 
(MMT).86 Non-fatal overdose may have other consequences for PWID, including potential 
seizures, physical injuries sustained when falling during the overdose, burns, assault while 
unconscious, and temporary paralysis.87 Further, non-fatal overdose is a risk factor for a 
subsequent fatal overdose.88 In 2011, accidental opioid overdose was the leading cause of 
accidental death among adults. Since that time, a series of health policies have been introduced 
to prevent overdose. As mentioned earlier in this chapter, prescription drug monitoring programs 
(PDMPs) were introduced to prevent over-prescribing. Several states have adopted 911 Good 
Samaritan Laws89,90 which encourage any bystander to call 911 to respond in the event of an 
overdose without fear of being arrested for possession. Overdose prevention training and 
naloxone distribution have been implemented in a variety of community settings, including with 
law enforcement. State and city-funded naloxone initiatives expanded community-based 
organization capacity to dispense naloxone. In 2015, a standing order was approved by New 
York State (NYS Public Health Law 3302 Section 80.138) to permit lay healthcare workers to 
distribute naloxone without a written prescription. Emergency departments are piloting co-
prescribing of naloxone for individuals who have been admitted for overdose, including 
prescriptions for family members and friends.91 The expansion of overdose prevention initiatives 
to prevent fatal overdose from occurring have been widespread, but they are limited to 
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preventing fatal overdose and not necessarily the practices or situation that may lead to overdose 
to begin with.   
 
Injection-related infections and overdose cost lives. In addition to these risks, PWID also 
experience risks that aren’t directly related to health but may impact their wellness. 
 
1.2.4 Social Risks 
In addition to blood-borne infections, SSTIs, and overdose, PWID are also more likely to 
experience adverse social outcomes. PWID experience high rates of arrest and incarceration,92–94 
homelessness74, and experiences of stigma.95,96 PWID may be arrested due to public drug use97 
or possession of injecting equipment, which is directly associated with receptive sharing of 
injecting equipment.98 If a PWID is in the process of obtaining housing or in a transitional 
housing unit, incarceration may repeatedly impact their ability to maintain stable housing and 
result in recurrent homelessness.99,100 Experiences of stigma from community members, family, 
and social services providers are common and contribute to PWID exclusion and, in turn, self-
destructive health behaviors95,101–103 The role of social consequences of injection drug use impact 
risk behavior and wellness.  
1.2.5 Community Risks 
Aside from the costs due to injection-related infections and lives lost to overdose, there are 
several ways in which injection drug use impacts communities. First, PWID who fear arrest of 
syringe possession may improperly discard syringes in the community, including in parks or 
garbage cans. The impact may be accidental needle stick and subsequent infection of anyone 
who comes into contact with an improperly discarded syringe.104,105 Second, PWID may inject in 
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public restrooms and leave behind injection-related paraphernalia.106 Third, the purchasing and 
selling of drugs near an area where PWID use drugs may result in drug use in public view.107  
Injection drug use poses considerable health and social risks to PWID and the communities in 
which they live. In the next section, I will describe strategies that have been implemented to 
reduce harm associated with injection drug use among PWID.  
 
1.3 Approaches to minimizing risk for PWID  
1.3.1 US Approach to Drug Use  
The US spends over $51 billion per year on what is known as the war on drugs.108,109 In 1971, 
President Nixon declared a War on Drugs which aimed to fund drug control agencies and law 
enforcement to arrest and imprison anyone involved in the procurement, distribution, and use of 
illicit drugs.108,110 In the late 1970s, there were several attempts to decriminalize marijuana 
possession in at least eleven states but were later abandoned. By the 1980s, President Ronald 
Reagan continued the zero-tolerance approach to drugs and funded anti-drug education 
programs, including the DARE education program and ‘Just Say No’ campaign. By the end of 
the decade, 64% of US citizens reported that drug use was the country’s top concern compared to 
2% to 6% in the beginning of the decade.111 This shift to the criminalization and abstinence-only 
approaches to drug use resulted in an 800% increase in rates of incarceration and further 
establishment of abstinence-based approaches to drug use.109,112  
 
Over forty years later, the US is facing record-breaking numbers of overdose deaths and new 
outbreaks of HIV and HCV. The US represents 5% of the world population but accounts for 25% 
of people in prison.113 Healthcare spending on substance use exceeds $78 billion per year.10 The 
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war on drugs has not resulted in decreased drug use.114 Over the past fifteen years, the tide has 
shifted to reconsider approaches to drug use. In 2011, the Office of National Drug Control Policy 
(ONDCP) recommended wide distribution of naloxone after it was reported as the leading cause 
of accidental death in the US among young adults.115 Syringe exchange programs (SEPs) have 
demonstrated efficacy in drastically reducing the number of new HIV cases attributed to 
injection drug use and have been established in 42 states since 1990.116 In 2016, the federal ban 
on syringe exchange funding was lifted, providing additional financial support to syringe 
exchange programs. Developments in medication assisted treatment (MAT) including 
buprenorphine has been expanded, reducing case load restrictions and expanding provider 
prescribing to nurse practitioners and physician assistants.117 Several cities around the country 
are piloting Law Enforcement Assisted Diversion (LEAD)118 programs, referring people who use 
drugs to support services instead of jail. The ACA expanded Medicaid services in select states 
and moved from a fee-for-service environment to a pay-for-performance model, increasing 
accountability for health care providers to provide high quality care.11 In 2016, the Obama 
administration signed the Comprehensive Addiction and Recovery Act (CARA)117, which 
authorized $181 million per year to develop a comprehensive effort to address the opioid 
epidemic. The approach includes six pillars for coordinated response; prevention, treatment, 
recovery, law enforcement, criminal justice reform, and overdose reversal. The tide has been 
slowly shifting to incorporate evidence-based interventions that offer options for people who use 
drugs, including options for people who are not readily or willing to enter treatment.  
 
However, the future of many of the programs that cover services for people who use drugs is 
uncertain. The Trump administration ran a campaign on the premise that it would repeal and 
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replace the ACA. This was attempted and failed in March 2017, but may be reintroduced. The 
repeal of the ACA and replacement with the American Health Care Act (ACHA) and proposed 
block grants would restrict access to Medicaid and Medicare; public insurance covers or 
subsidizes services for people who use drugs including, but not limited to, HCV testing and 
treatment, HIV testing and treatment, MMT, MAT, and routine primary care, outpatient mental 
health services. In addition to potential health service cuts, the public health research that 
evaluates and guides public health interventions are under threat. The Trump administration 
proposed a 20% cut ($5.8 billion) to the National Institute of Health (NIH) and has alluded to 
reforms in the Centers for Disease Control (CDC) budget. In short, services for people who use 
drugs may again be limited or unavailable. However, one positive proposal by the administration 
is an additional $500 million designated to the Department of Health and Human Services 
(DHHS) to expand services to prevent overdose and increase access to drug treatment. However, 
the specifics on how those funds are designated is unclear.    
 
Many strategies to address the risks associated with illicit drug use may focus on reducing risk 
by eliminating drug use entirely. Based on recent increases in illicit drug use and costs described 
earlier in this chapter, I believe that strategies must acknowledge and accept that drug use is part 
of our society and requires an approach that offers options to people in various stages of drug 
use. Therefore, in this dissertation research I focus on interventions that address risk by 
providing resources and education to make drug use safer. 
1.3.2 Harm Reduction Approach 
Harm reduction is an approach to addressing health and social consequences of drug use. The 
approach is centered around the respect for autonomy of PWID and with the primary goal of 
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reducing immediate health and social risk behaviors to promote wellness.119 Harm reduction 
acknowledges that drug use exists in our society and applies interventions that reduce the most 
immediate risk at that time for the person.120 The belief that any positive change, from reducing 
risky injection practices that may result in the transmission of a blood-borne infection to 
behavior change that reduces the likelihood of being arrested, is in unto itself a success. Many 
harm reduction strategies integrate the trans-theoretical model of behavior change, also known as 
the Stages of Change121 model; this model suggests that individuals move through a series of 
stages in order to adopt health behaviors or minimize unhealthy onces.121 Techniques such as 
motivational interviewing122,123 are applied to facilitated movement between the stages of change 
to address self-identified risk behaviors that have negative health, social, or emotional impacts. 
Harm reduction is not in opposition to abstinence-based programs; it fits on a spectrum of 
addressing drug use for people who are currently using while maintaining that if a persons goal is 
abstinence that they are provided support to achieve abstinence. In addition to promoting 
individual behavior change, harm reduction is also a social movement to address practices and 
policy that are potentially harmful or hinder health and social wellness of PWID. Some examples 
of harm reduction driven practices and policies include Housing First models, community 
distribution of naloxone, and Law Enforcement Assisted Diversion (LEAD)118. Housing First 
models prioritize housing for individuals with serious mental health and/or substance use 
disorders as a pathway to addressing other risk behaviors; it has been demonstrated to be cost-
effective at improving access to medical and mental health services .124–126   Community 
distribution of naloxone, an opioid overdose antidote that can be administered by injection or 
nasal spray, reduces overdose by educating community members on signs of overdose and 
making naloxone widely available. Naloxone distribution has been promoted among PWID, 
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family and friends of PWID, social service providers, and law enforcement as a cost-effective 
method of reducing mortality.127–129  LEAD programs address low-level drug and sex work 
crimes by redirecting potential offenders to community-based services instead of jail. These 
programs are currently in a pilot phased in select cities in the US but early evaluation indicates 
improvement in housing and employment stability for participants and potential cost-savings as 
an alternative to incarceration.118 Harm reduction is a valuable and effective framework for 
addressing high risk behavior of PWID and social policies that may impact their health and 
wellbeing.  
1.3.3 Harm Reduction Interventions 
Next, I describe three interventions that are specific to addressing injection-related harms. I 
discuss the approach, strengths, and limitations as it relates to the US. These three interventions 
include medication assisted treatment (MAT), syringe exchange programs (SEPs), and 
supervised injection facilities (SIFs). While these interventions may also address non-injection 
drug use risks, I will be focusing on the elements that address the issues specific to injection drug 
use outlined in the previous section of this chapter.  
1.3.3.1 Medication Assisted Treatment (MAT) 
MAT is an intervention designed to replace illicit opioids with legal, medically-administered 
opioids including methadone and buprenorphine. Methadone maintenance therapy (MMT) is 
designed to be provided in daily, monitored doses in conjunction with care coordination and 
medical treatment.130 Studies have shown that MMT reduces crime, injection-related risk 
behaviors, heroin use, and premature mortality.131 However, access and coverage of MMT may 
be limited in some states. While the number of MMT programs has remained consistent (~1,200 
programs) in the US, the number of individuals accessing MMT has increased from 227,000 to 
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306,000.132 Fortunately, access to buprenorphine has increased in recent years. Buprenorphine is 
an opioid agonist that reduces symptoms of withdrawal among opioid users. Patients are 
provided a sub-lingual tablet that blocks both symptoms of withdrawal and any effects that 
would normally be experienced if using concurrent opioids. Unlike MMT, buprenorphine can be 
offered at either a MMT program or a primary care clinic setting and are provided in take-home 
doses. One preference for buprenorphine over methadone is the flexibility being able to self-
administer similar to any other medication.133 While effective, similar to MMT, access to 
buprenorphine due to provider availability, provider willingness, stigma, or logistical barriers 
often remains a barrier to treatment.134–136 One way to address some of these barriers may be to 
integrate buprenorphine at SEPs, an environment where there are active PWID who may or may 
not have access to buprenorphine.137 Recent changes in the Comprehensive Addiction Recovery 
Act (CARA 2016) expanded existing prescribing limitations to increase patient case loads and 
permit non-MD providers to prescribe buprenorphine.117 These changes may result in a scale up 
of access to buprenorphine and, in turn, reduce injection drug use.  
1.3.3.2 Syringe Exchange Programs (SEPs) 
Syringe exchange is a public health intervention designed to provide sterile injecting equipment 
for PWID to reduce the transmission of disease.116 While the concept started with exchanging 
syringes (i.e. provide one used syringe, receive one sterile syringe), most syringe exchange 
programs provide syringe distribution (i.e. receive as many syringes as requested) to minimize 
sharing of injecting equipment.138 The establishment of harm reduction as a public health 
approach in the United States was primarily conceived in response to the HIV/AIDS 
epidemic.139,140 In 1984, the first government sponsored syringe exchange program opened in 
Tacoma, WA, in response to the growing HIV incidence among injection drug users.141 In New 
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York, the first syringe exchange was established in May 1992. Since then, SEPs have been 
credited with substantially reducing HIV incidence among PWIDs6,4–67 as well as improving 
linkage to health care, drug treatment and other support for individuals who are poorly served by 
the health care system in NYC.145,146 Despite the research on the efficacy of these programs to 
prevent infections, syringe exchange programs do not exist in every state and access to syringes 
is limited. Federal funds for syringe exchange were banned until 2016147, which exception of a 
brief overturn in 2010. In light of recent increases overdose rates, new cases of hepatitis C, and 
HIV outbreaks, several traditionally conservative states have declared public health emergencies 
and moved to implemented syringe exchange programs.63 Expanding syringe exchange is one 
pragmatic approach to reduce new infections and injection-related risk. However, participants of 
SEPs continue to report that they are fearful of carrying or returning syringes to the SEP due to 
potential arrest. In New York, the public health law and penal code permit participants of SEPs 
to carry hypodermic syringes if they are also in possession of a SEP enrollment card. However, 
carrying injecting equipment with residue may be a potential charge. Research has shown that 
the presence of police affect the ability of PWID to access sterile injecting equipment. As a 
result, SEPs are somewhat limited without further modification of the penal code and 
cooperation with law enforcement. SEPs are also limited to providing sterile injecting equipment 
before an injection and do not address social and environmental factors where risk behavior is 
likely to occur.148 We know that social and environmental factors are an important piece of 
minimizing risk behavior. Next, I will discuss an intervention designed to provide both sterile 
injecting equipment and a safer environment for injection drug use to minimize risk.  
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1.3.3.3 Supervised Injection Facilities (SIFs) 
Supervised injection facilities (SIFs) expand harm reduction tactics to consider the social 
environment. SIFs may also be referred to as Drug Consumption Rooms (DCRs) or Medically 
Supervised Injection Sites (MSIS). SIFs are facilities where PWID can self-inject using pre-
obtained drugs in a hygienic environment under the supervision of trained medical staff. SIFs 
provide a space for individual to self-inject and are commonly integrated among other social 
services, including but not limited to access to healthcare, housing, entitlement, and drug 
treatment services.149 While there are varied models of SIFs, the common features include 
medical oversight and well-lit, hygienic spaces for individual to inject drugs. There are various 
eligibility requirements, ranging from a minimum time of participation in the program to level of 
drug consumption. The primary objective of this intervention is to reduce drug overdose deaths, 
soft-tissue infections, transmission of blood-borne pathogens, and community issues related 
public injection150.  Public injection drug use, or injecting in a non-residential place, is associated 
with exacerbated injection-related health risks described earlier in this chapter. SIFs have been in 
operation for over 30 years, with the first site opening in Switzerland. Currently, there are over 
100 SIFs operating in 66 cities in eleven countries around the world.151 There is only one SIF in 
North America; Insite, located in Vancouver, Canada.152 The research on SIFs is extensive. SIFs 
have been found to significantly reduce overdose mortality152–154, HIV infections155, hepatitis C 
infections156, public drug use157, and improperly discarded syringes in communities.158,159 They 
have accomplished this by reducing syringe and injecting equipment sharing160,161 and offering a 
supervised, hygienic environment to consume drugs safely. SIFs also increase access to other life 
saving services, such as drug treatment162 and housing placement.163 Contrary to popular belief, 
the presence of a SIF does not increase crime or public nuisance.164,165 PWIDs who access SIFs 
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report that injecting in a supervised setting reduces unsafe injection practices, including reusing 
equipment, and also protects against other concerns such as fear or arrest and overdose.166,167 
PWID also report feeling less shame and stigma compared to injecting in a public setting.168,169 
Aside from protection from health and social risks, SIFs are a cost-effective intervention. 
Multiple studies have indicated cost savings by averting new HIV infections alone, with 
Vancouver estimating a cost-savings of at least $6 million per year.170,171 Despite the 
overwhelming evidence that SIFs are a cost-effective, evidence-based approach to minimize 
injection-related risk among PWIDs and the communities they live in, the US has not adopted 
this intervention. In the next section of this chapter, I will discuss the importance of 
understanding place of injection drug use and how it is related to risk in the US. 
1.4 Current Literature & Gaps 
Research on public injection drug use or the potential cost-savings of SIFs in the US is limited. 
The first study on the relationship between place and injection-related risk behavior was 
conducted in a cohort of PWIDs in Baltimore in 1994; the main findings were that injecting at a 
friend’s residence or in a semi-public area was associated with sharing syringes and failure to 
disinfect syringes.172 The study does not include receptive sharing of injecting equipment beyond 
syringes and place are limited to four categories; own residence, friend’s residence, shooting 
gallery, and a “semipublic area”. Others articles have discussed the importance of place related 
to HIV risk or geo-spatial techniques for measuring where risk behavior occurs, but do not 
measure the association between place of use and sharing of injecting equipment.173–175 In 2009, 
the National HIV Behavioral Surveillance (NHBS) study of 514 PWID reported that 
approximately 30% injected drugs in a public place.176 While the NHBS collected data on place 
of drug use and sharing of injecting equipment, the types of locations are similarly limited and 
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no publications have been produced to date on this topic.25 Since that time, there have been 
several studies related to public injection drug use and SIFs in the US. One recent study found 
that 56% of business owners surveyed in New York City (NYC) reported finding injection-
related paraphernalia in their bathroom.106 Another recent study estimated that a single 13-booth 
SIF would save San Francisco $3.5 million per year in averted HIV cases alone.177 In a different 
survey of PWID at a SEP, 85% indicated they would use a SIF if it were available in San 
Francisco.178 However, none of the studies report more specific details on prevalence or risks 
associated with public injection drug use. As mentioned earlier in this section, an important 
component in making the connection from SEPs to SIFs was the framing of public injection drug 
use as a public health issue. The purpose of this dissertation is to define and describe public 
injection drug use in NYC from the perspective of PWID, the association between public 
injection drug use and health risks, and the experience of PWID injecting in public places to 
contextualize both health and social risks.  
1.5 Contribution to the literature 
There is a new and developing national conversation about how to address the HCV and 
overdose epidemics that includes implementing SIFs. Some states, including New York, 
California, Massachusetts, Vermont, and Maryland have introduced legislation to support SIFs. 
In 2014, a coalition of social service providers to begin to discuss alternatives to public injection 
drug use was established. In 2015, the coalition launched a campaign for SIFs and advocated 
with NYC city council and the NYC Department of Health and Mental Hygiene (NYCDOHMH) 
for a feasibility study. In 2016, NYC city council allocated $100,000 to NYCDOHMH to 
conduct a feasibility study. In partnership with the New York Academy of Medicine (NYAM), 
the coalition secured an additional $100,000 for implementation following the feasibility study. 
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Meanwhile, the mayor of Seattle approved two SIFs to open by the end of 2017. In April 2017, 
San Francisco assembled a task force and introduced state legislation (CS AB 186) to permit 
counties to approve SIFs. Other local municipalities, including Baltimore MD, Ithaca NY, 
Portland OR, and Boston MA have discussed similar activities to implement SIFs. In Vancouver, 
one of the key elements of developing support for SIFs was a robust research initiative to 
identify prevalence of public injection drug use and associated adverse health and social 
consequences for the individual and the community of the Downtown East Side. While there was 
over 20 years of research in other countries that demonstrated the efficacy of SIFs, officials and 
community members request local statistics to justify both political and financial capital to 
implement these controversial programs. This dissertation is the first research to investigate 
public injection drug use and associated risks in NYC.  
 
1.6 Purpose of the dissertation  
This dissertation research will provide the rationale for moving beyond the provision of sterile 
injection equipment to SIFs by (a) describing patterns of where PWIDs are currently injecting 
drugs, (b) measuring the association between place and risk of HIV and HCV transmission 
(receptive sharing of injecting equipment), (c) describing factors associated with public injection 
drug use versus non-public injection drug use, (d) exploring experiences of injecting in 
difference places among PWIDs, and (e) describing initial attitudes towards SIFs among PWIDs.  
 
The collection of research is both novel in topic and approach, since literature related to 
injection-risk and supervised injection facilities are primarily quantitative or qualitative. The 
findings are also timely and relevant to current discussion on drug use in the US. The cumulative 
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results from the subsequent research articles will serve as a foundation for research and policy 
related to the implementation of SIFs in the US. 
1.7 Study Design & Sources of Data 
1.7.1 Overview  
I selected a mixed-methods approach to investigate public injection drug use in NYC to achieve 
the most comprehensive and participant-driven approach to understanding the context and risks 
of where PWID inject drugs. I used two sources of data: (1) quantitative data from the Injection 
Drug User Health Alliance Citywide Study (IDUCS) multi-wave cross-sectional survey of PWID 
in NYC, and (b) focus group sessions at two SEPs in NYC. 
1.7.2 Overview of IDUCS Parent Study 
The Injection Drug Users Health Alliance (IDUHA) is a coalition of 14 SEPs in NYC. 
Established in 2002, IDUHA aims to improve the health and quality of life of PWID through 
advocacy and direct service provision. In 2014, IDUHA implemented the IDUCS across all 14 
SEPs in NYC. The primary goals of the IDUCS were to (a) describe service utilization across 
SEPS sites, (b) identify patterns in health, substance use, perceptions of life change and risk 
behavior, and (c) measure changes in risk behavior, health, and access to services over time. A 
full description of the development and execution of the IDUCS is described in an article under 
review. Findings from the most recent study wave are described in a separate article that has 
been accepted for publication as of March 2017.  
Study	Development	
IDUHA formed a monitoring and evaluation committee comprised of staff with expertise in 
research and program evaluation in order to design the IDUCS study. The study was a 
collaboration between all NYC SEPs, and included involvement of participants and peer 
educator SEPs staff. All levels of staff were engaged in the development and implementation of 
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the study. Harm reduction program staff provided onsite supervision of field interviewers at all 
locations where data was collected.  
Programs	and	Sites	
Harm reduction programs were defined as any organization possessing a waiver for syringe 
exchange services issued by the New York State Department of Health (NYSDOH) in the five 
boroughs of NYC. The study took place at any site where harm reduction services were 
provided, including drop-in centers, storefront services, mobile units, single resident occupancy 
(SRO) hotels, and street-based outreach locations. See Appendix A for a map of the IDUHA  
program sites.  
Peer	Educators	
Peer educators are individuals who have experience with drug use and provide syringe exchange 
services and education to PWID in their social networks. Peer educators connect with PWID 
who may not otherwise go to a program site, expanding access to syringe exchange and health 
education. Peer educators have contributed to successful community-based distribution of 
overdose prevention education and training, including naloxone distribution.179 The input of peer 
educators is included in SEP program design, educational materials, outreach strategies, and 
other aspects of engagement. Peer educators provided input on the survey instrument, including 
suggestions for phrasing of questions for clarity and cultural competence. Peer educators also co-
facilitated several topics for field interviewer training sessions.  
Study	Population	
The participants in the study were a point-in-time cross-section of people receiving services from 
any of the NYC SEPs. Eligibility criteria for the study included: (a) enrollment in at least one of 
the 14 programs; (b) ability to complete a face-to-face interview in English or Spanish; and (c) 
self-reported age of at least 18 years.  
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Study	Design	
The IDUCS used convenience sampling in order to yield the largest and most representative 
sample across all programs among participants accessing SEP services. The study also utilized 
field interviewers with paper-based surveys due to the fact that some participants only access 
services at mobile or street-based sites. Face-to-face interviews were used to ensure the surveys 
were completed fully and correctly. Field interviewers read all questions and answer choices 
aloud. The IDUCS used a repeated cross-sectional design to (a) conduct a pilot phase to ensure 
feasibility of the approach and to gather feedback on the survey instrument; (b) yield large 
sample sizes across all harm reduction sites; and (c) add a longitudinal component with matched 
cases to measure health and behavior change over time. The IDUCS survey was approved by the 
New York City Department of Health and Mental Hygiene (NYCDOHMH) Institutional Review 
Board (IRB).     
Survey	Instrument	
The main survey topics were determined through a combination of identifying gaps in existing 
data, specific requests from government and private funders, and areas of focus related to health 
care reform and Medicaid expansion. The survey included 10 domains (see Appendix B): socio-
demographic characteristics, utilization of SEPs services, housing, legal status, general drug use, 
injection drug use, overdose, health care utilization, mental health, and satisfaction with services. 
Measures were adapted from the CHAIN180 study on HIV and housing, NYCDOHMH Overdose 
Prevention survey181, the National Survey of Drug User Health (NSDUH) (SAHMSA), and the 
National HIV Behavior Surveillance (NHBS)176,182,183 study. The survey was pilot tested with 12 
participants before Wave 1 of the study. To minimize social desirability bias, they survey 
included scripted prompts and feedback from peer educators to ensure the language, order, and 
delivery of questions were sensitive and respectful. An external PhD-level researcher in the field 
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provided feedback and guidance on the survey development. The survey was conducted via face-
to-face interview and took approximately 15 minutes to complete. See Appendix C for the Phase 
3 Survey Instrument.  
Unique	Code	
A unique code was utilized in the last two survey waves as a way to match cases in order to 
measure changes over time. Field interviewers created the code at the beginning of each 
interview. The 7-digit code consisted of a combination of the following: first initial of last name, 
first initial of first name, two-digit day of birth, two-digit year of birth, and first initial of gender 
identification. These items were chosen since they were unlikely to change over time and would 
be easy for participants to recall.   
Field	Interviewers	
The survey was administered by 68 trained field interviewers. Field interviewers were recruited 
from SEP volunteer programs, academic institutions, e-mail lists, and online job postings. The 
majority of field interviewers were undergraduate-level students with an expressed interest in 
harm reduction. All field interviewers completed human subjects and ethics in research training. 
Field interviewers received a minimum of 16 hours of classroom-based training provided by the 
monitoring and evaluation committee and peer educators. Topics included an overview of harm 
reduction history, programs and services, outreach and engagement, drug use, safer sex and sex 
work, interviewing techniques, and trainings specific to the survey instrument (see Appendix D). 
In the latter two waves of the study, two training topics were added including cultural 
competency and when to refer participants to a program staff member. Peer educators facilitated 
the cultural competency sessions. Interviewers engaged in role-play and practice interview 
sessions.  
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Recruitment	&	Survey	Procedures	
Recruitment took place at 57 sites, including 18 offices and 6 mobile units. Participants were 
recruited upon arrival at a site where syringe exchange services were being offered. Interested 
participants were referred directly to a field interviewer to determine eligibility. If eligible, 
participants provided written consent. Participants were given a round-trip MTA Metro Card as 
incentive for their participation.  
 
Figure 1A. IDUCS - Participant recruitment by survey wave 
  IDUCS-P1 
January 2014 
(N=1,042) 
 IDUCS-P2 
June 2014 
(N=1,303) 
 IDUCS-P3 
June 2015 
(N=1,235) 
  n %  n %  n % 
Field Interviewers  45   17   15  
 
Site Borough 
         
Manhattan  372 35.6  516 39.6  481 38.9 
Bronx  402 38.6  515 39.5  404 32.7 
Brooklyn  189 18.1  185 14.2  211 17.1 
Queens  70 6.7  48 3.7  84 6.8 
Staten Island  9 1.0  39 3.0  55 4.5 
          
Site Type          
Office-based  744 71.4  908 69.7  825 66.8 
Street-based outreach  20 1.9  20 1.5  48 3.9 
Mobile van or fixed unit  275 26.4  251 26.9  332 26.9 
SRO or apartment  3 0.3  24 1.8  5 0.4 
Other  0 0  0 0  25 2.0 
Other included: food pantry, church, bus stop, subway entrance, park facility, deli, fast food 
restaurant  
 
 
Data	Compilation	
Field interviewers conducted electronic data entry, with oversight by the IDUCS Project 
Coordinator. In Wave 1, quality assurance was conducted on 10% of the surveys: any 
inconsistencies between the paper-based survey and the electronic database were logged. 
Minimal errors were identified and were corrected and reviewed by the committee for 
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agreement. In Wave 2 and Wave 3, the Project Coordinator and committee members conducted 
the quality assurance activities.  
1.7.3 Current Study  
For this research, I included unduplicated data from Wave 2 and Wave 3. I added an additional 
selection criteria of self-reported injection drug use in the past three months to include only 
individuals who would report on places of injection drug use. I selected variables based on 
previous literature on public injection drug use, current and related health policies, and themes 
from focus group sessions. The final list of variables included in this research is in Appendix E. I 
reviewed missing data by variable by wave and mapped out original IDUCS variables and 
coding (see Appendix F), new variables and coding (see Appendix G), and group comparisons by 
wave (see Appendix H). The procedures for handling missing data are included in methods 
sections of the subsequent chapters.  
1.7.4 Qualitative sub-study – focus group sessions 
The purpose of the focus groups sessions was to (a) understand how PWID define what makes a 
place ‘public’ for injection drug use, (b) identify and discuss risk by place of injection drug use 
using photos of local places known to have injection drug use, (c) explore factors that 
contributed to deciding where to inject drugs, (d) discuss socio-demographic considerations 
related to risk, and (e) initial attitudes towards the concept of a SIF. The facilitator guide was 
developed with a research assistant and reviewed and modified several times in coordination 
with committee member Dr. Zarcadoolas (see Appendix I). The sub-study incentives were funded 
by the Doctoral Student Research Grant of the CUNY Graduate Center School of Public Health. 
The sites were selected based on access to participants and difference in organizational structure. 
I was serving as the Executive Director of one of the the sites at the time and the second site was 
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interested in learning the findings of the focus group topic. The first site is one of the newer and 
smaller SEPs in NYC and the second site is one of the oldest and largest sites in NYC. I was 
interested in these two sites because they were both interested in exploring SIFs as a prospective 
intervention and because they varied in services and culture. This study was approved by the 
City University of New York (CUNY) City College Institutional Review Board (IRB) in June 
2015.     
1.7.5 Focus group sessions  
In July 2015, I conducted five focus group sessions to explore participant experiences of public 
injection drug use. A total of 32 individuals participated in the sessions. Participants were 
recruited onsite by the researcher and research assistant and screened for eligibility (see 
Appendix J). All participants provided written consent (see Appendix K) to participate. Prior to 
the focus group sessions, participants completed a brief 14-item questionnaire with questions 
form the original IDUCS study (see Appendix L). Focus group sessions were one-hour long and 
audio recorded. All participants received refreshments and a $10 pharmacy gift-card for their 
participation.  
1.7.6 Focus group analysis 
I used thematic analysis to develop a list of main themes and sub-themes with a research 
assistant. We started with five themes based on the different sections of the facilitators guide. We 
both reviewed the transcripts independently to identify general themes that were related to the 
study topic. Then, we discussed overall impressions in person including differences between 
groups, initial impressions by site, and definitions of public injection drug use. Using a grounded 
theory approach184,185, we developed a coding schema and included definitions and constructs of 
each theme. Then, we reviewed and coded the transcripts using the coding schema to identify 
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excerpts related to each theme. I conducted member checks with three participants of the focus 
group sessions to clarify themes and presented excerpts and coded themes. At the end of the 
process, we created a database to easily extract and review excerpts for discussion. We used 
Dedoose™, an online qualitative data management software, to organize and store coded 
transcripts.186  
1.8 Analytical Approach 
1.8.1 Overview 
The study design flow chart is reflected in Figure 1B. I used a multi-phase model to analyze and 
synthesize the quantitative and qualitative data. Multi-phase designs are used when one source of 
data cannot fully explain a single phenomenon and is usually embedded within a larger study.187 
The multi-phase model uses aspect of the transformative framework188 which is an approach to 
analyzing data that is informed by other aspects of the study. It is used particularly with 
marginalized populations, often in studies on gender, sexual orientation, and disability.  Multi-
phase study designs also incorporate both sequential (e.g. conduct quantitative analysis, interpret 
results, conduct qualitative analysis, then interpret) and convergent parallel (conduct quantitative 
and qualitative at the same time, then interpret) elements of data collection and data analysis. In 
this study, the quantitative and qualitative data informed each other at different points in both 
analysis and study design. Below I describe the rationale for this approach and how each source 
of data informed the other.  
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1.8.2 Qualitative Informs Quantitative 
In this study, I had access to the IDUCS survey data and could analyze frequencies and 
relationships between place of injection drug use, risk behavior, socio-demographic 
characteristics, and other reported behaviors. However, the data alone was not going to be able to 
describe why PWID injected where they did and the relationship between place and risk, 
particularly the interplay between different risks. Further, I was interested in describing initial 
reactions to SIFs and their future implementation in NYC. Therefore, I developed a qualitative 
sub-study to answer these questions. I also developed the qualitative component to inform the 
approach to quantitative analysis. There were two ways in which the qualitative data informed 
the quantitative analysis. First, I did not have a solid definition of what ‘public injection drug 
use’ meant to the study population and existing literature varied in the way they defined public 
injection. Therefore, I developed a definition of public injection drug use based on feedback 
from focus group participants on (a) what generally makes a place public versus private and (b) 
after discussing specific types places whether they would describe them as public or private. This 
informed how I operationalized the public injection variable in the IDUCS survey data. The 
second way in which the qualitative data informed the quantitative analysis was in the inclusion 
of additional variables in models describing factors associated with public injection drug use. 
Themes from the qualitative data, including risk of overdose and arrest, were included in the 
quantitative models based on their prominence in focus group discussions.  
1.8.3 Quantitative Informs Qualitative  
The quantitative analysis also informed the qualitative study design. I conducted preliminary 
analysis on frequencies by place of injection drug use to inform which photos I would present for 
discussion in the focus group sessions. After reviewing the most frequent places of injection drug 
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use, I measured the association between each place of injection drug use and reported receptive 
sharing of injecting equipment. Based on places that had higher reported receptive sharing of 
injection drug use, we incorporated probes in the facilitator guide to understand why certain 
places may have higher reported receptive sharing of injecting equipment.  
1.9 Organization of the Dissertation 
The subsequent chapters include three research articles that answer the dissertation aims 
described below followed by a final discussion chapter specific to policy recommendations.  
 
In Chapter 2, I aim to describe where PWID inject drugs in NYC and whether public injection 
drug use is associated with the receptive sharing of injecting equipment using the IDUCS survey 
data. I hypothesize that public injection drug use is associated with increased odds of receptive 
sharing of injecting equipment and, thus, elevated risk of HCV transmission. This chapter is a 
first step in forming a public health rationale for reducing public injection drug use.  
 
In Chapter 3, I describe socio-demographic and behavioral characteristics associated with public 
injection drug use using both IDUCS survey data and focus group session data. I hypothesize 
that public injectors are more likely to report overall higher risk, including unstable housing, 
arrest, and non-fatal overdose. This chapter frames other health and social issues associated with 
public injection that has been minimized in other places where SIFs exist.  
 
In Chapter 4, I describe the experiences of public injection drug use, competing health and social 
risks that factor into where PWID inject, and initial reactions to SIFs as a potential intervention 
in NYC using focus group data. I hypothesize that PWID will perceive public places as higher 
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risk for both health and social risks compared with non-public places. I also hypothesize that 
there are many competing priorities that impact risk behavior and that PWID will perceive a SIF 
to address these competing priorities. This chapter takes a deeper dive into understanding 
Chapter 2, describing potential reasons why PWID sharing injecting equipment. It also illustrates 
more clearly how a SIF may address some of these risk behaviors and initial acceptability of a 
SIF.  
 
In Chapter 5, I synthesize the findings from Chapters 1 to 4 to discuss strengths of the study, 
limitations, policy recommendations, and the overall contribution to the literature.  
 
1.10 Specific Aims 
Aim 1: To describe where PWID inject drugs and measure the association between public 
injection drug use and the sharing of injecting equipment (proxy for risk of HIV and HCV) using 
bivariate and multivariate logistic regression with IDUCS survey data.  
 
• Sub-Aim 1a: To describe the frequency of public injection drug use among PWID and 
whether public injection drug use is associated with receptive sharing of injecting 
equipment in the past three months.  
o Hypothesis 1a: Public injection drug use is associated with increased odds of the 
receptive sharing of injecting equipment. 
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Aim 2: To describe socio-demographic and behavioral characteristics of public injectors 
compared to non-public injectors using a mixed-method approach using IDUCS survey data and 
focus group session data. 
• Sub-Aim 2a: To describe characteristics associated with public injection drug use using 
bivariate logistic regression with cross-sectional IDUCS survey data 
o Hypothesis 2a: Public injectors are more likely to be unstably housed, more likely 
to report past year arrest, and more likely to report past year overdose.  
• Sub-Aim 2b: To describe the relationship between characteristics and public injection 
drug use through thematic analysis from focus group data. 
o Hypothesis 2b: Public injectors are more likely to report risk behavior compared 
with non-public injectors.  
Aim 3: To describe how PWID view health and social risks of injecting in public places 
compared with private places through the use of thematic analyses with data from 5 focus group 
sessions.  
• Sub-Aim 3a: To describe how public places are different from non-public places for 
injection drug use. 
o Hypothesis 3a: PWID will perceive public places as higher risk for health and 
social risks compared with non-public places. 
• Sub Aim 3b: To describe how different health and social priorities interact with each 
other by place of injection drug use.  
o Hypothesis 3b: PWID will describe competing health and social priorities and 
risks when describing what makes a place safe for injection drug use.  
• Sub-Aim 3c: To describe initial reactions and attitudes towards SIFs among PWID. 
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o Hypothesis 3c: PWID will view a SIF as positive potential intervention to address 
risks associated with public injection drug use. 
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Chapter 2: Public injection drug use and risk: an observational study of 
people who inject drugs in New York City 
 
2.1 Introduction 
 
Illicit drug use and associated harms are increasing at alarming rates in the United States (US). 
One in ten Americans report over the age of 12-years old report that they’ve used illicit drugs in 
the past three months.189 Non-medical use of opioid analgesics, known as “prescription pain 
killers”, have contributed to a rise in heroin use and, in turn, injection drug use.22,190,191 Since 
2011, several states have identified outbreaks of HIV and viral hepatitis C (HCV) due to 
injection drug use.63,65,192,193 In 2014, US surveillance data indicated that there were 
approximately 30,000 new cases of HCV in one year, representing a nationwide increase of over 
150% since  201041.  
 
People who inject drugs (PWID) account for 6% of new HIV infections and approximately 80% 
of new HCV infections in the US.19469 There are approximately 1.2 million people living with 
HIV and 3.2 million people living with HCV in the US; approximately 13% are unaware of their 
HIV status56. Early detection is key to prevent transmission to others via sharing injecting 
equipment. In New York, the development of rapid testing, pre-exposure prophylaxis (PrEP) 
medications, and linkage to treatment have been successful in reducing the number of new cases 
of HIV195, resulting in a state-plan to end the HIV/AIDS epidemic by the year 2020.58 However, 
efforts and initiatives for HCV prevention and treatment have been slower and less widespread. 
HCV is ten time more infectious than HIV196 and can survive outside of the body in injecting 
paraphernalia for up to three weeks.197 Minimum age requirements for rapid HCV testing, 
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inadequate insurance coverage for treatment, and hesitance of providers to offer treatment to 
current substance users serve as barriers to test and treat PWID.73,198,199   
 
One of the primary risk factors for contracting HIV and HCV is sharing injecting equipment (i.e. 
syringes, cookers for preparing drugs, or cotton filters) with an individual who is infected.200–203 
Using any injecting equipment that somebody else has already used is referred to as receptive 
sharing. Factors associated with receptive sharing include female gender44,45, younger age46, 
homelessness47, and a recent positive HCV test48, number of injection episodes per day49, any 
methamphetamine use50, and cocaine as the primary drug of choice for injection51, having a 
concordant hepatitis C status with an injecting partner52, and a close relationship53 and trust54 in 
the individual with whom they are injecting. Syringe exchange programs (SEPs) have 
demonstrated to be effective at reducing HIV and HCV transmission among PWID by providing 
sterile injecting equipment and safe injection education.116,204 In New York, SEPs have been 
credited for substantial decreases in new HIV cases among PWID.205,206 SEPs use a harm 
reduction approach to drug use; addressing immediate harms of drug use as a key first step to 
health and wellness.207 Access to a sterile syringe for every injection reduces receptive sharing of 
injecting equipment.208 However, studies continue to document inadequate access to injection 
equipment due to inconvenience, fear of arrest, and experiences of stigma.96,209–211  
 
SEPs are further limited as a prevention intervention because, while they provide sterile injecting 
equipment, they rely on PWID applying safer injection practices elsewhere. For PWID who are 
unstably housed or homeless, they may be injecting in public places due to shelter and supportive 
housing requirements of abstinence. One recent study found that 56% of managers of small 
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business with public bathrooms (i.e. restaurants, cafes) reported that they had encountered drug 
use or evidence of injection drug use (i.e. blood, syringes, injecting equipment) in the past three 
months.106 International studies found that public injection drug use was associated with a variety 
of risky injection practices, including self-reuse and receptive sharing of injecting equipment, 
inadequate preparation and cleaning of skin injection sites, and rushing injections.150,212,213 In 
addition to HIV and HCV transmission risks, these practices increase the risk of skin and soft 
tissue infection (SSTIs) which may develop into painful abscesses, staph infections, and 
endocarditis.27–30,214 Hospital stays due to SSTIs tend to be longer and more costly compared to 
non-SSTIs.14 One study of one public hospital found that SSTIs accounted for $11.5 million in 
spending over a 12-month period.13 Injection-related health risks and associated costs are 
preventable but require a level of intervention that addresses risk behavior in real time.  
 
In order to prevent potential adverse health outcomes associated with public injection drug use, 
over 100 supervised injection facilities (SIFs) have been established in eleven countries around 
the world.149 SIFs are places where PWID may bring their own pre-obtained drugs to inject 
under the supervision of health professionals. The purpose of SIFs are to address challenges 
related to public injection drug; these include injecting in unhygienic environments, rushing 
injection due to fear of arrest or public view, fatal overdose, unsafe injecting techniques, and 
sharing injecting equipment. Over 70 peer-reviewed journal articles have demonstrated that they 
are effective in preventing HIV and HCV, fatal overdose, abscesses and wounds, and public 
injection.151,153,215 Beyond the primary goals, SIFs also increase connection and enrollment in 
other supportive services including drug treatment and medical services. They also are estimated 
to save millions of dollars a year by averting HIV infections alone.155,171,216 A recent study in San 
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Francisco suggests that one SIF may save the city $3.5 million per year.177  Despite the 
abundance of evidence that SIFs are both cost-effective and save lives, this model has not been 
implemented in the US.  
 
New York City (NYC) has the largest population of people who inject drugs (PWID), with 
multiple sources estimating at least 105,000 current PWID.26,183,217 However, we do not know 
how many people inject in public places and how public injection is related to risky injection 
practices in the US. In this study, we aim to describe where PWID are injecting drugs and 
whether public injection drug use is associated with increased reports of receptive sharing of 
injecting equipment. We use reported receptive sharing of injecting equipment as a proxy for the 
risk of HCV transmission since we do not have biomarkers or seroconversion data. The 
relationship between the receptive sharing of injecting equipment and HCV seroconversion is 
well documented.197,218,219 We hypothesize that public injection drug use is associated with 
increased odds of receptive sharing injecting equipment.  
 
2.2 Methods 
In this study, we describe where PWID are injecting and the relationship between public 
injection drug use and receptive sharing of injecting equipment. We use observational survey 
data from the Injection Drug Users Health Alliance Citywide Study (IDUCS).74 The present 
study was approved by the City University of New York (CUNY) City College Institutional 
Review Board. 
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2.2.1 Overview of the Parent Study 
The IDUCS is a multi-wave cross-sectional study which aimed to describe service access, health 
status, and risk behavior among people who use drugs in NYC.74 The study is the largest 
community-based survey of people who access SEps in the US. IDUCS was administered in 
three waves: Wave 1 in January 2014 (n=1,042), Wave 2 in June 2014 (n=1,303), and Wave 3 in 
June 2015 (n=1,235). The first wave served as a pilot to test the survey instrument since several 
of the measures were not adapted from previously validated sources.  The survey instrument was 
revised between Wave 1 and Wave 2 for clarity. Since it was possible for PWID to participate in 
the survey across all three waves, a personal identifier code was added to the survey instrument 
in Wave 2 in order to identify duplicates. Field interviewers generated the personal identifier 
using a combination of date of birth, gender, initials, site, and the participant’s mother’s name. 
Eligibility criteria to participate in the study included (1) self-reported age of 18 years or older, 
(2) enrollment in at least one of the SEPs (3) the ability to conduct an interview in English or 
Spanish, and (4) the ability to provide written, informed consent. Participants were recruited 
using convenience sampling across 14 SEPs at 57 unique sites across all five boroughs of NYC. 
Sites included drop-in centers, mobile units, non-traditional venues such as single-resident 
occupancy hotels and shooting galleries, and street-based outreach sites. Participants were 
recruited onsite by staff members of the SEP. Interested participants were referred to research 
personnel to determine eligibility. Interviewer-administered interviews were conducted by 
trained field interviewers using paper-based surveys. Participants were provided a $5.00 round-
trip metro card for their participation.  
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2.2.3 Current Study 
Study Population 
Our study includes data from the last two waves of the IDUCS (n=2,538). We excluded the first 
wave due to the lack of a personal identifier to identify duplicates. Using the personal identifier, 
we identified 117 duplicate responses. We retained the Wave 3 response to reflect the most 
recent injection drug use patterns (n=2,421). In addition to the four eligibility criteria from the 
parent study, we added an extra eligibility criterion of current injection drug use, defined as any 
injection drug use in the three months preceding the survey. A total of 820 participants met these 
criteria. We dropped 33 participants who had missing data in any of the variables included in this 
study after ensuring that there were no significant differences across select variables between the 
final sample and excluded cases. No variable had more than 4 missing responses and there were 
no significant differences between the sample with missing data and the final sample. Our final 
sample size for this study is 787 participants.  
 
2.2.4 Measures 
The main outcome measure in this study is Receptive Sharing of Injecting Equipment. Receptive 
sharing of injecting equipment is defined as whether a participant reported receptive sharing of a 
syringe (yes vs. no), a cooker (yes vs. no), or a cotton filter (yes vs. no) that somebody else had 
already used. Participants who reported the receptive sharing of any type of injecting equipment 
are included in the Any Receptive Sharing group. Participants who did not report any receptive 
sharing of injecting equipment are included in the No Receptive Sharing group. In this study, Any 
Receptive Sharing is the proxy for the risk of HCV transmission and considered a risky injection 
practice.  
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The main explanatory variable is Public Injection. In the IDUCS survey instrument, participants 
were asked if they had ever in the past three months injected in the following categories (yes vs. 
no); street or park, stairwell, abandoned building, public bathroom, bus or subway or train, car or 
other vehicle, bathroom of a syringe exchange program, shooting gallery, home of a friend of 
family member, or your own home. We created a new variable Public Injection to measure the 
association between injecting in a public place and receptive sharing of injecting equipment. 
Public Injection is defined as injecting in any of the following places: street or park, stairwell, 
abandoned building, public bathroom, bus or subway or train, car or other vehicle, bathroom of a 
syringe exchange program, or a shooting gallery. We reviewed previous literature on public 
injection drug use to inform which categories are considered “public” versus “non-
public”.25,220,221 We determined that injecting in the categories of (a) home of a friend of family 
member or (b) your own home were not considered public. Participants who reported only 
injecting in these two categories are not included in Public Injection.  
 
We include socio-demographic and potential confounding variables in the analyses. We selected 
potential confounders based on previous studies related to receptive sharing of injecting 
equipment and public injection drug use.158,161,221–223 Socio-demographic characteristics include 
age in years (under 30, 30-39, 40-49, and 50+), gender (male vs. female), and race/ethnicity 
(white, Black, Latinx, other). Other variables included housing (street-homeless, unstable, 
stable), arrest or incarceration in the past year (yes vs. no), syringe source in the past three 
months (options include syringe exchange program, pharmacy, from a 
friend/relative/acquaintance, from street or shooting gallery; yes vs. no for each), and past 30-day 
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substance use (options include alcohol, marijuana, methadone, heroin, crack, cocaine, 
methamphetamine, other opioids, benzodiazepines; yes vs. no for each). 
 
2.2.5 Statistical Methods 
First, we conducted descriptive statistics and present frequencies to describe the full sample. 
Next, we used bivariate logistic regression to compare participants who reported receptive 
sharing of injecting equipment with participants who did not report receptive sharing of injecting 
equipment. We reviewed unadjusted odds ratios, confidence intervals, and p-values to guide 
interpretation of significant associations. To test the hypothesis that public injection is associated 
with receptive sharing of injection equipment, we constructed a multivariate logistic regression 
model. We decided to include all of the variables from the bivariate logistic regression 
procedures with a p-value of 0.20 or less in the final multivariate logistic regression model. We 
used Chi-square tests and Cramer’s V to assess associations between independent variables and 
refine the model.224 All significant and non-significant variables are reported in the full model. 
All analyses were conducted using SPSS Statistics version 24.225  
 2.3 Results 
2.3.1 Sample Characteristics 
A total of 787 participants were included in the analyses. The majority of participants were male 
(73%) and over the age of 40 years old (77%) (see Table 1). Over half of participants were 
homeless (29%) or unstably housed (42%). Nearly half had been arrested or incarcerated in the 
past year (44%). Syringe exchange programs were the most common source of syringes (94%). 
The most commonly used drugs in the past 30 days include heroin (83%), methadone (68%), 
cocaine (39%), and benzodiazepines (38%). Nearly all participants reported using at least one 
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opioid in the past 30 days (98%) and over a third reported the use of an opioid and 
benzodiazepine (38%).  
 
2.3.2 Place of Injection Drug Use 
Nearly two-thirds (64%) of participants reported public injection drug use. Injecting in one’s 
own home (71%) was the most common of any category, followed by the home of a friend or 
family member (59%) and public restroom (48%). Injecting on the bus, subway, or train (11%) 
was the least common of any category.  
 
2.3.3 Receptive Sharing of Injecting Equipment 
One quarter (25%) of participants reported they had receptive sharing injecting equipment at 
least once in the past three months. The following factors were significantly associated with the 
receptive sharing of injecting equipment at a p-value of <.05: younger age, black race/ethnicity, 
homelessness and unstable housing, past year arrest or incarceration, public injection, receiving a 
syringe from a friend/relative/acquaintance, receiving a syringe from the street or shooting 
gallery, and past 30-day use of heroin, crack, cocaine, and methamphetamine.  
 
Public injection was significantly associated with increased odds of reusing of injecting 
equipment in the unadjusted model (OR=3.46, CI: 2.31-5.19) and the adjusted model 
(AOR=1.66, CI: 1.04-2.65) (see Table 2). Receiving syringes from a friend, family member or 
acquaintance was the strongest factor associated with receptive sharing of injecting equipment 
(AOR=2.30, CI: 0.49-1.15). Unstable housing (AOR=1.96, CI: 1.19-3.25) and past year arrest or 
incarceration (AOR=1.69, CI: 1.15-2.48) were also significantly associated with the receptive 
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sharing of injecting equipment. Substance use factors that remained significant in the full model 
include past 30-day crack use (AOR=2.11, CI: 1.39-3.21), heroin use (AOR=1.97, CI: 1.119-
3.47), and cocaine use (AOR=1.523, CI: 1.04-2.23).  
2.4 Discussion 
Our findings offer a new understanding of where PWID are injecting drugs and that public 
injection drug use is significantly associated with risky injection practices. It also may 
preliminarily serve as a rationale for implementing SIFs as a cost-effective and complimentary 
strategy to address risky injection practices that may contribute to new HIV and HCV outbreaks. 
This is the first study in the US to examine the association of public injection drug use. 
 
2.4.1 Main Findings & Policy Implications  
There are two main findings in this study. First, over half (64%) of PWID engaged in SEPs are 
injecting in public places. The prevalence of public injection in this sample is higher than the one 
other study (National HIV Behavioral Surveillance Study, 2009) on place of injection drug use in 
NYC (64% vs. 30%).25,226 This may mean that there are more people injecting in public places 
compared with past years. As described earlier in this article, public injection drug use poses 
risks to the PWID. Public injection also poses safety risks to the communities where there is 
public injection, primarily improperly discarded syringes.164,227 While it was not a primary aim 
of the study, we learned that over half (71%) of the study participants reporting they were street 
homeless or unstably housed during the same timeframe as reported public injection. Limited 
access to affordable housing and sobriety requirements of shelters and supportive housing may 
be one explanation for the prevalence of public injection. Housing First (HF) models prioritize 
housing over other supportive services, including drug treatment, and is based on the belief that 
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stable housing and stability is key to ensuring other supportive services are effective. The result 
is that PWID are not under threat of being kicked out of housing due to drug use, or provided no 
other option except to inject in public spaces, and are connected to supportive services. HF 
models have demonstrated to be both cost effective and successful in engaging and retaining 
chronically homeless adults in care.125,228 However, while housing policy reform is a first step, it 
is not the last. Nearly 20% of study participants who were stably housed reported public injection 
drug use. Implementing SIFs in areas of high public injection drug use may be one 
complementary strategy to ensure PWID have a safe, supervised place to inject.       
 
Second, public injection is associated with a 63% increase in the odds of receptive sharing of 
injecting equipment. Only 12% of participants who injected in only non-public places reported 
any receptive sharing of injecting equipment compared to 38% of participants who injected in a 
public place. This is consistent with international studies that were conducted in the context of 
comparing injecting practices of PWID.229 In the US, punitive drug policies and policing 
practices, including Stop and Frisk230 and drug possession laws of the federal Controlled 
Substances Act231, are barriers to carrying sterile injecting equipment.98,232,233 They are also 
barriers to returning used syringes to SEPs or hazardous waste disposal sites due to fear of 
arrest.164,234 In New York, while a participant of a SEP may carry syringes with residue if they 
carry an enrollment card, drugs and injecting equipment with residue may result in arrest 
according to current law (New York Penal Code § 220.45). In short, if PWID do not have 
confidence to carry their own injecting equipment or a safe pathway to return used injecting 
equipment, the more likely they are to remain in the community for receptive sharing or be 
disposed of improperly.  
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The policy solutions to address public injection drug use and risky injection practices include 
both drug policy reform and improvements in syringe access. For drug policy reform, one 
approach to reduce barriers to safe injection practices would be to decriminalize drug use 
altogether. In Portugal, all drug use has been decriminalized since 2001 and has resulted in a 
decrease in drug use and an increase in drug treatment.235–237 Current US drug policy impedes 
harm reduction efforts. We found in our study that the source where PWID obtain syringes is a 
significant factor related to the receptive sharing of injecting equipment. Participants who 
obtained syringes from friends, family members, acquaintances or the street or a shooting gallery 
had significantly higher odds of receptive sharing of injecting equipment. Whereas receiving 
syringes from a SEP was associated with decreased odds of reusing injecting equipment, 
although not significantly. Consistent with the research on SEPs, access to sterile injecting 
equipment decreases the likelihood of reusing injecting equipment.210,234 However, PWID 
continue to receive syringes from other sources due to logistical and social barriers described 
earlier in this article.  There are several ways to approach improving access to sterile injecting 
equipment. First, expand funding and support for SEPs and target their establishment in areas of 
high HCV and HIV prevalence. Funding and authorization is currently operated on a state level; 
a federal mandate to authorize SEPs in all states due to the emerging HCV epidemic would be 
the most effective, widespread approach to improving access to sterile injecting equipment. 
Second, pharmacy-based syringe access programs may be a cost-effective strategy to quickly 
reach a wide geographic area in the absence of SEPs. Third, decriminalize the possession of 
syringes and injecting equipment across all states. SEPs and pharmacy-based programs only 
promote access to sterile injecting equipment if PWID are legally able to obtain, carry, and 
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return the injecting equipment without fear of arrest. Lastly, SIFs should be implemented in areas 
where there is a concentration of PWID who otherwise are injecting in public places. In addition 
to minimizing the consequences of public injection, SIFs may also serve as a place to connect 
with high risk PWID for healthcare services. By connecting PWID with a regular source of care 
and preventing SSTIs, existing healthcare reform initiatives that focus on reducing preventable 
emergency department admissions may be more successful and cost-saving.   
 
While it was not the primary aim of the study, there are several other findings that are worth 
mention. The use of crack was the substance use factor most strongly associated with receptive 
sharing of injecting equipment. Injectors who smoke crack are more likely to report injecting 
more often and overall higher frequencies of drug use compared with injectors who do not 
smoke crack.238 A PWID who uses crack may have more injections per day and, in turn, 
increased episodes of injection where they may be more likely to report receptive sharing of 
injecting equipment.  We also know that smoking crack is also associated with both drug and 
sexual risk behaviors, trading sex for drugs or money, and HIV seroconversion.239–241 
Considering these risks, interventions to minimize risky injection practices should target people 
who also smoke crack. Drug consumption rooms (DRCs) which include safer smoking rooms 
may be one alternative in conjunction with SIFs to minimize risk among PWIDs.242 
 
2.4.2 Strengths & Limitations 
There are several limitations of this study. This study is limited to an urban-dwelling population 
in NYC and may not be generalizable to all communities. Cross-sectional data prohibited any 
temporal associations between receptive sharing of injecting equipment and independent 
	 50	
variables. The measures of place of injection drug use are adopted from the NHBS25 study but 
have not been validated in any other study. The definition of each category of place of injection 
drug use was subjective and may vary in terms of their physical and social attributes. Housing 
status was defined as where an individual slept most often in the past three months and, 
therefore, an individual may have experienced variations in housing status during the three 
months prior to the survey. Lastly, receptive sharing of injecting equipment is limited to 
occurring once over the past three months and does not account for the level of receptive sharing 
beyond one time. Despite these limitations, this study represents the largest sample of PWID in 
NYC on the topic of place of injection drug use. It also unearths that PWID are commonly 
injecting in public places in NYC and that injecting in a public place is associated with risk 
behavior. As a national conversation emerges on alternatives to public injection,153,243,244 these 
findings offer recent data to support a public health rationale to integrate SIFs and DCRs in 
NYC.  
 
2.4.3 Conclusion 
Public injection drug use is prevalent in NYC and is associated with increased odds of receptive 
sharing of injecting equipment and, in turn, HCV transmission risk. Our study provides a new 
understanding of public injection drug use in NYC and a public health rationale for the 
implementation of new evidence-based strategies to address injection-related risk. Solutions to 
public injection drug use include improving access to affordable housing and shelter for PWID, 
drug policy reform, improving syringe access, and implementing SIFs.  
 
2.5	References		
To be formatted in separate article 
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Table 2A Socio-demographic and behavioral factors association with receptive sharing of injecting equipment in the past 3 months among PWID (n=787) 
    TOTAL Any receptive sharing  No receptive sharing             
  N %  N %  N %  OR   95% CI   p-value  
Total  787 100%  195 25%  592 75%       
Gender                
Male  575 73%  137 70%  438 74%  0.83  .58-1.19 0.309 
Female  212 27%  59 30%  154 26%  -     
Age                
Under 30  101 13%  30 15%  71 12%      
30 to 39  179 23%  67 34%  112 19%      
40 to 49  249 32%  58 30%  191 32%      
50 of over  258 45%  40 21%  218 37%  0.44  .30-.65 <.001*** 
Race/ethnicity                
white  211 27%  54 28%  157 27%  -     
black  126 16%  16 8%  110 19%  0.42  .23-.78 .006** 
Latino  406 52%  114 58%  292 49%  1.14  .78-1.66 .51 
other  44 6%  11 6%  33 6%  0.97  .46-2.05 .94 
Housing Status a                
Homeless  232 29%  75 38%  157 27%  3.38  2.09-5.47 <.001*** 
Unstable  329 42%  92 47%  237 40%  2.75  1.73-4.36 <.001*** 
Stable  226 29%  28 14%  198 33%  -     
Arrested or incarcerated in the past 
year  343 44%  119 61%  224 38%  2.57  1.85-3.59 <.001*** 
Public Injection 
(past 3 months)  503 64%  161 83%  342 58%  3.46  2.31-5.19 <.001***  
In the past 3 months, injected drugs at 
least once in…                
Street or park  296 38%  119 61%  177 30%  3.66  2.61-5.13 <.001***  
Stairwell  248 32%  103 53%  145 24%  3.44  2.45-4.82 <.001***  
Abandoned Building  170 22%  75 38%  95 16%  3.28  2.28-4.71 <.001***  
Public Bathroom  380 48%  134 69%  246 42%  3.08  2.18-4.35 <.001***  
Bus, Subway or Train  88 11%  33 17%  55 9%  1.99  1.25-3.16 .004**  
Car or other vehicle  202 26%  77 39%  125 21%  2.43  1.71-3.44 <.001***  
Bathroom of a syringe exchange 
program  176 22%  57 29%  119 20%  1.64  1.13-2.37 .009**  
Shooting gallery  118 15%  55 28%  63 11%  3.29  2.19-4.94 <.001***  
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Home of a friend or family member  465 59%  142 73%  323 55%  2.27  1.59-3.25 <.001***  
Your own home  561 71%  128 66%  433 73%  0.71  .50-1.00 .05  
Syringe Source (past 3 months)                
Syringe Exchange Program  737 94%  180 92%  557 94%  0.73  .39-1.38 .33  
Pharmacy  371 47%  107 55%  264 45%  1.50  1.08-2.08 .01*  
Friend, Relative or Acquaintance  195 25%  85 44%  110 19%  3.41  2.40-4.85 <.001***  
Street or Shooting Gallery  117 15%  59 30%  58 10%  3.97  2.64-5.98 <.001***  
Past 30 days Drug Use                
Alcohol  292 37%  81 42%  211 36%  1.28  .92-1.79 .14 
Marijuana  246 31%  55 28%  191 32%  0.83  .58-1.18 .29 
Methadone  539 68%  140 72%  399 67%  1.23  .86-1.76 .25 
Heroin  652 83%  176 90%  476 80%  2.26  1.35-3.78 .002** 
Other Opioids b  174 22%  52 27%  122 21%  1.40  .96-2.04 .08 
Crack  183 23%  73 37%  110 19%  2.62  1.84-3.74 <.001*** 
Cocaine  305 39%  106 54%  199 34%  2.35  1.69-3.27 <.001*** 
Crack and Cocaine  118 15%  49 25%  69 12%  2.54  1.69-3.83 <.001*** 
Methamphetamine  27 3%  12 6%  15 3%  2.51  1.16-5.47 .02* 
Benzodiazepines c  301 38%  85 44%  216 36%  1.35  .97-1.87 .08 
Any opioid (heroin, methadone 
and/or opioid analgesic)  770 98%  194 99%  576 97%  5.39  .71-40.90 .10 
Any opioid + benzodiazepines  300 38%  85 44%  215 36%  1.36  .98-1.88 .07 
*** p<.001  **p<.01   *p<.05 
a Housing status defined as homeless (street homeless), unstable housing (jail, prison, rooming with others, shelter, temporary housing, hospital, drug 
treatment), stable housing (own home or live with friend/family member) 
b Other Opioids include opioid analgesics or “pain killers” such as hydrocodone, Oxycontin, Percocet, Vicodin  
c Benzodiazepines or “downers” include anti-anxiety medication such as Klonopin and Xanax 
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Table 2B. Factors associated with receptive sharing of injecting equipment in the past three months among PWIDs in NYC using a multivariate 
logistic regression model (n=787) 
           
         AOR   95% CI   p-value     
Public Injection a  (past three months)  1.66  1.04-2.65  0.033*     
Unstable Housing b  (past three months)  1.96  1.19-3.25  0.009**     
Arrested or incarcerated (past year)   1.69  1.15-2.48  0.007**     
Alcohol Use (past 30 days)  0.93  0.63-1.35  0.69     
Heroin Use (past 30 days)  1.97  1.12-3.47  0.02*     
Crack Use (past 30 days)  2.11  1.39-3.21  <0.001***     
Cocaine Use  (past 30 days)  1.52  1.04-2.23  0.03*     
Methamphetamine Use (past 30 days)  1.73  0.70-4.31  0.24     
Benzodiazepine Use (past 30 days)  1.14  0.77-1.68  0.50     
Syringes from a friend, family or acquaintance 
(past 30 days, yes vs. no)  
2.30 
 
0.49-1.15 
 
<0.001*** 
    
Syringes from the street or shooting gallery 
(past 30 days, yes vs. no)  
1.83 
 
1.10-3.03 
 
0.02* 
    
Model adjusted for age, gender and race/ethnicity              
*** p<.001  **p<.01   *p<.05           
a Public Injection defined as injecting at least once in the past three months in the following categories: street or park, stairwell, 
abandoned building, public bathroom, bus or subway or train, car or other vehicle, bathroom of a syringe exchange program, or a 
shooting gallery. 
b Unstable housing includes street homeless and unstable housing categories (jail, prison, rooming with others, shelter, temporary 
housing, hospital, drug treatment) 
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Chapter 3: Characteristics associated with public injection drug 
use: a mixed-methods study  
 
3.1 Introduction 
 
The United States (US) has seen a steady rise in injection drug use as individuals transition from 
non-medical use of prescription opioid analgesics (also known as prescription painkillers) to the 
use of heroin.17,20 In 2014, there were 2.3 million Americans who reported using prescription 
opioids non-medically.245 Individuals who use prescription opioids non-medically are nine times 
more likely to start using heroin compared with those who don’t.5 Recent research has described 
a pathway to the initiation of injection drug use via non-medical use of opioid analgesics; an 
individual develops a need and tolerance to opioids and find that heroin is cheaper and more 
accessible than opioid analgesics.22 This has resulted in a new cohort of new injectors who, in 
addition to overdose, are at risk of contracting HIV, HCV, and bacterial infections.190,246–248 
Recent outbreaks of HIV and HCV across the country have been attributed to new cohorts of 
people who inject drugs (PWID).16,62,190 Compounded by the concurrent opioid overdose 
epidemic, the demand for effective interventions to reduce risk and improve health among PWID 
has become a national priority.  
 
PWID are vulnerable to a variety of negative health outcomes. PWID comprise 22% of people 
who are living with HIV infection and 48% of people who report living with HCV.32,41 The 
transmission of blood-borne infections (HIV, HCV) and bacterial infections can lead to painful, 
costly, and potentially fatal outcomes. Risky injection practices, including self-reuse or receptive 
sharing of injecting equipment, inadequate preparation and cleaning of an injection site, and 
rushing injections, increase the risk of HIV/HCV transmission and bacterial infections.52,53,249,250 
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Over 80% of individuals who contract HCV will go on to develop chronic liver disease.251 
Treatment for HIV for HCV are costly and, particularly for HCV, may be inaccessible or 
unaffordable in many states. Bacterial infections may quickly develop into staph infections and 
endocarditis, resulting in costly emergency department (ED) admissions and hospital stays.13,14 
The burden of injection-related infections costs lives and healthcare spending, and is largely 
preventable.  
 
To prevent risky injection practices, states have implemented syringe exchange programs (SEPs) 
and pharmacy-based syringe access programs to offer sterile injecting equipment and safe 
injection education to minimize injection-related risk among PWID.138,252 SEPs have been 
heralded as the gold standard for reducing injection-related infections and transmission among 
PWID.253 However, PWID continue to experience barriers to consistently using one sterile 
syringe for every injection.254–258 Some of these barriers include inadequate access to storing 
injecting equipment due to homelessness or unstable housing, fear of arrest due to punitive 
policing and drug policies, logistical barriers including distance and hours of operation, and 
experiences of stigma.96,147,254,259 Furthermore, state-by-state regulations to authorize SEPs and 
pharmacy-based syringe access programs mean that PWID who reside in states without syringe 
access programs have even more limited access.147 SEPs are also limited to providing prevention 
interventions that rely on the ability of PWID to apply safe injection practices. A recent study 
found that 64% of PWID inject in public places and that public injection drug use is associated 
with increased odds of receptive sharing of injecting equipment (Chapter 2). Even if PWID are 
able to obtain sterile injecting equipment, it is not enough to prevent risky injection practices.  
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Outside of the US, supervised injection facilities (SIFs) have been established to prevent the 
health and social harms of public injection drug use. SIFs are sanctioned places where PWID can 
bring pre-obtained drugs to prepare and inject under the supervision of healthcare personnel.  
Since 2003, North America’s first SIF has demonstrated to reduce fatal overdose, public 
injection, risky injection practices, new cases of HIV and HCV, and emergency department visits 
due to injection-related infections.153,260 It has also demonstrated to increase engagement and 
retention in medical and drug treatment services while saving the city of Vancouver and 
estimated $6 million per year in healthcare spending. As of 2017, there are over 100 SIFs in 
operation in eleven countries, with at least three more planned by 2018.149 Despite the 
overwhelming body of research that demonstrates the efficacy of SIFs in preventing injection-
related infections and fatal overdose, the US has yet to adopt SIFs into the continuum of care 
options for PWID.  
 
In the US, the research on public injection drug use is limited. In 2009, the National HIV 
Behavioral Surveillance Study (NHBS) found that 30% of PWID surveyed in New York City 
(NYC) had reported that they had injected drugs in a public place in the past three months.176 
However, the association between public injection drug use and risky injection practices was not 
described. A more recent study found that over half (54%) of managers of fast food restaurants 
and small businesses with public bathrooms had found evidence of injection drug use (i.e. 
discarded syringes, blood, injecting equipment) in the past 3 months.106 With an estimated 
105,000 people who inject drugs (PWID) in NYC, 114,183 understanding characteristics and risks 
associated with public injection drug use may direct and inform new interventions for PWID. 
Furthermore, healthcare reform efforts in New York have focused on reducing the number of 
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preventable ED admissions.261 One of the strategies includes identifying and connecting high 
utilizers of the ED to a more regular source of primary care. Consistent with the international 
literature, SIFs reduce preventable ED admissions and connection to both regular health care and 
drug treatment.162,244,262,263 If public injectors report more frequent visits to the ED and lower 
engagement with primary care, the findings of this research may provide insight into how to 
connect and engage with high utilizers of the ED to reduce healthcare spending.  
 
In this study, we use a mixed-methods approach to explore characteristics and risk factors 
associated with the public injection drug use. We hypothesize that PWID who inject in public 
have a higher risk profile. This is the first mixed-methods study to focus on public injection drug 
use and describe characteristics associated with public injection drug use in NYC.  
  
3.2 Methods 
Our study includes 1) cross-sectional survey data from the Injection Drug Users Health Alliance 
Citywide Study (IDUCS) and 2) focus group data from a qualitative sub-study. We selected 
multi-phase mixed-methods design264 to fully describe the relationship between risk behavior 
and public injection drug use.  
 
In this study, we used the qualitative data to both inform the analytic approach and to describe 
the relationship between public injection drug use and risk behavior. First, we describe the 
quantitative study. Then, we describe how we used the qualitative sub-study to operationalize the 
outcome variable and select additional explanatory variables. Lastly, we describe the qualitative 
sub-study. The current study was approved by the City University of New York (CUNY) City 
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College Institutional Review Board. Funding for the qualitative sub-study was provided by the 
Doctoral Student Research Grant at the CUNY Graduate Center.  
3.2.1 Quantitative Study  
The IDUCS is a study of PWID enrolled in NYC SEPs. The multi-wave, cross-sectional study 
aimed to measure SEPS service access, health status, and risk behavior among PWID in NYC. 
Using convenience sampling, PWID were recruited at 57 unique sites of 14 SEPs in all five 
boroughs of NYC. Sites included drop-in centers, mobile units, community tabling events, and 
during street-based outreach sessions. Eligibility criteria included (1) self-reported age of 18 
years or older, (2) enrollment in one of the SEPs, (3) the ability to conduct an interview in 
English or Spanish, and (4) the ability to provide consent. The development of the survey 
instrument and methodology is described elsewhere.74 Interviewer-administered surveys were 
conducted by trained field interviewers. Eligible participants were provided with a $5.00 metro 
card for their participation at the end of the survey. 
 
Quantitative Sample 
Our study includes unduplicated responses from Wave 2 (June 2014) and Wave 3 (June 2015) 
(N=2,421). We excluded responses from Wave 1 (January 2014) since it served as a pilot and did 
not have personal identifiers to identify duplicate responses. In addition to the four eligibility 
criteria of the parent study, we added an extra criterion of reporting injection drug use in the past 
three months to select only participants who would have been asked questions related to where 
they injected drugs in the past three months. A total of 820 participants met these criteria. There 
were few missing data points, but we excluded participants who had any missing data (n=65). 
Each measure had at least one missing data point but did not exceed 10 per measure. An analysis 
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of the sample characteristics between cases with complete data and cases with missing data did 
not yield any significant differences or patterns, appearing to be missing at random. Our final 
sample size for the quantitative analyses is 755 participants.   
Analysis  
Our analysis aims to describe characteristics and risks associated with public injection drug use 
compared with private injection drug use. First, we constructed the primary outcome variable 
guided by the results from the qualitative sub-study described later in this section.  
Construction of the Outcome Variable  
The IDUCS survey collected data on where participants had injected drugs in the three months 
preceding the survey. Participants were asked if they had ever injected drugs in the following 
places; the street or park, a stairwell, an abandoned building, a public bathroom, a bus or subway 
or train, a car or other vehicle, a bathroom of a syringe exchange program, a shooting gallery, the 
home of a friend of family member, or their own home. While some of the places were more 
clearly identifiable as public (e.g. park or street), there were several categories that could be 
categorized as either public or private (e.g. public restroom). Therefore, we developed a 
qualitative sub-study to discuss what makes a place private or public for injection drug use with 
PWID to guide how to define public injection. The participants of the sub-study were recruited 
from two of the sites included in the IDUCS survey with the intention of capturing a similar 
population that would have participated in the IDUCS survey.  
 
Explanatory Variables  
We selected 25 explanatory variables from IDUCS for this study. We initially included socio-
demographic variables to describe the sample. We also included potential covariates, including 
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housing status and general drug use, based on previous research. Based on the key themes from 
the qualitative sub-study, we added variables related to arrest, overdose, drug treatment, and 
mental health.  Lastly, we include variables of health service access due to current policy 
discussions related to improving minimizing preventable ED admissions through enhanced 
access to primary care services among people who use drugs.80,261 Below we describe how the 
data were collected in the IDUCS and the process and rationale for re-coding variables for this 
study. 
 
We selected the following variables to describe the population: (1) age, measured in years. We 
created a new variable to categorize age: under 30, 30-39 years old, 40-49 years old, and over the 
age of 50-years old. We decided on these categories based on patterns of association with public 
injection and natural cut points, and to have age categories consistent with those presented in 
health department data for future comparison; (2) gender, coded as self-identified gender (male 
vs. female); and (3) and race/ethnicity (white vs. black vs. Latinx vs. other).  
 
We selected the following variables as potential covariates identified in previous research265,266: 
(1) housing status, reported as where they had slept most often in the three months preceding the 
survey. IDUCS includes three categories; street-homeless, unstably housed, and stably housed. 
Street-homeless is defined as any public place (street, park, subway, bus station, ATM lobby, 
building stairwell, roof or basement). Unstably housed is defined as a shelter for homeless 
people, jail or prison, single room occupancy facility or welfare hotel, drug treatment or a 
program, three-quarter housing, non-drug treatment setting (supportive housing or transitional 
housing), or a hospital or nursing home or hospice. Stably housed is defined as living with 
	 62	
friends, family, or a partner or your own place (apartment or a house that is your home); (2) 
general drug use, measured as having used any of the following drugs at least once in the 30 days 
preceding the survey. Drugs include alcohol, marijuana, methadone, heroin, crack, cocaine, 
methamphetamine, other opioids (include opioid analgesics known as “pain killers”), or 
benzodiazepines (yes vs. no for all drug types).  
 
We selected the following variables based on key themes from the qualitative sub-study as being 
related to place of injection drug use: (1) past year arrest or incarceration, reported as arrest or 
incarceration within the past year preceding the survey (yes vs. no); (2) overdose, reported as 
whether they had ever experienced an overdose in their lifetime (yes vs. no), experienced an 
overdose in the past year (yes vs. no), or whether they had witnessed an overdose in the past year 
(yes vs. no); (3) methadone use, reported as whether they were currently enrolled in a methadone 
program at the time of the survey (yes vs. no) or if they had used methadone not prescribed in the 
30 days preceding the survey (yes vs. no); (4) suboxone use, reported as whether they were 
currently prescribed suboxone, an opioid replacement therapy, at the time of the survey (yes vs. 
no) and whether they had used non-prescribed suboxone, bought off the street or from a friend, 
in the 30 days preceding the survey (yes vs. no); (5) mental health symptoms, reported as 
whether they had experienced symptoms of of depression, anxiety, and/or hallucinations in the 
past three months (never vs. sometimes vs. often). We created a binary variable for the 
multivariate model and collapsed sometimes and often compared with never for a measure of any 
depression, anxiety, or hallucination symptoms.  
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We selected the following variables based on current health policy discussions related to 
healthcare reform and initiatives to reduce drug-related harm: (1) past year ED admission, 
reported as whether a participant had been admitted to the ED in the year preceding the survey 
(yes vs. no); (2) have a primary care provider (PCP), reported as having a PCP at the time of the 
survey (yes vs. no). 
 
3.2.2 Qualitative Sub-Study 
As noted above, we used a qualitative sub-study to guide our development of a definition of 
public injection, to develop our main outcome variable public versus private injection based on 
the survey data, and to determine which participant characteristics and risk factors to include in 
our quantitative models. Here were describe this qualitative approach. We conducted five focus 
group sessions July 2015 at two SEPs that were included in the IDUCS parent study. Both SEPs 
were located in Manhattan, provide both office-based and outreach-based syringe exchange to 
PWID, and operate in underserved communities. The major differences between the two SEPs 
are in the organizational history (8 years of operation versus 21 years of operation) and size (10 
staff versus 30 staff). Participants were recruited using convenience sampling in drop-in centers 
of both SEPs during the afternoon where syringe exchange services were offered. Interested 
participants were screened for eligibility, which included the same eligibility criteria as the 
IDUCS study with an additional requirement of reporting any injection drug use in the past three 
months. Eligible participants were included in the focus group session at the site.  
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Specialized Session 
After completion of the first four focus group sessions, we noticed that the median age of the 
focus group participants (48 years) was higher than the IDUCS sample median age (44 years). 
To ensure that our qualitative data reflected a more comparable distribution of participants by 
age, the last session recruited participants under the age of 30 years old. For this session we used 
snowball sampling, where one participant recruited other individuals under the age of 30. We 
were successful and reduced the group median age to 44 years of age.  
 
Focus Group Procedures 
Focus groups were led by the two researchers, both with expertise in SEPs and facilitating 
groups with PWID. The focus group followed an open-ended facilitators guide, which was 
designed to discuss three main topics: 1) what makes a place public versus private for injection 
drug use; 2) what factors influence where a PWID injects drugs; and 3) risks associated with 
injecting in public places. Groups were audio-recorded and lasted approximately 60 minutes. 
Participants were provided with a $10 pharmacy gift card for their participation.  
 
Focus Group Data Analyses 
Focus group audio recordings were transcribed by the two researchers and reviewed for 
accuracy. We used a multi-step process to analyze the focus group data using thematic 
analysis.267–269 First, we independently reviewed the transcripts for general themes. Then, we met 
to discuss the general themes related to the study objectives.  Using grounded theory, we came to 
consensus on what the key themes through discussion and enhanced definition. The most 
frequently discussed themes that emerged included; 1) defining privacy; 2) risks by public place 
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of injection; 3) risks by private place of injection; and 4) components that make a place safe. 
Both team members applied parent codes (key themes) and child codes (sub-themes) to all five 
transcripts. The lead researcher conducted member checks with three unique individuals and 
presented the definitions and key themes for clarity. All analyses were conducted using Dedoose 
™,186 a cross-platform qualitative and mixed method analytic software system, to code and 
excerpt narratives from the focus group sessions.  
 
3.2.3 Data Integration 
We used the findings from the qualitative sub-study to understand what makes a place public 
versus private from the perspective of PWIDs to have the most culturally accurate definition of 
public injection drug use for the quantitative analyses. Then, we reviewed the data for key 
themes related to public places to determine what other variables may be critical to include in the 
quantitative analyses. We selected narratives that described the relationship between the 
variables and places of injection drug use that participants identified as public, including how the 
factors were related to each other. We learned that, consistent with the risk environment 
framework, that there are competing perceived risks depending on the place of injection drug use 
and that these risks impede the ability for PWID to practice safe injection techniques. The rich 
narratives of the qualitative sub-study could provide an in depth discussion of how PWID define 
privacy or how different social, environmental, and health factors influence and explain risk 
behavior. However, for the purposes of this study, we describe factors associated with public 
injection drug use and some preliminary discussion of how these factors may be related to risky 
injection practices.   
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3.2.4 Statistical Methods 
We first describe the characteristics of the sample, including the prevalence of public versus 
private injection. Then, to determine characteristics associated with public injection versus 
private injection, we conducted bivariate logistic regression to produce odds ratios to measure 
associations of all 25 explanatory variables and public versus private injection. We reviewed 
odds ratios, 95% confidence intervals, and p-values to guide our interpretation of associations. 
We adopted an alpha of .05 to guide interpretation of significant findings. All statistical analyses 
were conducted using SPSS Statistics version 24.225   
 
3.3 Results 
The nature of the multi-phase design in mixed-methods research involves an iterative process of 
using two different sources of data to describe different aspects of one phenomenon. In this 
study, we used a qualitative sub-study to inform both the methodology of the study and describe 
the quantitative results of the study. For clarity, we are presenting the findings from the 
qualitative sub-study first to describe how we defined public injection drug use and which factors 
to include in the quantitative analyses. Then, we will present the main findings from the 
quantitative study to report characteristics associated with public injection.  
 
3.3.1 Qualitative Sub-Study Results 
We developed the qualitative sub-study design to define public injection drug use as the primary 
outcome variable, select variables to include in the quantitative analyses, and describe the 
environment where PWID inject as it relates to risk behavior.  
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Defining Public Injection 
Previous studies have described public injection in a variety of ways, ranging from only street-
injection drug use to multi-level categories of public injection drug use, including ‘public’, 
‘semi-public’, and ‘private’ places.25,157 We felt it was important to have a definition of public 
injection that was developed using narratives of PWID to ensure that it was relevant to NYC 
environments where people inject and derived from people who have experience injecting in 
public places. We reviewed excerpts from the section of the focus group that discussed what 
makes a places private for injection drug use, which we conceived of as the opposite of what 
would make a place public.  
 
Key Themes 
We identified four key themes related to what makes a place public versus private: physical 
features, control over who has access to the space, trust in the people who are present in the 
space, and exposure to being seen or arrested. What made a place public or private was a 
combination of these themes.  
 
 
Physical features. Participants were asked explicitly what made a space public and what made a 
space private. Some descriptions were related to physical features of a space:  
 
“Nobody has a key, curtains on the windows…” 
“The doors have double locks… mine has like seven” 
“Walls all around you so people can’t see” 
	 68	
 
Sense of control. Some descriptions included physical features but described a sense of control 
over the space, including the ability or right to a space, such as “you pay rent”, “ownership”, or 
“on the lease” of a space.  
 
“…you’re the only one that goes in there, its your apartment, you have keys, your lease, its not 
an SRO, its not a building like a shelter building like the [name of transitional housing 
residence] stuff where people are in and out…its yours. Your name on the lease, you decide who 
comes and who goes…” 
 
Trust in people who are in the space. There was some discrepancy about whether having a 
dedicated room was considered private. Some participants felt that a room in an apartment with 
roommates or supportive housing was not private:  
 
“…What makes it private for me is that you don’t have to give up some of your privacy for 
somebody [to] get in your house, like that right there, where you can walk around naked you can 
walk around in your underwears when its hot, I’m just saying if you have someone in your house 
that your renting to so that means you’re shutting down your privacy…” 
 
“Well, I live in a different room but the other rooms you have to be let in with a key by the 
security or whoever you want to call them… so I don’t know if I’d consider that private because 
its not your private place…” 
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However, some participants described knowing who was in the space was the element of control 
that was the most important consideration. In the following excerpt, one participant describes the 
impact of knowing and trusting who was in the space even if behind a closed door: 
 
“…your home bathroom, your boyfriends bathroom, your friends bathroom, so long as there’s 
someone you can trust that’s not gonna call the cops on you… and if you think they’re gonna call 
the cops on you just put the lock on the door and make sure you have the window open so you 
can throw the needle out when the cops come…” 
 
“… if you have your own room, that’s privacy right there. So long as you can lock the door and 
you know who is out there, I’d say that’s private.” 
 
Exposure to being seen or arrested. Throughout all five focus group sessions, policing were 
significant frameworks of the day-to-day reality of decision-making related to injection drug use. 
Most of the narratives related to whether a space was private or public was discussed in the 
context of avoiding being seen, primarily by law enforcement: 
 
“So long as you know who is out there and nobody is watching you, its private. If someone is 
watching you, it could be more on the public side… but if you have some time, that’s really what 
its about for me (the privacy)…” 
 
“…in my house and I don’t have to worry about somebody watching me, or like he said the 
cops…” 
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We learned that while the combination of these key themes made a place public or private, if a 
place had physical features of privacy but was high on the spectrum of potential arrest or not 
having a sense of control, it was identified as public. We saw this in the majority of the 
narratives that identified non-residential places as public, even if they had some of the physical 
features of privacy. It was clear that ‘Own Place’ was considered private and, while there were 
some discordant perspectives, ‘Home of a friend or family member’ was categorized as a private 
place due to reduced likelihood of arrest and some expected knowledge of who was in the space. 
While a shooting gallery may be a residence, participants expressed in all focus groups that there 
was increased risk for arrest and general distrust in other PWIDs at shooting galleries. The other 
categories of place of injection drug use were considered public. We define a public place in the 
context of injection drug use as “any place where a PWID has a low sense of control of who can 
access the space and how long they have to prepare, administer, and clean up after an 
injection.” 
 
Factors Associated with Public Injection Drug Use 
Participants in all sessions acknowledged that injection drug use is not safe and that “safety” of a 
place depended on “safe from what”. Participants described their experiences of injecting in a 
public place (see Figure 3A). The four key themes associated with public injection include fear 
of arrest, level of withdrawal, fear and shame of ‘being caught’ or ‘seen’, and rushing injections. 
Rushing injection was often described in the context of the first three key themes, but also 
related to preparation and use of sterile injecting equipment. For this reason, we maintained it as 
a separate key theme to describe the interplay between fear of arrest, level of withdrawal, and 
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being caught or seen. The narratives related to rushing injections also explain the mechanism of 
risk for inadequate preparation and injection-related risk behavior. The more a participant is 
fearful of arrest, in withdrawal, or avoiding being caught, the more likely they are to rush 
injections. If they are rushing an injection, they are less likely to prepare the injection site and/or 
use sterile injecting equipment. The key theme associated with private injection was fear of 
overdose. Participants described that the primary concern injecting in a private place was a fear 
of overdosing and not having a bystander to call 911 or administer naloxone, an antidote for 
opioid overdose.  
 
Based on these findings, we included measures of overdose history, drug treatment, and mental 
health in the subsequent quantitative analyses. We also include two measures of taking either 
methadone or buprenorphine not prescribed as potential proxies for withdrawal. Many 
participants described these as strategies for coping with withdrawal and have been described in 
the literature.270 
 
3.3.2 Quantitative Study Results 
Sample Characteristics  
Characteristics of participants in the survey sample are presented in Table 1. Over half of 
participants (64%) reported injecting in a public place in the past three months. Nearly three 
quarters of the sample were male (73%) and two–thirds (66%) were under the age of 50 years 
old. Over half of the sample was Latino (52%). Less than one third was stably housed (29%). 
Public injectors were significantly more likely to be male, under the age of 50, white, and 
unstably housed or homeless compared to private injectors.  
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There were several factors associated with public injection drug use. In the bivariate analyses 
(see Table 2), being male, under the age of 40, non-black, homeless or unstably housed, arrested 
or incarcerated in the past year were significantly associated with public injection. All measures 
of overdose (lifetime, past year, and witness) were also significantly associated with increased 
odds of public injection. The use of alcohol, heroin, or cocaine in the past 30 days were 
associated with public injection. While participants who were enrolled in methadone programs 
were 34% less likely to report public injection, participants who had bought methadone off the 
street or from a friend were 120% more likely to report public injection. Unlike methadone, 
being prescribed buprenorphine was not associated with decreased odds of public injection but 
increased odds, although not significantly. Having a primary care provider (PCP) decreased the 
odds of public injection by 64% compared with participants who did not have a PCP. Not 
surprisingly, having been admitted to the ER in the past year increased the odds of public 
injection drug use by 50%. Lastly, participants who reported sometimes having hallucinations 
were significantly more likely to report public injection.  
 
3.4 Discussion 
This is the first study in the US to focus specifically on public injection drug use. Our findings 
offer an enhanced definition of what aspects of a physical and social environment make a place 
public defined by PWID. They also contextualize the environment where injection drug use takes 
place and describe how injecting in a public place increases risk behavior. The findings offer a 
new and valuable perspective to inform future interventions and require both health, housing, 
and drug policy reform. 
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There are five main findings in this study. First, over half (64%) of the participants in the survey 
reported public injection drug use. Public injectors were significantly more likely to report 
homelessness and unstable housing, past year arrest or incarceration, overdose experience, 
alcohol use, heroin use, cocaine use, enrollment in a methadone program, taking methadone not 
prescribed, taking buprenorphine not prescribed, past year ED admission, and hallucinations 
compared with non-public injectors. Public injectors were also significantly less likely to report 
they had a primary care provider (PCP). In short, consistent with international studies150,212, 
public injectors have a higher risk profile compared with non-public injectors. In the qualitative 
analyses, we identified four key themes associated with public injection; fear of arrest, level of 
withdrawal, fear and shame of ‘being caught’ or ‘seen’, and rushing injections. These findings 
expand upon Chapter 2, which identified that public injection was associated with receptive 
sharing of injecting equipment, by further illustrating the role of the physical and social 
environment that may result in risky injection practices. Our findings support the potential 
benefit of implementing SIFs in NYC. As described in earlier in this chapter, SIFs may minimize 
risky injection practices and fatal overdose by offering a sanctioned and supervised space for 
drug use. Furthermore, the implementation of SIFs may support existing health care reform 
efforts261 to connect high risk individuals to a usual source of care and, in turn, reduce 
preventable ED admissions. Acceptability studies have found that PWID would utilize a SIF if 
one were available.178,250,271,272 In addition to preventing new infections and reducing ED 
admissions, SIFs are cost effective. A recent study in San Francisco found that one SIF may save 
the city $3.5 million per year by averting new cases of HIV infections alone.177 Given that 
injection-related infections can result in longer and more costly hospital admissions13, a SIF may 
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also contribute to cost savings by preventing SSTIs. The establishment of a SIF may minimize 
risks associated with public injection and provide a hub for high risk PWID to connect with other 
services.  
 
Second, unstable housing is the strongest factor associated with public injection drug use. Nearly 
half (45%) of participants in the focus group sessions and over two-thirds (71%) of the 
participants in the survey reported they were unstably housed. While we found that some 
participants who reported they were stably housed injected in public places, unstable housing is 
the characteristic most strongly associated with public injection. In the qualitative sub-study, the 
majority of the participants were stably housed but reflected on recent instances of injecting in 
public places. Housing is a critical social determinant of health and may be a root cause of 
compounded health and social risks.273–275 Consistent with research on HIV prevention and risk 
behavior, unstable housing is associated with a myriad of health risks.276–278 These risks include 
risky injection practices, sexual practices, experiences of violence, mental health 
symptoms.274,279,280 Very practically, a person who is unstably housed does not have a consistent 
place to inject drugs or store sterile injecting equipment. In NYC, housing options for PWID are 
limited. Most services offered for homeless or unstably housed adults require ongoing abstinence 
from drugs and alcohol in order to receive services. Particularly in congregate housing settings 
for groups of people, abstinence is required in order to prevent disruptions and ‘contamination’ 
of other co-habitants who may be in recovery. However, we know that the ‘all or nothing’ 
abstinence-based approach to housing placement contributes to a cycle of homelessness for 
many. Housing First (HF) models124,125,228,281, as opposed to the aforementioned ‘treatment first 
models’, aim to prioritize permanent housing as quickly as possible before supportive services.  
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HF models typically target homeless people with co-occurring mental health and substance use 
disorders and does not require abstinence. Studies have shown that HF is a cost-effective 
approach to engaging and retaining homeless adults in permanent housing, but is far from 
widespread.282 Given the risks associated with public injection drug use and high prevalence of 
unstable housing in this study, adopting and expanding HF models may be one strategy to reduce 
public injection drug use.   
 
Third, PWID reported that fear of arrest as a primary factor taken into consideration when 
determining whether a place was ‘safe’ to inject. The quantitative analyses indicated that public 
injectors were twice as likely to report past year arrest or incarceration. Since our study is 
observational, we cannot infer causality. However, it may make the most theoretical sense that 
public injection increases the odds of arrest; if a PWID is injecting in public, they may be 
targeted by law enforcement. We added an additional survey question in the focus group sessions 
to inquire if, among participants who reported past year arrest, their arrest had been cited as 
public drug use; over one quarter (27%) reported their arrest was cited as public drug use. This is 
consistent with other studies on syringe access; police presence and fear of arrest impede a 
PWIDs ability to obtain and store sterile injecting equipment and apply safe injection 
practices.94,211,283,284 In recognition of the existing drug policies and war on drugs in the US, 
approaches to reducing public injection drug use must be accompanied by drug policy reform. 
One approach is to decriminalize all drugs. In 2001, Portugal decriminalized all drugs. Contrary 
to initial opponent beliefs, drug use decreased and drug treatment uptake increased during the 
first decade.235–237 In the absence of decriminalization, strategies to promote diversion to support 
programs in place of arrest and incarceration may be more effective. The SIF in Vancouver was 
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one component of a municipal drug strategy based on four principles; harm reduction, 
prevention, treatment, and enforcement. The latter focused on promoting education, community 
safety, and cooperation with local law enforcement to direct PWID to the SIF instead of 
handcuffs. Similar initiatives in the US, including Law Enforcement Assisted Diversion (LEAD), 
have demonstrated success in early pilot programs.118 In tandem with HF models, addressing 
substance use as a public health issue instead of a criminal justice issue will promote engagement 
and retention in support services for PWID.  
   
Fourth, PWID may choose to inject in public due to fear of overdose. While there was some 
discordance on whether or not injecting in a public place was ‘safer’ to avoid fatal overdose, we 
found that individuals who had reported lifetime overdose, past year overdose, and witnessing 
overdose were more likely to report public injection. There may be several explanations for this 
association. First, participants who are rushing injections in public places may be less likely to 
adequately prepare and review how much they are injecting. Another explanation may be that 
having experienced or witnessed an overdose may impact awareness or fear of overdose, and 
incentivize injecting in a public place to increase the odds of being found if they overdose. 
Several participants described public places as safer in this regard. Participants also described the 
extent to which a person was experiencing opioid withdrawal as being a key factor in 
determining where to inject. The most in withdrawal, the more likely to inject in a public place. 
Not surprisingly, heroin use and using methadone and buprenorphine not prescribed were 
associated with public injection drug use. While cocaine use does not cause withdrawal, it is 
likely significantly associated with public injection due to the increased frequency of cocaine 
injections and, in turn, injection episodes per day. Enrollment in a methadone program was 
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protective against public injection. Expanding access to medication assisted therapy (MAT) may 
be one strategy to minimize public injection drug use. MAT has been effective in reducing 
injection drug use to minimize injection-related risk but access remains limited due to limited 
availability of trained providers.135,285 Methadone treatment reduces both cocaine use and 
injection frequency, which may have implications for minimizing injection related risk.286 Lastly, 
having a PCP is associated with decreased odds of public injection while ER admission is 
associated with increased odds of public injection. In consideration of the recent healthcare 
reform initiatives in New York to prevent emergency room admissions and improve access to 
primary care, our study further describes that being connected to primary care may be another 
strategy to connect with PWID to reduce risk of ER admission.287–289 As we mentioned, the 
implementation of SIFs, HF models, and diversion programs are health and drug policy 
interventions that have been demonstrated to connect PWID with support services.  
 
Lastly, this study offers a new definition of public injection drug use that is derived from 
narratives of PWID. What makes a place public is a combination of physical attributes and the 
social environment. The majority of participants spent time describing that control over a space 
is most central to whether or not it is private or public. The physical attributes, including having 
a lock or doors, were secondary and described as components obtaining control. Control was 
described as being able to take your time, knowing who to expect in a space, and generally being 
able to “relax” and “be yourself”. Several participants described that one benefit of injecting in a 
private place compared to a public place is not being judged by others. This is consistent with the 
international literature describing experiences of injecting in public.266,290 Participants also 
generally described having privacy and control as inconsistent in their lives. A general sense of 
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lack of control may be related to perceived self-efficacy, which is an important characteristic in 
promoting behavior change to improve health and wellness among PWID.291   
 
There are several limitations in this study. Our study is observational and cannot infer causality. 
We utilized convenience sampling for both the focus groups and survey and, therefore, may 
present a volunteer bias. Participants in this study were already connected to SEPs and may not 
represent the higher risk and disengaged PWID. However, these limitations may impact our 
findings in that they are only conservative estimates and actual risk may be higher among public 
injectors who are not engaged in any services. One of the primary strengths is the mixed-
methods approach to inform the categories of place of injection drug use by PWID themselves. 
We were able to include additional variables beyond what we learned in previous research on the 
topic to determine differences in risk behavior based on narratives from the focus group sessions. 
The study design and inclusion of additional variables are an appropriate strategy to understand a 
complex phenomenon such as public injection drug use.  
 
Conclusion 
 
PWID are injecting in public places in NYC. Public injectors are associated with a higher risk 
profile compared with non-public injectors. The reasons for public injection are complex and 
involve a combination of inadequate access to housing, stigma, fear of arrest, and fear of 
overdose. PWID are aware of how to apply safe injection practices but report that they are 
unable to do so under the existing circumstances. Solutions to minimize public injection drug use 
are complicated and involve reform of existing health policies, drug policies, and housing 
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policies. SIFs offer an evidence-based approach to address many of the reported contextual 
issues related to applying safer injection practices. In light of the hepatitis C and overdose 
epidemics, it is critical to explore the implementation of SIFs and take steps to reform existing 
health, drug, and housing policies to reduce risks and costs associated with injection drug use.  
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Table 3A. Sample characteristics and a comparison of participants reporting public injection drug use among 
PWID in the IDUCS survey (n=755) 
  
             
  Total  No Public 
Injection 
 Public 
Injection a 
   
  N %  N %  N %  Chi-
Square 
p-value 
            
TOTAL  755 100%  275 36%  480 64%    
Gender*             
Male  548 73%  187 68%  361 75%  4.57 0.034* 
Female  207 27%  88 32%  119 25%    
Age***             
Under 30  97 13%  20 7%  77 16%  50.84 <0.001*** 
30 to 39  171 23%  40 15%  131 27%    
40 to 49  235 31%  83 30%  152 32%    
50+  252 33%  132 48%  120 25%    
Race/ethnicity*           10.99 0.012* 
white  198 26%  62 23%  136 28%    
black  120 16%  59 21%  61 13%    
Latino  394 52%  138 50%  256 53%    
other  43 6%  16 6%  27 6%    
Housing Status b ***   0%        125.15 <0.001* 
Homeless  222 29%  33 12%  189 39%    
Unstable  315 42%  100 36%  215 45%    
Stable  218 29%  142 52%  76 16%    
             
 
*** p<.001  **p<.01   *p<.05 
a Public injection is defined as having injected in one of the following places in the past three months: street or 
park, stairwell, abandoned building, public bathroom, bus/train/subway, car or vehicle, SEP bathroom, or 
shooting gallery   
b Housing status defined as homeless (street homeless), unstable housing (jail, prison, rooming with others, 
shelter, temporary housing, hospital, drug treatment), stable housing (own home or live with friend/family 
member) 
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Table 3B. Bivariate associations between participants characteristics and public injection drug use among 
PWID in the IDUCS (N=755) 
       
Participant 
Characteristics     
Number reporting public 
injectiona /N with 
Characteristic (%) OR 95% CI p-value 
Demographics       
Gender* Male  361/548 (65.9) 1.43 1.03-1.98 .03 
 Female  119/207 (47.8)    
       
Age*** Under 40  208/268 (77.6) 2.74 1.95-3.84 <.001 
 40 or older  272/487 (55.9)    
Race/Ethnicity* white  136/198 (68.7) -   
 black  61/120 (50.8) 0.47 .30-.75 .01 
 Latino  256/394 (65.0) 0.85 .59-1.22 .37 
 other  27/43 (62.8) 0.77 .39-1.53 .77 
Housing Statusb ***       
 Homeless  189/222 (85.1) 10.70 6.74-17.00 <.001 
 Unstable/Temporary  215/315 (68.3) 4.02 2.79-5.79 <.001 
 Stable  76/218 (34.9) -   
Past year arrest***       
 Yes  247/329 (75.1) 2.50 1.82-3.42 <.001 
 No  233/426 (54.7) -   
Overdose        
Lifetime*** Yes  255/360 (70.8) 1.84 1.36-2.49 <.001 
 No  224/394 (56.9) -   
Past Year* Yes  87/110 (79.1) 1.89 1.11-3.22 .02 
 No  162/243 (66.7) -   
Witness** Yes  260/379 (68.6) 1.54 1.14-2.08 .01 
 No  220/375 (58.7) -   
Past 30 days drug use       
Alcohol** Yes  195/279 (69.9) 1.56 1.14-2.13 .01 
 No  285/476 (59.9) -   
Methadone Yes  320/513 (62.4) 0.85 .62-1.17 .32 
 No  160/242 (66.1) -   
Heroin** Yes  415/626 (66.3) 1.94 1.32-2.84 <.001 
 No  65/129 (50.4) -   
Opioid Analgesics Yes  100/168 (59.5) 0.80 .56-1.14 .22 
 No  380/587 (64.7) -   
Crack Yes  117/173 (67.6) 1.26 .88-1.81 .21 
 No  363/582 (62.4) -   
Cocaine** Yes  206/291 (70.8) 1.68 1.23-2.30 <.001 
 No  274/464 (59.1) -   
Methamphetamine Yes  18/25 (72.0) 1.49 .62-3.62 .38 
 No  462/730 (63.3) -   
Benzodiazepines Yes  182/282 (64.5) 1.07 .77-1.45 .67 
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No  298/473 (63.0) -   
Participant 
Characteristics     
Number reporting public 
injectiona /N with 
Characteristic (%) OR 95% CI p-value 
Methadone Program 
Enrollment** Yes  268/449 (59.7) 0.66 .48-.89 .01 
 No  212/306 (69.3) -   
Methadone Not 
Prescribed**  Yes  82/105 (78.1) 2.26 1.39-3.68 <.001 
 No  398/650 (61.2) -   
Bupe Prescribed Yes  26/34 (76.5) 1.91 .85-4.28 .12 
 No  454/721 (63.0) -   
Bupe Not Prescribed* Yes  32/39 (82.1) 2.74 1.19-6.28 .02 
 No  448/716 (62.6) -   
Have a PCP*** Yes  140/249 (56.2) 0.37 .23-.59 <.001 
 No  109/140 (77.9) -   
ER Past Year** Yes  265/389 (68.1) 1.50 1.11-2.02 .01 
 No  215/366 (58.7) -   
Mental Health       
Depression  Often  170/261 (65.1) 1.14 .81-1.60 .45 
 Sometimes  115/180 (63.9) 1.08 .74-1.58 .70 
 Never  195/314 (62.1) -   
Anxiety Often  191/298 (64.1) 1.07 .76-1.50 .70 
 Sometimes  112/174 (64.4) 1.08 .73-1.60 .70 
 Never  177/283 (62.5) -   
Hallucinations*  Often  22/34 (64.7) 1.11 .54-2.28 .78 
 Sometimes  52/69 (75.4) 1.85 1.05-3.28 .03 
 Never  406/652 (62.3) -   
       
*** p<.001  **p<.01   *p<.05 
 
 a Public injection is defined as having injected in one of the following places in the past three months: street or 
park, stairwell, abandoned building, public bathroom, bus/train/subway, car or vehicle, SEP bathroom, or 
shooting gallery   
b Housing status defined as homeless (street homeless), unstable housing (jail, prison, rooming with others, 
shelter, temporary housing, hospital, drug treatment), stable housing (own home or live with friend/family 
member) 
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Figure 3A: Key themes and sample excerpts related to public injection versus private injection  
Key Theme Sample Excerpts Relationship to Outcome 
Variable Category 
Fear of Arrest: Participants most 
often described rushing injections in 
the context of avoiding arrest or being 
‘seen’ or ‘caught’. 
 
 
 
“Their past, their inhibitions, their 
drugs, they don’t give a shit where 
they inject, anywhere is safe for them 
as long as they don’t get arrested. 
That’s what makes it safe. Not 
getting arrested, so you can actually 
get that shot in that you’re trying to 
inject.” 
 
“[discussing a public bathroom] You 
know, you take a long time, you got 
people knocking on the door cause 
they’re waiting to use the bathroom 
and then like she said you can hit 
yourself in the wrong place, and you 
take even longer in there cause you 
know somebody’s waiting outside 
and you get all nervous”  
 
 
Public Injection 
Overdose: Participants described 
overdose as a risk they considered 
based on where they were injecting. 
However, there was not consensus 
whether there was higher or lower risk 
of overdose in a public places or a 
private place. 
One participant described a public 
bathroom or syringe exchange 
program bathroom as being 
protective against fatal overdose: 
 
“[speaking about a bathroom with 
multiple stalls]… alright so you 
could say it’s a little bit more safer 
because someone could actually help 
you if something did happen… that’s 
the only thing that I can think about 
because there are people around that 
could actually help you if you OD” 
 
“Well, the bathroom here [Syringe 
Exchange Program] you’re safe, 
because they check up on you. So, 
you safe, like, if you’re in your house 
and you shoot up in your house and 
nobody knows you shoot up in your 
house, you use and you OD…how 
they hell do they know that you OD, 
they don’t know that you use drugs, 
Private Injection 
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they say “wait a minute man, this 
guy been here more than this should 
take (knocking noise) they say “You 
ok?” (knocking sound)… there’s 
NARCAN right outside” 
 
In the same group, another 
participant described that the risk of 
fatal overdose can be just as high in 
a public place, even if there are 
bystanders around due to fear of 
arrest:  
 
“…And every time I used to go to the 
[park], and people were there 
smoking or whatever, they used to 
run out, they didn’t wanna be by 
when I was there, cause if I did OD 
and die, they didn’t wanna be an eye 
witness or nothing, they used to run 
out…” 
 
 
 
Drug Treatment & Withdrawal: 
Participants also described the level of 
opioid withdrawal a participant was 
experiencing, also referred to as “dope 
sickness”, was an important in-the-
moment consideration for where 
people injected drugs. Participants 
described tactics to avoid dope 
sickness, including buying methadone 
or buprenorphine if they were unable 
to procure their drug of choice. The 
more dope sick a PWID was, the more 
likely they were to inject in a public 
place. 
 
 
“how am I supposed to focus on 
anything I’m supposed to do if I’m 
spending two hours in the morning 
trying to get straight…then the rest 
of the day I’m just trying to feel 
normal and not let anyone see what 
I’m doing. It’s exhausting…” 
 
“… sure, if I had those pills, the 
one’s that go under the tongue, I 
might keep one of them just in case… 
my friend has some, I know where to 
get them, its not that hard… but only 
if you can’t cop…” 
 
Public Injection  
Fear and Shame of Being ‘Seen’ or 
‘Caught’: Participants in every group 
discussed the importance of avoiding 
injecting in public so others would not 
“need to see that”. There was a lot of 
concern related to being seen by 
children, or others injecting in public 
and leaving discarded syringes. Several 
participants described attempting to 
prevent others from injecting in places 
where there was a high likelihood of 
 
“… there’s some people that just 
look at you like, wow, there he goes 
just not caring and throwing his 
works over there… I try to avoid 
using anywhere where’s there be 
kids at… they don’t need to see that, 
don’t need to see me disgusting and 
doing bad things.” 
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being seen by children. The tone in all 
sessions when describing children or 
the perception of the general public 
was somber and slow. Often in the 
same breath, participants would 
describe the shame or guilt they felt 
about injecting in public places. 
 
“…you know, I never wanted to do 
this but I do and now people see me 
like a menace in society, running 
around not giving a shit, can’t take 
care of myself… I wouldn’t want to 
see me either in their 
neighborhood… more and more 
every day I think maybe it’s getting 
better and then BAM I’m right back 
there injecting out there… ” 
 
 
Rushing Injections: Participants 
described both anxiety related to 
injecting in a public place, being 
hurried and/or “paranoid” or 
“scatterbrained” because of the fear of 
arrest or being seen. Participants also 
described that they were unable to 
focus and take the time they needed to 
prepare and and safely administer an 
injection. This was mentioned several 
times in the context of also storing 
previously used injecting equipment to 
avoid arrest versus going to a syringe 
exchange to get clean syringes.  
 
There was very little unprompted 
discussion related to access to 
syringes, reuse of injecting 
equipment, and general risk of 
bloodborne pathogens. However, 
when prompted to describe if there 
were differences in access to 
supplies or ability to prepare an 
injection, participants consistently 
shared that injecting in a public place 
means rushing injections: 
 
“doesn’t let you focus on that – it 
takes a back seat if you worried 
about the police…all you’re thinking 
about is get your hit without getting 
hit up”. 
 
“here at the [site name] they got 
everything you need… in the 
bathroom you can take your time… 
when you’re out there on the streets, 
sometimes in between cars or 
whatever, the last thing I’m thinking 
about is using those cookers and ties 
because shit I don’t got time for that 
if somebody be watching me… 
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Chapter	4:	Calculated	risks	and	trade-offs:	the	experience	of	public	
injection	drug	use	and	attitudes	towards	supervised	injection	facilities	
 
4.1 Introduction 
The population of people who inject drugs (PWIDs) is growing. New York City (NYC) has the 
largest population of PWIDs in the United States (US).61,189,226 PWIDs are at risk for a variety of 
adverse health outcomes; transmission of HIV and viral hepatitis C (HCV), bacterial infections, 
endocarditis, abscesses, and opioid overdose. At a time when overdose rates are at an all-time 
high and new outbreaks of HIV and viral hepatitis C (HCV) attributed to injection drug use, the 
need for expanded evidence-based interventions and new initiatives to address injection-related 
harm is critical.     
 
In New York City (NYC), there are approximately 105,000 PWID.176,245 A recent study found 
that 64% of PWID surveyed reported that they had injected in a public place in the three months 
preceding the survey. PWID that inject in public places (i.e. street, parks, public restrooms) 
report higher risk behavior than PWID who do not inject in public places (i.e. own home, 
residence of a friend or family member).150,212,229 Public injectors tend to be younger, homeless 
or unstably housed, and are more likely to report they had witnessed or experienced and opioid 
overdose in the past year (Chapter 3). They are also more likely to report that they had been 
arrested or incarcerated in the past year. Public injectors are also more likely to report they had 
been admitted to the emergency department (ED) in the past year, but less likely to have a 
regular source of primary care. Beyond these health risks, PWID who inject in public report 
experiences of shame and internalized stigma.103,169,173  
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In addition to the health and social consequences of public injection for PWID, there are health 
and safety ramifications for the community at large. First, public injection drug use is associated 
with increased presence of improperly disposed injecting equipment, including 
syringes.158,212,271,283 Used syringes in parks or public trash receptacles may result in an 
accidental needlestick injuries which may lead to the need for post-exposure prophylaxis, which 
can be expensive and cause adverse side effects.292–294 PWID may leave improperly discarded 
injecting equipment behind due to fear of arrest for carrying injecting equipment with drug 
residue.158,167,233,295 Syringe possession laws vary by state and municipality and create a barrier to 
obtaining and returning injecting equipment to hazardous waste collection sites. Second, the 
consequences of risky injection practices may lead to preventable abscesses and wounds that are 
often treated in the ED and result in costly hospital stays.13,80,296 In one study, a public hospital 
found that injection-related infections accounted for $11.5 million in overall hospital costs.13 
Further compounding cost, if a PWID contracts HIV or HCV, the average lifetime cost of 
treatment for HCV is $64,490 (depending on the genotype)70 and $379,00059 for HIV. The 
majority (90%) of participants of syringe exchange programs (SEPs) in NYC receive publicly 
funded insurance.74 Minimizing public injection drug use has potential life and cost saving 
benefits for PWID and the communities in which they reside.   
 
In the US, the unprecedented increases in opioid overdose and new cases of HIV and hepatitis C 
among younger injectors is sparking a national discussion about the efficacy of existing drug 
policies and interventions. Several states of authorized SEPs as a result of declaring public health 
emergencies due to new outbreaks of HIV infection attributed to injection drug use.16,62,190 In 
early 2016, the long-existing ban on federal funding for syringe exchange programs was 
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lifted.147,297 While SEPs are included as a key component in both state and federal HIV and HCV 
prevention guidelines, they do not address the issue of public injection. Public injection drug use 
has been effectively minimized in over 100 cities around the world by implementing supervised 
injection facilities (SIFs).149 SIFs are sanctioned spaces where PWID may bring their own pre-
obtained drugs to inject under the supervision of healthcare staff. SIFs aim to reduce public 
injection and, in turn, reduce risky injection practices that lead to HIV, HCV, and bacterial 
infections, fatal overdose, and connect PWID with support services. Research has documented 
that SIFs effectively address all of the above and save money.153,170,171 Contrary to what 
opponents posed as potential threats before the establishment of a SIF, they do not increase 
crime, public nuisance, or drug use.153 PWID who access SIF services are twice as likely to enter 
drug treatment compared with PWID who do not access SIF services.162,229,298  
 
In the past year, several cities have started to introduce legislation and funded feasibility studies 
to authorize the establishment of SIFs.299–302 Medical professionals, researchers, and elected 
officials have written about the potential benefits of implementing SIFs, particularly in response 
to the growing opioid overdose epidemic. One recent study estimated that San Francisco would 
save $6 million per year by averting new cases of HIV if one single SIF were established.177 
Some SEPs are already operating as de-facto SIFs, operating the bathrooms on the premises as 
underground pseudo-injection sites.303 While there is no law prohibiting the establishment of a 
SIFs in the US, a complex set of federal, state, and municipal policies and laws serve as potential 
barriers to opening and operating a SIF without fear of prosecution.304  
 
89 
 
One of the key questions to answer as the US considers establishing SIFs is whether PWID 
would use such services. Prior to opening SIFs in other countries, studies showed that PWID 
overwhelmingly reported that they would use a service if it were available to them.152,166,305 
Perceived impacts on how a SIF would change their injection practices include beliefs that they 
would increase the likelihood of hand washing before and after, using sterile supplies, and not 
rushing injections.305–308 Acceptability of using a SIF across these pre-implementation studies is 
high, with over 86% reporting they would use a SIF if it were available.150,165,309 Post-
implementation, the SIF in Vancouver, Canada has supervised over one million injections and 
had not resulted in any overdose deaths.171  
 
In the US, research on feasibility and acceptability of a SIF is limited. One study of PWID who 
inject prescription opioids in Rhode Island indicated that 63% would use a SIF if it were 
available310; and earlier study of PWID in San Francisco indicated 85% would use a SIF, and 
75% of those individuals reported they would use it at least three times per week.178 Willingness 
to use a SIF was associated with recent homelessness, accidental overdose, heroin use, non-
medical use of fentanyl, and using prescription opioids alone.310 There have yet to be any studies 
on SIF feasibility in New York, home to the largest population of PWIDs.  
 
In this study, we aim to understand and describe the experience of public injection drug use 
among PWID enrolled in SEPs in NYC. We also describe initial attitudes towards the concept of 
a SIF, how a SIF many change their current experiences injecting drugs, and whether they would 
use a SIF if it were available to them.  
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4.2 Methods 
4.2.1 Participants 
The study was conducted in July 2015 in two syringe exchange programs (SEPs) in NYC. We 
conducted five focus group sessions at two different SEPs in NYC. We recruited participants 
using convenience sampling in the drop-in centers of both SEPs during times when syringe 
exchange services were offered. We promoted the focus groups the day of the focus group 
session to capture individuals who were representative of receiving services on a weekday 
afternoon. Eligibility criteria included 1) currently enrolled as a participant of the SEP, 2) over 
the age of 18-years old, 3) ability to speak English, 4) ability to provide written, informed 
consent, and 5) report injection drugs in the past three months preceding the focus group session.  
 
The lead researcher and research assistant met with participants individually to determine 
eligibility and describe the purpose of the focus groups. Eligible participants provided written 
informed consent, read aloud by the research team member to ensure clarity. Consented 
participants were assigned to a focus group session. No focus group session permitted more than 
8 individuals and ranged from 5 to 8 participants. Participants were given a $10 gift card for their 
time. This study was approved by the Institutional Review Board at the City University of New 
York City College.  
 
4.2.2 Study Sites 
One of the SEPs has a 21-year history of providing syringe exchange services to PWID in 
Manhattan and the Bronx via street-based and mobile-unit outreach. The other SEP has been in 
operation for less than half of the time (8 years) and services a smaller geographic area in 
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Northern Manhattan only. Both organizations offer drop-in center services, care coordination, 
onsite HIV and hepatitis C testing, and have bathrooms available for participants of the program.  
 
4.2.3 Focus Group Procedures 
The lead researcher facilitated all of the focus group sessions with assistance provided by a 
research assistant. Both individuals have experience facilitating groups with PWID in NYC and 
with syringe exchange services. The research assistant took notes on participation of each 
participant and general a priori themes discussed prior to the session. Once the focus group 
sessions commenced, participants were asked to complete a 14-item survey with measures taken 
from the Injection Drug Users Health Alliance Citywide Survey (IDUCS). The lead research 
read allowed each question one at a time and allowed time for participants to complete their 
response. The research assistant provided assistance if an individual participant had questions. 
Next, the lead researcher described her experience working in syringe exchange programs and 
interest in understanding the issues that PWID had related to injecting in public places. The 
session followed a semi-structured guide that was developed by the research team and an 
external qualitative researcher. The sessions were comprised of four sections: 1) discussion of 
risk by place of injection drug use using photos of local places known to have injection drug 
user, 2) a narrative presenting a vignette to discuss factors that influence where a PWID injects, 
and 3) a one-minute video of a participant accessing services at a SIF for discussion. Focus 
group sessions were approximately one-hour long. All sessions were audio recorded. 
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4.2.4 Specialized Session 
Upon review of the survey results from the first four focus groups compared to the IDUCS, it 
was identified that the mean age was higher (48 years of age) for the focus groups sessions 
compared to the IDUCS 2014 report (44 years of age). For this reason, the recruitment of the 
fifth session focused on recruiting individuals under the age of 30. Using snowball sampling, one 
younger participant recruited other individuals under the age of 30 to participate in the last group 
session, which reduced the median age to 44-years to be more reflective of the city-wide 
participant demographics of syringe exchange programs. 
 
4.2.5 Data Analysis 
Audio-recorded files were transcribed and reviewed for accuracy by the two researchers. Both 
the audio and written transcriptions of the focus groups using web-based software within two 
weeks of all of the sessions using Dedoose™.186 Using a multi-step process, we used thematic 
analysis to analyze the focus group data.267–269 Each researcher reviewed the transcripts 
independently to identify general themes that were related to the study topic. The team discussed 
the overall impressions, differences between groups, and any initial impressions related to 
differences by site. We used grounded theory184,185 to develop a coding schema to identify major 
key themes. We agreed upon an initial coding schema and reviewed the transcripts again 
applying thematic codes. Then, we met again to discuss the presence of themes, constructs to 
define themes, and collapsed several themes with sub codes. We developed consensus through 
discussion, mapping out key themes and the presence or absence of themes by group, site, and 
demographic characteristics. The lead researcher selected three individuals to conduct member 
checks, presenting the definitions and understanding of themes related to public injection drug 
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use. Each of the members validated that the key themes related to public injection and risk 
reflected their experiences. One of the participants who presented a particularly complex 
narrative about weighing risk was included in the member checks to ensure that the excerpt and 
narrative reflected his experiences.  
 
4.3 Results 
4.3.1 Sample Characteristics 
Over three-quarters of the participants were over the age of 40 years (75.8%) with an average 
age of 44, ranging from 21 to 57 years of age. Over half of the participants were male (54.5%) 
and nearly half of participants identified as Latino (45.5%). Most participants reported having 
their own place in the past three-month period (54.5%), followed by over one third reporting 
temporary or unstable (36.4%) and a few who were street-homeless (9.1%). Almost half of 
participants had reported being arrested in the past year (48.5%), with over one quarter reporting 
the arrest was cited as public drug use (27.3%). [See Table 1] 
 
4.3.2 Drug Use & Risk Behavior 
The majority of participants reported heroin use (88%) in the past three months, followed by 
methadone (73%) benzodiazepines or ‘downers’ (49%) and/or alcohol (49%). Most participants 
had been tested for hepatitis C and HIV (97% and 94% respectively), and over one third 
reporting a positive hepatitis C diagnosis (34%) compared to one individual reporting they were 
HIV positive (3%). Over half of participants had survived an overdose in their life (53%), over a 
quarter reporting self overdose in the past year (28%) and the majority witnessing an overdose in 
the past year (72%). Less than a third of participants reported the sharing of injecting equipment, 
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including sharing of a syringe (22%), a cooker (28%) and/or a cotton filter (28%).  [See Table 1 
& 3] 
 
4.3.3 Place of Injection Drug Use 
The two most common reported places of injection drug use in the past three months were the 
street or park (32.3%) and own home (32.3%), followed by home of a friend/family/partner 
(19.4%) and syringe exchange program bathroom (16.1%). When reviewing whether a 
participant had ever injected in a particular location over the course of the past three months, a 
majority report injecting a syringe exchange program bathroom (69.7%), own home (66.7%), 
and/or the home of a friend/family/partner (57.6%). [See Table 2]  
 
4.3.4 Group Interaction 
Participants readily shared their experience with injection drug use with the research team and 
fellow participants. There was a general sense of familiarity among the participants in all 
sessions, often referring back to experiences they had injected together in the past or describing 
places of injection that were local. Participants were actively engaged and there was only one 
participant who participated minimally. In general, participants appeared to be enthusiastic to 
discuss the challenges of injection drug use and readily offered solutions and strategies to avoid 
arrest, overdose, and injection related risks. There were no notable differences by group or socio-
demographic characteristics related to participation. The sessions were lively, engaging, and 
appeared to be enjoyable. 
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4.3.5 Key Findings 
 
Finding 1: Finding a space to inject involves calculated risks and tradeoffs: getting beat up, 
ripped off, arrested, or die alone 
 
Public injection was defined as a place where a PWID has a low sense of control of who can 
access the space and how long they have to prepare, administer, and clean up after an injection. 
A description of how PWID define privacy and risks by type of location are described in a 
previous study (Chapter 3). Examples of public places include the street or park, stairwells, 
abandoned buildings, syringe exchange program bathrooms, and subway stations. After being 
shown a series of photos of places where PWID are known to inject, the primary risks identified 
included (a) fear of arrest, (b) fear of overdose, (c) general lack of time to prepare and administer 
an injection, (d) being seen by the general public or friends that do not know they inject, and (e) 
general sanitation of a space.   
 
One of the differences across the groups were related to increased risks for women who are 
injecting in public places.  Both male and female participants described that certain places “may 
be safer for me but I wouldn’t tell my girlfriend to go there without me”. Several participants 
described stories related to hearing or experiencing violence, being robbed, or being raped in 
public places that were more hidden from general public view.  
 
“…I got my privacy down there so I take my time and relax… but you know, like (NAME) was 
just there and some dude hit her on the head with a rock and robbed and raped her… I don’t go 
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there anymore, no matter what… its good maybe if you have other people so you don’t get 
arrested by the church… but if I’m alone, it’s gotta be somewhere people can hear me scream at 
least…”  
 
Other risks that were discussed but in less detail were related to experiencing mistrust in other 
PWID, worrying about needing to inject others, share drugs with others, or PWID accidentally or 
purposefully sharing equipment:  
 
“ …why would I go to a friends house knowing I’m going to have to hit the friend off too? And I 
just got my shit, I need my fix” 
 
“… they [other drug users] could have used your stuff behind your back, that’s true, when you 
were gone, you know and that true and they can give you some disease, and that’s another 
unsafe thing…. Like maybe when you left to the store, maybe they don’t act like they’re junkies 
but they are behind you back and, bop, they stick it up and have some type of disease, and you 
get it when you use your equipment.” 
 
In consideration of these risks, many of the shared experiences involved elaborate planning to 
find a place to inject. This included rotating which public restrooms they inject in throughout the 
day to avoid being kicked out of businesses, being rushed out of a space due to police presence, 
and losing drugs and injecting equipment due to a lack of stable space to inject.  Participants 
described hiding or running away from the police by going into parks or highway underpasses to 
ensure they were able to administer their injection. One participant’s explanation of choosing a 
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place to inject where there are known improperly discarded syringes in order to avoid contact 
with police: 
 
“… Now, I see the black car, the undercovers, you know? Now, the tree will cover you. But your 
shoulder, lets say my shoulder right, they see it there and get out the car, so um, one of them 
says, “no, you can’t go there look at all those needles there” and the other guys says ok, then 
there “no but there are too many branches there, he’s gonna hear us coming” but I’m watching 
them, they find a spot where to come up, so as they’re coming up I got the needle in my hand, I 
was getting off. I’m running with the damn needle in my hand. Now I start running to the tree, 
there’s a big garbage can right? I’m hiding like this, getting off, trying to get that hit, they run 
right by me, they aint even see me, right? So I get the hit, I’m there in the corner of Amsterdam, 
right, now, they walking back, right? I took off my jacket, you know, cause they knew the color of 
the jacket, so I get up, I got a good hit, I take the works, break the needle off, put it in the 
garbage can, they walk right by me and say “hey, you little pecker head, we know you’re there in 
the bushes, we can see you” and I’m like right next to them, and they say if I catch you, I’m 
gonna whoop your butt…” 
 
This particular excerpt demonstrates intricate planning and attention to detail. Many of the 
narratives throughout the sessions included similar themes of planning in great detail. It is clear 
from the excerpt above that the individual is well aware of the potential risks of getting arrested, 
places where they can inject to avoid the risk, and the planning that goes into preparing one 
injection. 
 
98 
 
While injecting in a private place may decrease fear of arrest, it may increase the fear and 
likelihood of an accidental overdose. Participants described weighing these risks: 
 
“… you have to really really think about the big picture. The small picture is, yeah, you get hit 
up for this or that and they lock you up. Or do you hide, go over there by yourself crouching 
down so nobody can see you doing your hit… and then you’re gone. You’re a gonner… that’s the 
big picture of life. You gotta think about that all the time, every day.” 
 
On participant describes a tactic for avoiding both arrest and overdose:  
 
“… I started to do this thing, right, where down there on 167 I go into the bushes… yeah! You 
know the bushes over there, they can’t see you there. So, I get my stuff, I get my hit down there… 
so they can’t see me… but then I walk up and sit on the steps so if I catch an overdose, they see 
me right there and maybe they call 911…” 
 
Participants also described trade offs related to avoiding having to share drugs with other people, 
being able to take their time injecting, and having access to a sink to clean up. There was also 
themes and gestures (i.e. shaking heads, expressions of exhaustion and stress) describing all of 
the considerations and actions taken for every injection. One participant said that the constant 
weighing of risks was tiring and impeded the ability feel “like I can have a normal life”. 
 
 
Finding 2: PWID consider the community and public perception   
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While there were some comments about general belief in the public being responsive to an 
overdose, a general expression of shame and disempowerment was consistent across groups. The 
expression of shame related to public injection drug use was particularly specific to avoiding 
injecting, self or observed, in front of children: 
 
“It’s really disrespecting yourself, but kids, that’s the main thing I look at…” 
 
“And you know what, I don’t want my children seeing that… mommy, mommy there’s a man 
putting a needle in his arm over there… I mean, come on! Children don’t need to be subject to 
that” 
 
“It looks like a nice area and I think people will call the police, especially if there are children, I 
know I would if I see someone getting high on a bench and I have small children? Not in my 
area…” 
 
Participants were also aware of the impact of public injection related to improperly discarded 
syringes. Several participants went so far as to describe instances where they intervened to 
prevent other PWID from leaving improperly discarded syringes in the community: 
 
“… I was going down in 116th, and the guy was leaning on the gate all the kids are out there 
going like this, so I took three feet away from him made me turn around, “yo bro, yo bro, there’s 
kids right down there behind you man” … I did that again “yo bro! yo bro! There’s kids right 
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there, man!” and he got up, shook it, started walking got about 10 feet and said “yo man, thank 
you, thank you” … I just wanted to say that…” 
 
“I see the syringes right there, next door to here, right there on the steps and they know damn 
well they are sitting there, the syringes is there, pass by another man from another area, and 
those kids go about this building… he had the nerve to tell me and I said no you pick it up, you 
sat there, you pick that shit up! … Somebody got arrested around the corner too, they was sitting 
there shooting up. Regardless, you know a place where kids is and out and you go a big school 
right there, you have no respect for yourself period… you know what the hell you’re doing, that’s 
it” 
 
The statements about injecting in front of children or leaving improperly disposed drug 
equipment as a risk for children were strong and consistent despite there being no direct 
questions about children in the facilitators guide. Participants clearly identified this as both an 
individual concern and general community of PWID concern. The researchers identified that 
many of these narratives came up when discussing injecting in places like streets or parks in 
particular and almost used these stories to explain how they were attempting to compensate for 
the shame that they felt about injecting in public to begin with.  
 
Finding 3: SEPs are perceived as the safest place to inject 
“Well the thing is the safest place is here [syringe exchange program bathroom], cause they’re 
always checking you in the bathroom” 
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Injecting in a bathroom of a syringe exchange program was described as the safest because it had 
minimal risk for arrest and maximum protection from fatal overdose due to trained staff 
members.  
 
The salient theme of calculated risks and trade offs (Finding 1) appeared in the discussions of 
each of the seven places where we discussed “safe/unsafe” characteristics for injection drug use. 
Of all of the places, participants expressed identifying the least amount of both health and social 
risks in a syringe exchange program bathroom. It is recognized among harm reduction providers 
that participants inject in the bathroom of programs. Several programs have implemented 
overdose response structures, including staff trained to use the opioid overdose antidote called 
naloxone. Bathrooms may also include hazardous waste containers for safer disposal, safer 
injection supplies, or an intercom to communicate if there is an emergency. The two sites where 
the sessions were conducted included all of the aforementioned features. The following excerpts 
describe experiences using the syringe exchange program bathroom for injection drug use: 
 
“Yeah, I think its safer than in your own house, cause when I’m home, I’m by myself, so if I OD 
I’ll probably die right there, here I think is the safest place there is” 
 
“Here people I mean I’ve been watching, I mean I used to do it at home… I had tried to teach 
her [mom] how to use clean so I play safe where I know there’s NARCAN they know how to 
bring me back and this is a place where everybody knows me so…” 
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“They got the box to throw the syringes, throw the cooker, right, not on the floor and make sure 
there’s no blood on the floor because that blood is infected somebody else could get infected to, 
so if you drop a needle and you forgot make sure you go back and pick it up yourself cause 
nobody gonna pick it up for you” 
 
“It’s a change, you know, around … you get clean syringes, you got everything, all around the 
board to use it here in the bathroom is the safest place, I always said that” 
 
“You can focus, you can throw [away] your dirty needles…” 
 
As discussed in previous findings, the concept of privacy as a benefit has expressed value for 
preventing certain risks and, in other cases, promoting risk. In a SEP bathroom, the risks of 
arrest, fatal overdose, sharing of equipment, violence, and “people knowing what you’re doing” 
are reduced. In the context of increased privacy directly competing with the risk of fatal 
overdose, SEP bathrooms seemed to address both risks.  
 
Finding 4: SIFs would address many of the risks related to public injection and PWID 
would use them if available 
“You got me and all my friends lining up around the block for that… just let me know when its 
open”  
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Participants were shown a one-minute video of a participant accessing services at a supervised 
injection facility, from entering the site to collecting drug preparation equipment to injection to 
disposal. There was no explanation of the evaluation of the SIF related to individual and 
community benefits for the purposes of only demonstrating what the facility offered from a 
participant’s perspective of service access. After finishing the video clip, participants were asked 
to share what their reactions were to the video clip.  Responses were overwhelmingly positive 
manner across all groups, and in some cases participants expressed frustration that the services 
were not available to them now: 
 
“Wow! That’s so different! We need that here! (clapping)” 
 
“Why don’t we have one?” 
 
“What the hell, we aint got that here” 
 
“That make me feel a little jealous” 
 
“They’re tying her off? That’s a medical or physicians assistant or nurse… wow, I want a job 
there.” 
 
 “Yeah! We aint got nothing like that! We need that here! We need that here! I would talk about 
that and bring it up in the next conference meeting we have on Tuesday” 
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After discussing initial reactions, participants were asked to share what would be different in 
their own direct or observed experiences if a supervised injection facility were available to them. 
Specifically, what health and social risks would be minimized if a SIF were available (see Figure 
4A). They believed that SIFS would minimize risky injecting practices because they would not 
be fearful of being arrested or overdosing alone.  During the video clip, in most sessions a 
participant would comment on a scene where a participant of a SIF was able to wash her hands 
first followed by a medical professional assisting her with a tourniquet at a private, hygienic 
booth. The monitoring of the space was overwhelmingly viewed as positive, particularly as it 
related to preventing fatal overdose. Consistent with the earlier discussions about fear of arrest 
when injecting in a public place, participants commented on the impact it may have on their 
engagement with law enforcement. Participants also discussed the benefits of protecting 
themselves from overdose and other injection-related risks. While not as strong of a point of 
discussion earlier in the sessions regarding avoiding arrest and overdose as primary concerns, 
participants discussed the relationship between a safer space and prevention of missed injection 
and blood-borne infections.  
 
Participants were asked if a SIF were to open whether they thought people would use it, and the 
overwhelming majority expressed it would be well utilized and brought up the previously 
discussed risks, including avoiding injecting in front of children and preventing transmission, to 
support their opinions. However, participants, unprompted, discussed that they had doubts that 
the service would be available in NYC. Consistent with the themes of internalized stigma and 
negative public perception of PWIDs, most participants were skeptical if not adamant that SIFs 
would ever be available for use: 
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“Participant 1: Never ever ever …Cause what I think if they did that here… 
Participant 2: ‘cause that would give us more power” 
 
“But I’d like to say that is never… that’s you don’t show that no more cause its never gonna 
happen in New York City cause New York City is money money money, the police, everybody jail 
the judges, programs… it will never happen here. New York is about money. That would never 
happen here, never ever ever ever ever ever never…but a place like that is a beautiful thing…” 
 
While participants articulated their enthusiasm and theoretical impact of a SIF  in NYC, there 
was very little response or belief that this service would be integrated for use anytime soon.  
 
4.4 Discussion 
Our findings offer a deeper understanding of the complex experiences of PWID trying to manage 
risks related to injection drug use on a daily basis. They also describe the initial attitudes towards 
SIFs and their initial commentary on how they may address the risks of public injection drug use.  
 
We presented four key findings in this article. First, PWID are calculating social and health risks 
for every injection, many of which have potentially fatal outcomes. Previous research has made 
the connection between fear of arrest and the ability to apply safe injection practices due to 
rushing injections or reusing injecting equipment. Our study expands the understanding of other 
factors that may impact the ability to apply safe injection practices; the fear of violence and 
accidental overdose are risks included in the calculation of what makes a place ‘safe’ for 
injection drug use. Participants described in detail the various considerations taken into account 
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when identifying a safe place to inject, going so far as to inject in a public yet secluded place 
behind bushes to avoid being seen or arrested and later making themselves visible in case they 
accidentally overdosed. There are several health policy considerations to take away from these 
findings. First, the persistent fear of arrest and potential incarceration impede the ability of 
PWID to practice safe injection practices.167,283,295 As long as drug use is treated as a criminal 
justice issue resulting in arrest instead of a public health issue resulting in referrals to supportive 
services, existing evidence-based public health interventions can only go so far. Drug policy 
reform that includes decriminalization of drugs and diversion programs direct PWID to treatment 
instead of prison. Second, PWID are managing competing priorities that often work against each 
other. Public places were seen as safer in the event of preventing accidental overdose. Research 
validates this concern; 75% of accidental overdoses happen in the home in NYC.311 This may 
also explain findings in Chapter 2 and 3 about why PWID with stable housing continue to report 
public injection drug use. In recent years, New York has adopted policies and reformed existing 
legislation to support overdose prevention. These include (a) the 911 Good Samaritan Law,89 
which holds bystanders harmless for calling 911 even if they are intoxicated or are holding illicit 
drugs and (b) equipping law enforcement with naloxone, an opioid overdose antidote, in 
recognition that they are often the first responders on the scene of an overdose.312 Lastly, drug 
policy reform and health policies do not address the issue of potential violence. Particularly for 
female gender identified PWID, violence will continue to persist unless they have a supervised 
place for drug use or their own housing.213,280,313 Many shelters and transitional housing 
programs require sobriety, often validated through frequent drug tests and outpatient drug 
treatment requirements. For PWID who are not ready or willing to stop using drugs, access to 
affordable and stable housing will be a challenge. In order to minimize public injection drug use 
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and the associated harms, strategies must include drug policy, health, and housing policy 
reforms.  
 
Second, PWID are conscientious about injecting in public, particularly in front of children, and 
prevent others from doing the same. We identified this as a key theme throughout all of the focus 
group sessions and was particularly notable since it was not included as a discussion point in the 
original facilitators guide. In short, PWID do not want to be injecting in public. The rich 
narratives describing the shame and awareness of injecting in public contradicts the widespread 
stereotype of an injection drug user “junkie” who is careless and unable to think about anything 
except getting high.96,314,315 On the contrary, our study demonstrates that PWID are both capable 
and strategic about managing risks to themselves and others. These findings have important 
implications for understanding behavior change and interventions to reduce injection-related 
risk. SEPs rely on a PWID’s ability to apply safe injection practices outside of the program. The 
PWID in this study expressed knowledge and understanding of safe injection practices and the 
importance of using sterile injecting equipment, but the environment in which they inject 
interfered with their ability to apply safe injection practices.157,316 These findings further support 
the need for drug, health, and housing policy reform, but also contribute to the rationale to 
immediately implement SIFs in the interim to address immediate risks.   
 
Third, we learned that PWID are injecting in SEP bathrooms because they were perceived as the 
safest option. Participants commented on the benefit of having all of the sterile injecting 
equipment and disposal access onsite, privacy that minimize fear of arrest or violence, yet not 
too secluded to the point where an accidental overdose would not be identified quickly. In 2016, 
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in response to recurrent onsite overdoses in SEPs, the New York State Department of Health 
(NYDSOH) issued new regulations requiring SEP bathrooms to make physical space 
modification and develop training for staff to effectively respond to overdose incidents.317 While 
SEPs appear to be operating de-facto SIFs, injection drug use that may be occurring onsite is still 
unsupervised; overdoses are responded to only after they have occurred compared with SIFs that 
can identify early signs of overdose and apply preventative measures (i.e. administration of 
oxygen) to avoid the use of naloxone or injuries sustained from losing consciousness. Extended 
hypoxia can also result in permanent brain injuries.318 SEPs bathrooms may prevent overdose 
fatalities and drug-related arrest, but risky injection practices and preventable overdoses would 
be largely minimized by supervision.  
 
Lastly, the overwhelming majority of PWID expressed willingness and interest in using a SIF if 
it were available to them. For the reasons described above, public injection drug use is not 
desirable for the PWID or the community. Participants in all groups verbalized the connection 
between how a sanctioned, supervised environment with access to sterile injecting equipment 
would reduce risky injecting practices, fear of arrest, overdose, and connection to care.  
Participants in the study expressed strong reactions to SIF services, ranging from readiness to use 
the site tomorrow to recruiting friends to use the site to disappointment and anger that such 
facilities are not already available. Considering the narratives about the day to day complexities 
of injecting, losing friends to overdose, contracting HIV and HCV, and patterns of harassment 
and violence, it is understandable that participants would have a strong and anger-driven reaction 
to the absence of SIFs in NYC. At least one member of each group also expressed that they 
didn’t believe that NYC would adopt such a service and expressed that they felt looked down 
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upon in society and “not worth saving”. The concept of implementing a SIF would mean that the 
community cared about their health and safety, which is not a general belief among PWID. It is 
also not an unfounded belief. Experiences of PWID being stigmatized, blamed, and poorly 
treated is well documented.319–323 It is also perpetuated in research and service settings, with 
PWID often being labeled as ‘chaotic’, ‘non compliant’, or ‘hard to work with’.324–326 SIFs have 
demonstrated to connect PWID to drug treatment, medical services, and housing placement. The 
establishment of SIFs may contribute to existing healthcare reform efforts, including delivery 
system reform incentive payments (DSRIP) initiatives in New York, to connect high utilizers of 
the ED with a regular source of care. Managing the multi-daily risks of finding a place to inject 
is complex and competes with other priorities, including healthcare appointments. Several 
participants commented favorably on the scene where a SIF staff member assisted a PWID with 
tying a tourniquet, commenting on the benefit of having other support services available to them. 
Beyond the benefits of applying safe injection practices and potential cost and life savings by 
averting new cases of HIV and HCV, SIFs may be an effective strategy to engage and retain high 
risk individuals in healthcare.  
 
4.4.1 Strengths and Limitations 
There are several limitations to this study. First, the study did not fully describe any details about 
the operation of SIFs. Therefore, the perceptions of services are limited to what participants 
directly observed and interpreted from the one-minute video. The findings may not be 
generalizable to other settings, such as non-urban settings where there may not be access to 
syringe exchange programs with bathrooms for use or have a different context of where they 
inject. The focus groups did not specifically list out what a SIF may require as rules, such as 
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hand washing and not being able to share drugs, such as previous studies have and may over-
represent interest in the prospective use of a SIF. However, our study offers a new contribution 
to the understanding of the complex nature of injecting drugs in NYC and is the first to 
illuminate initial attitudes towards SIFs among PWIDs in the US.  
 
4.4.2 Conclusion 
SIFs are an evidenced-based intervention to minimize the health and social risks related to 
injection drug use. Our findings indicate that PWID are willing to use such services and, in the 
interim, are managing competing needs that may exacerbate health outcomes. Syringe exchange 
program bathrooms appear to already be de-facto SIFs and are viewed as the safest place for a 
PWID to inject, but are far from safe. In consideration of the overdose and hepatitis C epidemics, 
the US should consider implementing SIFs as a natural and necessary extension of services for 
PWID 
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Table 4A. Socio-demographic and risk behavior characteristics of PWID who participated in 
focus group sessions (N=33) 
  N 
 
% 
Age (mean, range)  
 (44.82, 21-57) 
  
Under 30 3 9.1 
30-39 5 15.2 
40-49 12 36.4 
50+ 13 39.4 
Gender     
Male 18 54.5 
Female 15 45.5 
Race/ Ethnicity     
white 6 18.2 
black  8 24.2 
Latino 15 45.5 
other 4 
 
12.1 
Housing Status  
(past 3 months) 
    
Street-Homeless  3 9.1 
Unstable 12 36.4 
Stable 18       54.5 
Arrested or incarcerated 
(past year) 
16 48.5 
Arrest cited as public use 9 27.3 
Overdose Ever 17 53.1 
        Overdosed in past year 9 28.1 
   Witness overdose  23 71.9 
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Table 4B. Places of Injection Drug Use by Most Frequent Location and Ever in Past 3 Months 
(n=33)  
 Most Frequent  Ever in Past 3 months  
Place of Injection Drug 
Use N % 
 N %    
Street or Park 10 32.3  16 48.5    
Stairwell 0 0  20 30.3    
Abandoned building 0 0  6 18.2    
Public bathroom 0 0  19 39.4    
Bus, subway, train 0 0  5 15.2    
Car or other vehicle 0 0  10 30.3    
SEP bathroom 5 16.1  23 69.7    
Shooting gallery 0 0  7 21.2    
Home of 
friend/family/partner 6 19.4 
 19 57.6    
Own home 10 32.3  22 66.7    
Other 0 0  5 15.2    
 
*Other includes airplane (1), Basement (1), Bus shelter (1), Empty lot (1), Beach (1),  Elevator 
(1), Hallway (1), Hospital (2), Hotel (4), Methadone clinic (1), restaurant (1), rooftop (4), shelter 
(5), storage unit (1), telephone booth (3), train platform (1), train tracks (1), under a bridge (2
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Table 4C. Drug Use by Type and Frequency for PWIDS (n=33)  
Drugs Used 
in Past 30 days N (%) Every 
day 
A few 
times a 
week 
Less 
than 
once a 
week 
Less 
than 
once a 
month 
Methadone  24 72.7 92.0 0 8.0 0 
Alcohol 16 48.5 37.5 37.5 6.3 18.8 
Marijuana 10 30.3 20.0 20.0 20.0 40.0 
Cocaine 12 36.4 25.0 16.7 33.3 25.0 
Crack 10 30.3 30.0 30.0 20.0 20.0 
Heroin 28 87.5 39.3 21.4 25.0 14.3 
Methampheta
mine 3 9.4 25.0 50.0 0 25.0 
Opiates 6 18.8 50.0 16.7 16.7 16.7 
Prescribed? 5 83.3     
Downers  16 48.5 53.5 33.3 6.7 6.7 
Any Opioid 18 4.0     
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Figure 4A. Potential for SIFs to reduce risk & perceived benefits 
Health Risks “Well, I see there’s a lot of people who is not… they don’t care about what is it 
you’re using or what is it you’re doing, you’re just being watched so you don’t 
kill yourself, and that’s the most important thing about that video… they 
making sure that you clean yourself, you’re going thru a process and it’s up to 
you to do that… but you know you go there and do what you gotta do and 
you’re being watched and you’re being monitored so if anything happens they 
know what to do” 
 
“…[it would be] somewhere she got the doctor her own things the supplies, the 
water, wash her hands…that’s a very safe environment and I wish they had 
something like that here in New York” 
 
“First of all you got a lot of people that have no veins, they can’t find, so that 
would be good for person to actually find the vein for them” 
 
“But there’s a lot of good that comes out of a place… the spread of HIV HCV 
all those types of diseases, is down. Overdoses and people dying is down.” 
 
 
Social Risks “You don’t have to worry about going to jail, you don’t have to worry about 
losing your life… it’s a safe haven” 
 
“Participant 1: Crime would go down, know what I’m saying? If it was more 
controlled 
Participant 2: I think so too” 
 
 
Perceived 
benefits and 
use of a SIF if 
implemented in 
NYC 
“I think people will go and try it out, I’ll be one of them. One thing that I like is 
that the person goes to clean up or whatever” 
 
“They would knock people out the box! I’d let everyone know about that new 
program” 
 
“'If they was to have something like that here it would help us out getting off 
the streets and have a big list of kids watching us, its enough that people leave 
the syringes out there for the kids to see that when the crack epidemic, the little 
bottles in the schools and stuff like that here, so I think it would be much better 
if they had something like that here” 
 
“Not only that but it would teach them safety and responsibility and I think that 
would help tremendously… it would make a big difference in the harm 
reduction community and in general the public health environment too because 
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a lot of people out there that use today that I see injecting when we on the sites 
they might have been injecting for 30 40 years and don’t have a clue” 
 
“And a lot of people getting infected with the supplies out there they have a 
50/50 chance of using somebody else’s stuff cause you don’t want to go look for 
something that’s cleaner… I think that would help a LOT” 
 
“…if you think people will be embarrassed? I don’t think so. People would take 
advantage of it.” 
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Chapter 5: Discussion 
 
5.1 Overview of the Dissertation 
The use of illicit drugs is at an all-time high in the US.1 Since 2011, overdose has been the 
leading cause of accidental death among young adults, surpassing motor vehicle accidents.327 
Every day there are at least 1,000 people who are treated for overdose in the emergency 
departments across the US.6 In addition to climbing overdose deaths, misuse of prescription 
opioids have led to increases in heroin use, injection drug use, and new epidemics of HIV and 
HCV.16,17,63,68,328 The need to identify new strategies and expand evidence-based approaches to 
reduce drug-related harms is critical to save lives and prevent another AIDS epidemic.  
 
The national dialogue on how to address drug-related harm stretches from small towns in the 
middle of the US to large urban centers. In the past five years, the Office of National Drug 
Control Strategy (ONDCP)115 has hosted a series of sessions with community members, parents 
of children lost to overdose, doctors, people in recovery, and harm reduction programs to seek 
alternatives to the existing strategies to address drug-related harm. MMT and buprenorphine 
have been effective in reducing injection-related harm but remain unavailable or inaccessible to 
many PWID around the country.131,133,135,329,330 SEPs have been an evidence-based intervention 
effective in reducing new cases of HIV and HCV by providing sterile injecting equipment and 
also provide overdose prevention and naloxone distribution.179,205,253 However, there remain only 
350 SEPs in 42 states in the US, mostly concentrated in urban centers.331 While SEPs slowly 
expand to new geographic areas, particularly in areas where there are declared states of 
emergency due to HIV outbreaks,65 the pace of expansion and corresponding funding are not 
enough to reach all PWID who need services. For the PWID who do have access to SEPs, they 
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may be able to receive sterile injecting equipment and naloxone but are left to prepare and inject 
drugs in environments that may be unhygienic, unsupervised, or rushed.154,157,332 SIFs are one 
evidence-based intervention that reduces intravenous transmission of HIV and HCV and reduces 
fatal overdose by providing a supervised, sanitary environment to inject drugs.171,333–336 Initial 
US-based research suggests that PWID would use a SIF178 and that SIFs would save both lives 
and money177. In the first few months of 2017, the case for SIFs and their potential role in 
addressing both the overdose and HIV/HCV epidemics have been cited by researchers337, 
medical providers338, and public health officials299 alike. While there are is not a law against SIFs 
in the US,304 there has yet to be a SIF implemented.  
 
The purpose of this dissertation is to describe public injection drug use in NYC, the association 
between public injection drug use and health risks, and the experience of PWID injecting in 
public places to contextualize both health and social risks. The findings of this research 
contribute to a public health rationale to implement SIFs. Prior to opening SIFs in Vancouver, a 
team of researchers at the University of British Columbia Centre for Excellence in HIV/AIDS339 
reviewed existing data provided by the local health department and conducted a series of studies 
to document the impact of public injection drug use.154,308,336 The findings were one of the 
important contributing factors to educate and provide a rationale for implementation of a SIF. 
While there is a growing national conversation about the role of SIFs in addressing drug-related 
harms, the US-based research on their potential impact is less known. Using a mixed-methods 
approach, I analyzed data from the IDUCS and conducted five focus group sessions with PWID. 
I hypothesized that PWID are frequently injecting in public places, injecting in public is 
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associated with increased report risk behaviors, and PWID would perceive that SIFs could 
address some of these risk behaviors.  
 
In Chapter 2, I tested the hypothesis that public injection drug use is associated with the 
receptive sharing of injecting equipment. Injecting equipment included syringes, cookers, and 
cotton filters. The relationship between receptive sharing of all three types of equipment and 
hepatitis C transmission is well documented.98,203,226 Therefore, the reported receptive sharing of 
injecting equipment serves as a proxy for risk of HCV transmission. A total of 787 PWID were 
included in the sample. I used frequencies and bivariate logistic regression to compare 
participants in two groups: participants who reported receptive sharing of injecting equipment in 
the past three months vs. no reported receptive sharing of injecting equipment.  To test the 
hypothesis that public injection drug use is associated with the receptive sharing of injecting 
equipment, I constructed a multivariate regression model with variables that produced a p-value 
less than .20. Both significant and non-significant findings are presented in the final model. The 
main findings and interpretations are summarized in the following section of this chapter.  
 
In Chapter 3, I test the hypothesis there are differences in risks between PWID who inject in 
public and PWID who inject only in private places. I used a multi-phase mixed-methods design 
to define public injection, the construction of the primary outcome variable, inform the selection 
of explanatory variables in the quantitative analyses, and describe key themes related risk and 
injecting in public places. A total of 33 PWID who receive syringe exchange services at SEPs in 
NYC participated in one of five focus group sessions. One of the focus group sessions was 
specific to PWID under 30. We identified four key themes related to what makes a place private 
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or public: physical features of a place, sense of control, trust in people who are in the space, and 
exposure to being seen or arrested. We define a public place in the context of injection drug use 
as “any place where a PWID has a low sense of control of who can access the space and how 
long they have to prepare, administer, and clean up after an injection.” Then, I identified key 
themes associated with public injection drug use: fear of arrest, overdose, level of drug 
withdrawal, and fear of being seen or caught. I selected additional variables to include in the 
model related to these key themes. Lastly, I selected two additional variables (ED admission and 
having a PCP) that are related to current health policy discussions around reducing drug-related 
harm.  After selecting additional variables, a total of 755 PWID were included in the quantitative 
analyses. The main findings and interpretations are summarized in the following section of this 
chapter. 
 
In Chapter 4, I tested the hypotheses that (a) PWID experience competing health and social risks 
depending on the place they inject drugs, and (b) PWID would perceive SIF services as 
beneficial to address experienced and observed risks associated with injection drug use. A total 
of 33 PWID participated in focus group sessions conducted in two SEPs in uptown Manhattan. I 
used a series of photographs of places where PWID inject to understand what considerations of 
the physical environment or social environment that would impact their injection practices based 
on risks discussed in the previous chapter. I also presented a one-minute video of a participant 
accessing services from start to finish at a SIF in Vancouver, Canada to document initial 
reactions to supervised consumption services. Using thematic analysis, I synthesized key themes 
to describe how experiences of injecting involved a series of calculated risks and trade-offs.  
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In the following section, I describe the findings from each chapter and the interpretation based on 
my analyses.  
 
5.2 Summary of the Findings 
5.2.1 Chapter 2 
There were four main findings in Chapter 2. The first finding is that over half (64%) of PWID in 
the study report they inject in public places. This is a novel finding for two reasons. First, this is 
the first study known to describe places of injection drug use in a variety of categories (10 
categories) compared to other studies (maximum 4 categories). It also demonstrates how 
pervasive injection drug use is in spaces used by the public and may, as a result, better frame 
addressing injection drug use is a community priority. To date, no published research has 
indicated prevalence or frequency of injecting drugs in public places in NYC. However, these 
findings are higher than the National HIV Behavior Surveillance (NHBS) survey report of PWID 
injecting in public places in 2009176 (30%) but consistent with international research that has 
indicated that 40-70% of PWID report recently injecting in a public place.157,229,265  
 
Second, PWID who inject in a public place are 63% more likely to report the receptive sharing of 
injecting equipment compared with PWID who do not inject in public places. This is a 
significant finding for public health officials and SEPs who are attempting to minimize reuse of 
injecting equipment to prevent the transmission of HCV and HIV. Providing sterile injecting 
equipment is not enough to prevent receptive sharing of injecting equipment. In order to 
minimize receptive sharing, access to sterile injecting equipment must be accompanied by a 
supervised and sanctioned space to prepare and inject drugs. SIFs are one evidence-based 
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intervention to minimize the receptive sharing of injecting equipment. However, drug policies 
and policing practices must also be addressed to ensure that these facilities are accessible to 
PWID who may fear being targeted or arrested by accessing the services. 
 
Third, PWID who obtain syringes from friends, family members, the street, or a shooting gallery 
have significantly higher odds of reporting receptive sharing of injecting equipment. Consistent 
with the research, access to sterile injecting equipment from pharmacies and SEPs is associated 
with a reduction in the reuse of injecting equipment. Receptive sharing of equipment is most 
likely to occur when PWID are injecting in groups. These findings add further support for 
addressing where injection practices take place to increase access to sterile injecting equipment 
and reduce the likelihood of receptive sharing of equipment. The implication of these findings 
may be that engagement in SEPs offer more than just injecting equipment that promote safer 
injection practices. SEPs must be scaled up in areas of existing and new areas where there are 
PWID. While the federal ban on funds for SEPs was lifted in 2016, the funds are limited and 
only certain states elect to receive them. Health officials in both states and local municipalities 
must include SEPs as a critical element of any HIV and HCV prevention strategy.  
 
Lastly, injectors who smoke crack were more likely to report receptive sharing of injecting 
equipment. While the association between risk behavior and smoking crack among PWID is well 
documented239,241, the association between using crack and receptive sharing of injecting 
equipment is a new contribution. It is also an important finding in terms of considering future 
interventions to reduce injection-related risk, such as supervised injection facilities (SIFs) versus 
Drug Consumption Rooms (DCRs). If a PWID also smokes crack and the use of crack is 
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associated with increased odds of receptive sharing, NYC should consider DCRs instead of SIFs 
to support PWID who use both drugs. Otherwise, a PWID who injects heroin or cocaine and also 
smokes crack may be less likely to attend if they are restricted to how they consume drugs.  
 
Amidst the growing hepatitis C epidemic, these findings indicate that SIFs or DCRs would at 
minimum reduce receptive sharing among PWID who would utilize such services. In the 
subsequent chapter, I aimed to fully describe factors associated with public injection drug use.  
 
5.2.2 Chapter 3 
In addition to establishing a participant-informed definition of public injection drug use, there 
were five main findings in Chapter 3. First, public injectors have a higher risk profile: they are 
more likely to be homeless, report past year arrest, past year ED admission, past year overdose, 
and less likely to be connected to a PCP. There were several additional factors significantly 
associated with public injection drug use in the quantitative analyses. These include being under 
the age of 40 years of age, past year arrest or incarceration, past 30-day use of heroin or cocaine, 
past year overdose, and witnessing an overdose. There were no differences between the 
specialized focus group with PWID under the age of 30 versus the other four sessions with 
regard to place of injection from the survey data or narratives. Future research should conduct an 
analyses of the cohort of younger injectors to determine if there are unique risk factors, but is 
outside of the scope of this dissertation. The findings specific to overdose offer additional 
rationale to implement SIFs to address the overdose epidemic.  
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Second, homelessness and unstable housing is associated with public injection drug use, 
confirming our original hypothesis. While this finding is not surprising since we can surmise that 
participants who were unstably housed at any point in the past three months were less likely to 
have a non-public place to inject, it is a new contribution to the literature. It also further 
contributes to the rationale that housing is health, and that access to affordable housing continues 
to be a critical social determinant of health.  
 
Third, PWID reported that fear of arrest as a primary factor taken into consideration when 
determining whether a place was ‘safe’ to inject. Fear of arrest weighed heavily into determining 
what place was safe to inject. Participants described tactics to inject quickly or avoid police. 
These findings are consistent with international studies and suggest that policing may impact the 
ability to apply safer injection techniques.  
 
Fourth, participants may choose to inject in a public place to avoid fatal overdose. The only risk 
factor that was more of a concern when injecting in a non-public place was fear of accidental 
overdose and, without bystanders to respond, potential death.  
 
Lastly, our study offers a new definition of public injection drug use derived from PWID and 
combines both physical and social components to describe what makes a place public.  
 
In conclusion, PWID inject in public places because they have to, not because they want to. 
Access to stable housing, policing, efforts to prevent overdose, and stigma are all related to the 
experience of public injection drug use. PWID report a variety of risks associated with public 
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injection drug use. In the subsequent chapter, I take a deeper dive into understanding how PWID 
address concurrent potential risks and initial attitudes and beliefs towards the prospective 
implementation of SIFs in NYC.  
 
5.2.3 Chapter 4 
There were three main findings from the focus group sessions. First, finding a space to inject 
involves a series of calculated risks and tradeoffs. The participants of focus groups outlined 
detailed descriptions of both past experiences of injecting in public and considerations if they 
were to inject in one of the places presented in the photographs. The dominating trade off was to 
risk being arrested by injecting in a more public place versus risk a potentially fatal overdose due 
to injecting in a private place and not having bystanders nearby. The most valuable contribution 
of this finding is that the discussion of reusing injecting equipment or sanitary conditions was 
secondary to arrest and overdose, along with subjection to violence and theft or being seen by 
someone else. These findings illuminate the findings in Chapter 2 – PWID focus on avoiding 
arrest and fatal overdose first and foremost and, therefore, addressing those perceived priorities 
first is a necessary step to support safer preparation and injection practices.  
 
Second, PWID are very aware of the potential impact of injecting in public on the community at 
large. This was a salient theme across all groups and was completely unprompted. Participants 
readily described the shame and negative self-talk when they were put in situations where they 
were injecting near parks or spaces where there are children. They described an intentional 
process to avoid injecting in public places near children and even prevent other PWID from 
doing so. Participants also described an intention to discard syringes properly to avoid others 
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being accidentally stuck with a used syringe, but recognized that policing was a barrier to doing 
so.  
 
Third, PWID identified that injecting in the bathroom of a SEP was the safest place to inject. 
Participants described that they felt safest because they were less likely to be arrested since SEP 
staff are aware of the activity that occurs in the bathroom. They also described that they had 
observed or knew that SEP staff could reverse an overdose if it occurred onsite. Several 
participants also noted that the availability of both sterile injecting equipment and safe disposal 
kiosks in the bathroom meant that they were more likely to use sterile equipment and less likely 
to discard syringes in the community. SEP bathrooms appear to be fulfilling a partial role in 
addressing the risk of arrest and fatal overdose. However, they are still unsupervised and 
unsanctioned. To date, there is no literature published on injection drug use in bathrooms of 
SEPs. Our study highlights that pseudo-SIFs are in operation and already serve as spaces for 
PWID to inject. SIFs are a natural and necessary extension of harm reduction services at SEPs in 
recognition of the prevalence of unstable housing and drug-related arrests. 
 
Lastly, participants had overwhelmingly positive reactions to the concept of a SIF and believed it 
would address the risk behavior described earlier in the focus group sessions. Participants were 
also quick to note that they did not believe that such a service would be available to them, rooted 
in a belief that NYC was more interested in policing and jail than health for PWID. Participants 
were very enthusiastic when it was presented that individuals in the city health departments were 
discussing SIFs as a potential intervention. Several asked specifically how to become involved in 
advocating for the service.  
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The most significant overall finding in this chapter is the connection between the calculated risks 
and prospective use of a SIF. The narratives in this chapter demonstrate elaborate planning, 
adjustments to plans, weighing of severe long-term and short-term risks, and considerations for 
themselves and for the community. This is an important counter-perspective to the more 
pervasive description of PWID in research, describing PWID as ‘erratic’, ‘unstable’, ‘chaotic’, 
and ‘non-adherent’.314,319,325,326 These narratives suggest that not only are PWID concerned with 
themselves and the community, they also make decisions on a daily basis that involve planning 
and multi-step processes. This indicates that PWID may indeed access prospective SIF or DCR 
services in NYC if they were available and may even support other PWID in doing so.  
 
5.3 Policy Recommendations  
To date, this is the first study in the US to fully describe public injection drug use. It is also the 
first study to report on attitudes towards SIFs and the potential acceptability in NYC. Based on 
the findings from this research and a review of existing legislation, health policies, and evidence-
based interventions, I have identified a relatively broad scope of recommendations that would 
begin to address both the underlying causes and consequences of public injection drug use 
described in this research. This is not an exhaustive list of recommendations; addressing drug use 
is complex and requires interdisciplinary action and reform. The following recommendations are 
specific to themes and findings in this dissertation research. 
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5.3.1 Recommendation #1  
Implement SIFs in the US as one part of a comprehensive approach to reduce public drug 
use. 
 
Based on my research findings, public injection drug use is associated with a variety of health 
and social risks. Implementing SIFs would likely reduce public injection drug use, and in turn (a) 
reduce the risk of transmission of HIV/HCV via offering sterile injecting equipment in separate 
single-person booths, (b) prevent fatal overdose, (c) reduce drug-related arrests due to public 
drug use, and (d) decrease healthcare costs associated with injection-related infections. The 
benefits of SIFs and have been described at length in the previous chapters.  
 
SIFs are not a silver bullet. However, in addition to preventing HIV/HCV/SSTIs and fatal 
overdose, they may support existing health care reform efforts. In New York, DSRIP initiatives 
aim to connect high risk individuals with a usual source of care to reduce preventable ED 
admissions. The barriers to primary care, including stigma and negative experiences with 
healthcare providers, are well documented.71,146,289,322,354 In Chapter 1, we described the costs of 
HIV and HCV treatment, SSTI admissions and potential complications, and opioid overdose. In 
Chapter 4, we identified that public injectors were more likely to report past year ED admission 
and less likely to have a PCP. In Chapter 5, participants described their willingness and interest 
in accessing services at a SIF, highlighting a portion of the video where a healthcare provider 
assists a participant with tying a tourniquet. In recognition of the barriers to care and the need to 
identify and connect high-risk individuals to a regular source of care, the establishment of SIFs 
may serve as a strategic and cost-effective way to connect and engage high utilizers of the ED.  
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Next, I describe several components of this recommendation including legal and health policy 
approaches to implementation. 
 
5.3.1.1 Select a pathway to implement SIFs  
There are various approaches to implementing SIFs that involve a combination of legislative 
change, research exceptions, and local authorization. All of the following pathways require 
community education of key stakeholders who may impact the establishment or authorization of 
a SIF. These individuals may vary by locale but are likely to include the following: public health 
officials and health departments, law enforcement and local precincts, community boards, 
elected officials, healthcare providers and administrators, drug treatment providers and 
administrators, business improvement districts, community-based organizations, and faith-based 
organizations. The funding of a prospective SIF varies by approach and locale.   
 
a) Open a SIF as a stand-alone service or as part of an existing organization. As of 
2017, all status and municipalities have the authority to establish SIFs as part of the 
“government’s duty to protect and preserve the welfare of their citizens” as part of the 
legal authority to fulfill police power.355 However, the risks of this approach may be that 
two existing federal statutes in the federal Controlled Substances Act that may be applied 
to the organization operating these services or individuals working within that 
organization.  The first is Section 844 which prohibits drug possession. Therefore, any 
person who enters a SIF that has pre-obtained drugs may be at risk of arrest. The second 
is in Section 856, which is known as the Crack House Status Law (21 USC § 856)231 
which makes it a felony to knowingly rent, lease, open, or use a place for the purposes of 
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producing, distributing, or using a controlled substance. The statute is amended by the 
Illicit Drug Anti-Proliferation Act of 2003 (S. 226)356 and any owner or worker in the site 
may be prosecuted. Therefore, by opening a SIF under the current conditions, a site and 
the clients who access it may run the risk of being prosecuted by the federal government.  
b) Obtain a federal research exemption, which is the approach that Vancouver used in 
2003. An exemption may be provided by the Center for Drug Evaluation and Research 
(CDER) under the Federal Drug Administration (FDA). However, the process of 
receiving a federal exemption may take years and, if granted, may put a hold on the 
ability to expand SIFs beyond the original sites listed in the exemption. In Canada, a 
research exemption was granted in 2003 and was challenged by the federal government 
several times when a new conservative administration was in place. While the one site 
was able to operate, the unintended consequence of the research exemption was that other 
sites that were needed were unable to open since they were not listed in the original 
exemption. Since the federal administration changed in 2016, several sites in Toronto and 
Ottawa are set to open based on local provincial and municipal government 
authorizations.  
c) Authorize a SIF via state or municipal legislation. Both state and city governments 
may declare a public health emergency and authorize legislation to sanction SIF services. 
Municipal governments have the power to enact local laws according to the state 
constitution Municipal Home Rule Law (N.Y. Const. art. IX, §§ 2(b)(1), 2(c), 3(d)(1); 
N.Y. Mun. Home Rule Law § 10). To date, there are several states which have introduced 
single legislation or recommendations as part of a broader drug reform strategy: New 
York, California, Maryland, Massachusetts, Vermont, and Washington. To date, two 
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municipalities (Seattle, WA and Ithaca, NY) have introduced municipal drug strategies 
developed by designated drug taskforce committees that include SIFs. In New York state, 
the drafted legislation suggests that the New York Department of Health or local health 
department may approve an application within 45 days of receipt to approve SIFs that 
meet a list of 10 requirements of programmatic operation. The legislation also indicates 
that SIFs will automatically be designated as syringe exchange programs (NY Comp. 
Codes R. & Regs. tit. 10, § 80.135) and opioid overdose prevention programs (N.Y. 
Comp. Codes R. & Regs. tit. 10, § 80.138). The legislation also specifies that individuals 
who rent/lease/own, operate, provide services, or received services at the SIF will not be 
prosecuted by state and local authorities. However, due to the two federal statues 
described in the first recommendation, it is possible that any of the entities may be 
prosecuted should the federal government intervene.  
 
5.3.1.2 Consider the implementation of DCRs instead of SIFs to account for PWID who smoke 
crack. Our findings indicate that PWID who use crack were more likely to report the receptive 
sharing of injecting equipment. If a PWID smokes crack in the same episode as injecting but are 
only allowed to use injectable drugs at a SIF, they may be less likely to access services. Black 
and Latino PWID report higher use of crack and are also more likely to be targeted by police. In 
order to not further perpetuate discrimination within public health services, including an 
inhalation room for PWID to smoke crack is essential. DCRs have been well evaluated and show 
similar outcomes to SIFs.  
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5.3.1.3 Scale up SEP bathroom services in the absence of a SIFs/DCR. Our findings suggest that 
PWID viewed existing SEP bathrooms as the safest place for injection drug use due to reduced 
fears of overdose and arrest. SEPs are also equipped with sterile injecting equipment onsite and 
hazardous waste disposal. SEPs are serving as pseudo-SIFs in the absence of other options. In 
September 2016, the NYCDOHM and NYSDOH included in the new fiscal year contracts for 
SEPs that they require a minimal set of standards for bathrooms that are used by participants317; 
monitoring system to prevent overdose, onsite naloxone, procedures for onsite overdose, 
stainless steel tables, high grade bleach and cleaning equipment, and hazardous waste containers. 
The next step would be to implement these minimum bathroom requirements for all service 
providers that serve PWID.  
 
While SIFs are one approach to minimize public injection drug use, associated adverse health 
outcomes, and connect PWID to other support services, they are only one piece of a broader 
continuum of care that is needed to improve population health. Therefore, the following 
recommendations address a broader framework of both the underlying causes and consequences 
of public injection drug use. 
 
5.3.2 Recommendation #2 
Scale up syringe access in areas of high rates of overdose, HIV incidence, and HCV 
incidence.  
 
SEPs have demonstrated to effectively minimize the transmission of blood-borne infections.116 
They are also sites where PWID may access naloxone to prevent overdose. Our findings describe 
that one quarter of PWID report receptive sharing of injecting equipment and experience barriers 
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to applying safer injection practices. If the participants in this study who are enrolled at a SEP 
continue to experience barriers, it is likely that individuals who have to travel long distances or 
do not have any access to SEP may have higher rates of risky injecting practices. Next, I describe 
several key legal and policy elements that are critical to ensure successful establishment and 
access for PWID of new SEPs.  
 
5.3.2.1 Decriminalize possession of syringes and drug paraphernalia. In New York, the Penal 
Law (§ 220.4) states that a person who possesses or sells a hypodermic syringe may be charged 
with a class A misdemeanor. The exception is if the syringe was distributed by one of the 24 
licensed SEPs and the individual can provide proof and verify that they are enrolled in a program 
(Public Health Law § 3300.81). For individuals who receive syringes from pharmacy-based 
expanded syringe access programs (ESAP), from friends, or are unable to verify proof of 
enrollment, the risk of carrying a syringe may be high for PWID. Decriminalization is essential 
to remove the barriers to access to sterile syringes and injecting equipment to prevent receptive 
sharing of syringes, injecting equipment, and/or improper disposal of equipment due to fear of 
arrest.  
 
5.3.2.2 Prioritize the establishment of SEPs in states and municipalities where there is a high 
prevalence of injection drug use using proxies of overdose data, HIV incidence, and HCV 
incidence. State and local health departments must allocate both funding and infrastructure to 
prioritize the implementation of SEPs. SEPs have been in legal operation in the US since 1992 
and, in New York, was established by a local Health Commissioner.357 Each state has their own 
version of local public health law and penal codes to support the establishment and operations of 
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SEPs. In addition to the introduction of legislation or local authorization, efforts to establish new 
SEPs must include community education and advocacy efforts with key stakeholders: 
community boards, PWID, neighborhood associations, local precincts, elected officials, health 
care providers, and faith-based organizations. Community education and support is critical to 
ensuring the success of SEP programs and access for PWID. 
 
5.3.2.3 Expand existing SEPs to new sub-populations where there is a high prevalence of 
injection drug use using proxies of overdose data, HIV incidence, and HCV incidence. In NYC, 
many of the SEPs reach an older population using street-based outreach methodologies to deliver 
resources and education in areas where PWID congregate to use drugs. For younger injectors, 
many of which reside in suburban communities, these outreach strategies may be less effective. 
Initiatives that involve social media or online message boards may be a more effect way to 
engage and connect young PWID to services. Studies of younger injectors (under 30 or 35 years 
of age) suggest that they are less informed about safer injection techniques, HIV and HCV 
prevention, and access to naloxone to prevent overdose.67,197,358 Providers must think “out of the 
box” to reach new injectors using platforms of communication that match the population. 
Connection to young PWID early or before injection initiation is important in developing safe 
practices and preventing disease transmission. 
 
5.3.2.4 Expand pharmacy syringe access programs. Particularly in suburban and rural areas, 
there may not be support or sufficient population of PWID to justify funding a stand-alone SEP. 
In recognition of a new and emerging sub-population of younger white PWID recent HIV and 
HCV outbreaks,16,63 strategies that provide both geographic access and some sense of 
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confidentiality (i.e. walking into a pharmacy versus a clinic or homeless services agency) is a 
practical strategy to make sterile injecting equipment available. Pharmacy access programs are a 
cost-effective supplement to improve syringe access in areas with SEPs and are essential in the 
absence of SEPs.142,359 These initiatives should also be accompanied by pharmacy education and 
access to naloxone.  
 
5.3.2.5 Adopt syringe distribution, not syringe exchange. While there are not restrictions to the 
number of syringes an individual can obtain from a syringe exchange in New York, several states 
have adopted capitation of the number of syringes or require that individuals return syringes in 
order to obtain new syringes. While the theory of syringe exchange (return used syringes to 
obtain sterile syringes) can minimize improperly discarded syringes in communities, it is not a 
practical or safe practice for many individuals. Particularly for individuals who are unstably 
housed or homeless, storing used syringes carries significant risk of being charged with 
possession due to drug residue.234,360 It may also not be possible for an individual to return 
syringes to the syringe exchange program every day due to distance or schedule conflicts. In 
cases where syringes must be returned to obtain new syringes, individuals may go into areas 
where there are discarded syringes and pick up used syringes from other people which may 
introduce accidental needle stick and, in turn, potential infection. In the absence of access to 
affordable housing and punitive drug policies, distribution models will more effectively promote 
using a sterile syringe for every injection and minimize receptive sharing.  
 
5.3.3 Recommendation #3  
Expand access to overdose prevention programs.  
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While a SIF (Recommendation #2) will prevent fatal overdose from occurring on the premises, it 
is one piece of a much larger and complex strategy to reduce fatal overdose. Strategies such as 
decriminalization and regulation of drugs (Recommendation #1), improving access to naloxone 
through SEPs (Recommendation #3), improving access to drug treatment (Recommendation #5), 
and improved training of providers in the area of harm reduction and substance use 
(Recommendation #7) are other components of an effective strategy to reduce fatal overdose. 
Other critical components include: 
 
5.3.3.1	Adopt	Good	Samaritan	Laws to support PWID who are witnessing an overdose to call 911 
without fear of arrest due to possession of drugs. PWID overdose in a variety of settings311 and 
the 911 Good Samaritan Law relieves bystanders from potential prosecution for possession of 
drugs. 
  
5.3.3.2 Mandate overdose prevention education and naloxone distribution in emergency 
departments (ED) following an overdose episode. Initial pilots of ED-based naloxone 
distribution programs have indicated success in training and distributing naloxone to high-risk 
individuals.91,361  
 
5.3.3.3 Adopt physician standing order policies and pharmacy-delivered protocols to promote 
distribution of naloxone to laypersons in all states. Standing orders to provide increased access to 
lay health workers and programs without a physician to distribute naloxone to PWID and their 
friends, family members, and other individuals who may be in proximity to a future overdose. 
There are currently 44 states that permit naloxone to be distributed via standing order and 5 
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states that permit pharmacist authorization.362 Expanding these protocols to every state is a cost-
effective way to improve access to naloxone and reduce overdose deaths. However, such policies 
must be accompanied by legislation to protect providers from civil liability or criminal 
action.363,364  
 
5.3.3.4 Increase co-prescribing of naloxone and opioid analgesics. Medical providers are in a 
unique position of building a relationship with patient who is using opioids. Initiatives to co-
prescribe naloxone and offer overdose education to individuals receiving prescription opioids is 
another complimentary component of overdose prevention and does not increase liability for the 
provider.364  
 
 5.3.4 Recommendation #4  
Improve access and coverage of evidence-based drug treatment.  
MAT is an effective intervention to minimize or eliminate injection drug use altogether. One of 
the driving factors of public injection as described by participants in the focus group sessions 
was experiencing withdrawal symptoms. Several participants discussed barriers to MAT; 
availability, travel and insurance logistics, and provider education contribute to limited 
access.134,136,365,366 In New York, providers have reported experiencing barriers to prescribing 
buprenorphine due to training requirements and the number of patients they are able to prescribe 
to at a given time.135 There have been several changes in the past year that have increased access 
to buprenorphine treatment. In July 2016, Section 303 of the Comprehensive Addiction and 
Recovery Act (CARA) was modified to allow nurse practitioners (NPs) and physician assistants 
(PAs) to prescribe buprenorphine after 24 hours of required training.117 While patient loads still 
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exist for the first year of prescribing (30 patients), patients who are already receiving 
prescriptions can be removed from the existing patient load in order to offer buprenorphine to 
new individuals seeking treatment. Furthermore, the department of Health and Human Services 
(HHS) Secretary may designate $25 million per fiscal year until 2021 to provide grants to state 
substance use agencies, health departments, and non-profit organizations to expand 
buprenorphine. With these additional funds, I recommend the following programmatic and 
health policy recommendations: 
 
5.3.4.1 Implement buprenorphine treatment at SEPs. To reach PWID, offering buprenorphine at 
SEPs may be one effective strategy to reach high risk current injectors. Previous research has 
indicated that SEPs may be an effective venue to improve access and adherence to 
buprenorphine.367,368 As per Recommendation #2, the implementation of SIFs would likely 
increase the number of PWID connected to drug treatment options. Participants of the SIF in 
Vancouver are twice as likely to enroll in drug treatment programs compared with PWID who do 
not receive SIF services.263 To reach suburban and rural PWID, outreach strategies and involving 
telemedicine and e-prescribing may be one effective way to cover a wide geographic area if 
substance use agencies are limited.  
 
5.3.4.2 Prevent the repeal of the Affordable Care Act (ACA). Insurance coverage of MMT and 
buprenorphine is critical and may be compromised for individuals in Medicaid expansion states 
or for individuals receiving insurance through state health exchange programs if the ACA is 
repealed. Access to effective drug treatment is a critical component of reducing injection drug 
use and, in turn, the consequences of public injection drug use.    
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5.3.4.3 Improve medical provider training in working with PWID. Provider training is essential 
to support a therapeutic relationship – one study found that 14% physicians felt that prescribing 
buprenorphine was just replacing one addiction for another and 12% felt that PWID were 
committing crimes and deserved punishment.338,369 Ensuring that medical training incorporates 
evidence-based approaches to working with PWID, including trauma-informed care and 
motivational interviewing, are essential to retain PWID in care. See Recommendation #7 for 
expanded recommendations.    
 
5.3.5 Recommendation #5 
Improve access to HCV testing and treatment taking lessons learned from the HIV/AIDS 
movement.  
The consequences of receptive sharing of injecting equipment is the risk of contracting HIV or 
HCV. One quarter (25%) of participants in the study reported that they had reused injecting 
equipment someone else had already used. Public injectors had higher than twice the odds (OR = 
2.5) of receptive sharing of injecting equipment compared with non-public injectors. One of the 
predictors of receptive sharing of injecting equipment is reporting that a PWID had the same 
HIV or HCV status as the person they were using with. However, we know that many PWID 
may be unaware of their current status.  
 
New York State committed to ending the AIDS epidemic by the end of 2020. The rate of new 
HIV diagnoses continues to decrease every year (4,600 in 2009 vs 3,400 in 2014) as a result of 
successful rapid testing and access to treatment initiatives. The three-point plan aims to (a) 
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identify undiagnosed individuals living with HIV and link them to health care, (b) link and retain 
HIV positive individuals in healthcare, and (c) facilitate access to Pre-Exposure Prophylaxis 
(PrEP) for non-HIV positive high risk individuals to keep them HIV negative. The policy 
recommendations in the End AIDS 2020 Blue Print are well-reviewed and comprehensive. They 
also include recommendations to implement SIFs and expand SEPs. While HCV is more 
prevalent and more infectious than HIV, the same advocacy and initiatives have not been the 
same for HCV. Approximately 200,000 New Yorkers are living with HCV with prevalence 
estimates of 40% among PWID.61 Therefore, I focus my recommendations to be aimed at 
initiatives to test and treat PWID for HCV.  
 
5.3.5.1 Amend public health law to allow HCV screening for minors. Currently, minors must 
receive parental consent for screening (see N.Y. PHL S 2504(1), PHL 27980, 2781, 2305). 
Similar to past efforts to remove age restrictions for HIV testing, the same should be modified 
for HCV to improve access to screening and early detection.  
 
5.3.5.2 Reform payer formulary restrictions for HCV treatment medications to be based on 
recommendations guided by the American Association for the Study of Liver Diseases (AASLD). 
Select insurance plans use restrictions based on severity of disease, co-morbidity, substance use, 
and mental health diagnoses as grounds for denying coverage of treatment. To improve access to 
treatment, insurance must cover treatment costs for the PWID and be based on clinical 
guidelines.  
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5.3.5.3 Expand patient navigation programs. In the IDUCS parent study, over half (56%) of 
PWID reported that they were HCV positive at their last test felt uninformed about treatment 
options.74 Patient navigation programs, including NYC’s Check Hep C program, offer care 
coordination and in-person escorts to promote engagement in HCV treatment.287,370,371 
Particularly for PWID who experienced interferon-based treatment and accompanying side 
effects, some PWID may feel reluctant to enter treatment.72,73 Patient navigation and educational 
initiatives to increase access to treatment is one approach to reduce the number of PWID infected 
with HCV and, in turn, risk due to receptive reuse of injecting equipment.  
 
5.3.5.4 Mandate HCV antibody to RNA reflex testing at all health centers and hospitals and 
support funding for reflex testing at CBOs. While expansion of rapid HCV testing has been a 
priority in the New York Health Department in the past five years accompanied by training and 
funding for CBOs, the availability and access to RNA reflex testing (requiring phlebotomist for a 
full blood draw and a laboratory) is limited.  
 
5.3.5.5 Expand and prioritize testing and treatment of HCV in prisons. The prevalence of HCV 
in the US is 1% while the prevalence in US prisons can range from 12% to 40%.372 Studies have 
shown that inmates continue to inject drugs in prison and share equipment for tattoos.373 
Expansion of testing and treatment initiatives in the criminal justice system is a cost-effective,374 
strategic approach to reducing the number of people infected and re-infected.  
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5.3.6 Recommendation #6 
Integrate and expand harm reduction services and approaches into traditional medicine. 
As described in Chapter 1, many PWID report experiences of stigma and poor treatment in the 
medical system.95,322 In a recent study of general internists, 46% reported they provided care for 
patients with substance use disorders (SUD) but only 20% felt very prepared to scree for SUD, 
9% to provide a brief intervention, and 9% to discuss medication treatment.369 Nearly one third 
(31%) reported that they believed that SUD is different than other chronic diseases because it is a 
choice.369  While treating substance use as a health issue versus a criminal justice issue is a step 
in the right direction, providers in the health system must be supported and trained in effective 
strategies to work with PWID.  
 
5.3.6.1 Expand comprehensive substance use training to all medical training programs. In 2016, 
the Association of American Medical Colleges (AAMC) developed new curricula specifically to 
focus on opioid-related education and training with 74 schools enrolled in the program. 
Initiatives that focus on incorporating harm reduction approaches to managing drug use instead 
of just eliminating drug use creates space for PWID and providers to communicate about both 
health and drug-related issues. Even for providers who are less likely to work with PWID, 
teaching tools such as SBIRT (Screening, Brief Intervention, and Referral to Treatment) to 
effectively screen and direct PWID to services may serve as an important tool to support 
providers in their self-efficacy and preparedness.375   
 
5.3.6.2 Develop partnerships with community-based organizations, including SEPs. New York 
dedicated $8 billion for Medicaid redesign initiatives, including Delivery System Reform 
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Incentive Payments (DSRIP)261, with the common goal of reducing preventable ED admissions. 
Funds were designated to hospital systems to develop initiatives to connect with high utilizers of 
the ED. Partnerships between hospitals and community-based organizations can improve patient 
engagement and retention in care, particularly if initiatives include patient navigation and 
alternative approaches to engagement.287,376 Our findings demonstrate that public injectors are 
more likely to report they had been admitted to the ED in the past year. In Recommendation #2, I 
highlighted that SIFs may serve as central hubs to identify, engage, and connect high utilizers to 
primary care. However, in the absence of SIFs, SEPs may also be able to serve in this function. 
Health care systems would benefit from partnering with SEPs that are connected to high utilizers 
of the ED and ultimately reduce costs and improve care.  
 
5.3.6.3 Advocate for Centers for Medicaid/Medicare Services (CMS) to approve billable harm 
reduction services. In 2014, a Service Provision Amendment (SPA) that included a list of 14 
harm reduction services was introduced to CMS for approved reimbursable services. One of the 
limitations of SEP expansion and reluctance to provide harm reduction services in medical 
settings is that the services (i.e. syringe exchange, supportive counseling, crisis intervention, 
managed drug use counseling) are not billable. This creates an over-dependence of SEPs on 
grant-based funding which limits the budget and potential to expand. It also does not provide any 
incentive for medical providers to offer harm reduction services beyond their own interest. 
Billable services would create both value and feasibility of providing these services.  
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5.4.6.4 Integrate overdose risk screening tools. Recent developments in measures to identify 
overdose risk, such as the Opioid Risk Behavior Scale (ORBS)377, should be adopted into 
routine primary care.  
 
5.3.7 Recommendation #7 
Expand access to affordable housing for people who use drugs.  
 
Unstable housing was significantly associated with public injection drug use. Housing is critical 
determinant of health and, in the context of injection drug use, is key in preventing public 
injection, storage of sterile injecting equipment, and proper disposal of injecting equipment. 
Injecting in unsanitary conditions, such as under bridges or in public restrooms, can further 
increase the risk of injection-related infections. While there are a variety of recommendations to 
be made to improve access to affordable housing in NYC, the two recommendations below are 
most relevant to public injectors.  
 
5.3.7.1 Adopt Law Enforcement Assisted Diversion (LEAD) in New York. As discussed in the 
Chapter 5 focus group findings, may individuals who are homeless or unstably housed come in 
contact with law enforcement. In the absence of decriminalization (Recommendation #1), 
incorporating diversion strategies to connect PWID with housing and health services is a more 
effective way to improve health.118 Particularly for HIV and HCV (see Recommendation #6), 
preventing incarceration is also HIV and HCV prevention. Arrest and incarceration may also 
disrupt a PWIDs ability to retain housing applications and processes.  
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5.3.7.2 Implement a Housing First Model (HFM),124,125 which is a proven method of ending all 
types of homelessness by providing ‘rapid re-housing’ to any individual who is homeless. To 
obtain housing, individuals are not required to achieve sobriety or complete clinical assessments. 
The result is that individuals are less likely to return to homelessness and municipalities see 
significant reductions the use of emergency rooms and crisis service institutions.126,228  
5.3.8 Recommendation #8  
 
Decriminalize all drug use, starting with minimizing individual drug possession laws 
 
While the focus of this dissertation is related to public injection drug use and SIFs as a potential 
strategy to improve the health of PWID, it would be remiss to not acknowledge that many of the 
driving factors of risk behavior and social consequences of drug use are due to the punitive US 
drug policies. Fear of arrest and past year arrest were related to both the quantitative and 
qualitative findings in this dissertation and describe an important social contextual factor that 
impedes risk reduction practices. The 40-year war on drugs has cost hundreds of billions of 
dollars108 and has not had any impact on the prevalence of drug use. The war on drugs has 
resulted in mass incarceration, with the US holding 25 percent of the worlds incarcerated 
population but comprising only 5% of the world population.83 In 2014, there were 1.5 million 
drug-related arrest; 80% of the arrests were for possession charges only.109 Community policing 
policies such as Stop and Frisk contribute to the well-documented disparity of drug-related 
arrests among Black and Latinx individuals230,340–342, contributing to and perpetuating a cycle of 
poverty and inequity.112,343,344 Black people comprise 13% of the US population345 but represent 
40% of those incarcerated in state or federal prisons for drug-related violations346, even though 
rates of drug use are similar to white people.245 The lack of regulation also means that drugs are 
consumed with varying levels of potency and contents (e.g. fentanyl in heroin347–350, levamisole 
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in cocaine351–353), further exacerbating overdose and drug-related infections. In Chapter 4, we 
heard many accounts from participants that fear of arrest was a driving factor in where they 
injected and in their ability to apply safer injection practices. The recommendations and potential 
policy approaches to decriminalization of drugs is a dissertation in unto itself. For the purposes 
of this research, it is important to recognize the impact of existing drug policies on the ability to 
implement the following policy recommendations.   
 
5.4 Strengths and Public Health Significance  
 
The primary strength of this culmination of research is how timely it is in the national discussion 
of addressing drug-related harm. The rates of illicit drug use increased by 15% between 2014 and 
2015 in the US.1,378 NYC experienced its fifth consecutive year of significant increases in fatal 
overdose.347 Various suburban and rural areas reported new cases of HIV and hepatitis C due to 
new cohorts of injectors.65,190 The entire country is discussing how to address the overdose crisis 
and potential of a new wave of the HIV epidemic. The time for public health interventions that 
are new and evidenced-based is now.  
 
Timeline	of	Research	Development,	Policy	Changes,	and	Advocacy			
At the time this study was conceptualized and proposed, there had been no mention of SIFs in 
the US in major media since a brief report in 2007. At that time, SIFs were suggested as part of a 
comprehensive approach to HIV prevention in San Francisco.379,380 After several indications 
from the local health department that there was internal support for moving forward, a federal-
level agency was alerted to the plans and threatened to cut federal funds for the department if 
they proceeded with supporting SIFs. Since that time, there have been several efforts to organize 
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around support for SIFs among harm reduction providers and overdose prevention advocates. 
While these advocates have spoken in internal circles about organizing strategies and stop-gaps, 
including allowing participants to inject on SEP premises in bathrooms, there has not been any 
public endorsement or initiatives since the incident in San Francisco. Given that there has 
traditionally been opposition to SEPs and unstable funding available, any pushing of the 
envelope was perceived as a potential threat to existing operations.  
 
In June 2014, in my role as the Executive Director of a SEP in uptown Manhattan, I spoke out in 
a major media outlet that I was permitting PWID to inject in the bathroom on the premises.303 I 
also included that we had added elements to the bathroom to make is safer for injection drug use, 
including a monitoring system and easily-accessible naloxone to reverse overdoses. The 
statement was immediately met with great concern from other leaders in the field and the board 
of the organization. Quickly thereafter, I formed a public injection working group to discuss how 
to address the lack of space for PWID to inject. The group consisted of researchers, directors of 
SEPs, government officials, policy makers, and peer educators of SEPs. The group met on a 
monthly basis and semi-monthly in sub-committees to write a collective position statement in 
support of onsite injection drug use at SEPs, a legal brief on potential ramifications of onsite 
injection and preliminary review of a SIF legal strategy, research overviews of SIFs, potential 
program models of SIFs, and a proposal to conduct a SIF feasibility study. 
 
During the same time, I produced and co-directed a short documentary titled Everywhere But 
Safe: Public Injecting in New York as an educational tool to discuss public injection drug use and 
introduce the ideas of SIFs. I collected over 80 hours of footage for what became a 34-minute 
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documentary film. The film features participants of SEPs in both NYC and upstate New York, 
peer educators, staff of SEPs, and government officials all speaking to why public injection drug 
use is a relevant and timely topic of discussion and action.  
 
In August 2015, we premiered Everywhere But Safe and hosted a town hall discussion on public 
injection. This included the directors of the NYSDOH AIDS Institute and NYCDOHMH Bureau 
of Alcohol & Drug Use Prevention & Treatment (BADUPCT), participants of SEPs, former staff 
of SIFs in other countries, and direct service workers. Two weeks later, we hosted a larger town 
hall event as the launch of the SIF-NYC campaign to promote SIFs in NYC. Over 650 people 
attended to learn about why public injection drug use is an important health topic to address 
overdose and hepatitis C transmission and to hear from leaders in other countries who had 
worked at SIFs. The NSYDOH AIDS Institute and NYCDOHMH hosted a private stakeholders 
meeting on public injection drug use in NYC and produced a preliminary report.  
 
Since that time, I have organized over 15 town hall-style events in 9 cities across the US using 
the film as a launching pad for discussion. The film has been viewed over 25,000 times and clips 
are used in legislative briefings and community education settings across the country. Several of 
these cities, including Seattle and Ithaca, have since then developed municipal strategies to 
address public injection by implementing SIFs. SIF-NYC has also grown to represent over 35 
organizations in NYC. In September 2016, the NYC City Council approved a $100,000 
feasibility study301 supported by the NYCDOHMH. Articles about SIFs as a viable and valuable 
approach to reduce the overdose and HIV/HCV epidemics have been produced in the New York 
Times, Forbes, Wall Street Journal, USA Today, Time Magazine, and the Associated Press. 
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Ireland, Slovenia, Scotland, and the United Kingdom have all announced plans to implement SIF 
and DCR services in the next year. Canada has opened two new SIFs in the past year with plans 
to expand to include 5 more sites by the end of 2017.  While my involvement in producing a 
documentary film and campaign were not part of this dissertation research, I would be remiss to 
not mention the profound impact it has had on public health policy in the past two years. While 
they have not been defended or published, the findings from this research have already informed 
policy through my own dialogue and uplifting of voices from the focus groups shared in spaces 
with policy makers. Particularly with regard to ensuring that the impact of policing and fear of 
arrest have on the ability to apply safer injection practices, which was missing from the vast 
majority of public health literature.  
 
5.4	Study	Strengths	
In addition to the timeliness and informal impact on policy, there are several strengths of this 
study that are worth highlighting.  
 
First, the mixed-methods approach to understanding public injection, risk, and attitudes towards 
SIFs was critical. The preliminary Chapter 2 findings indicating that public injection is 
associated with increased risk of receptive sharing of injecting equipment would not have meant 
much without the qualitative data describing rushing injections and sharing preparation 
equipment to avoid arrest. Understanding the social environment and the weighing of risks, 
including potential overdose and arrest, on a daily basis add both an explanation for the receptive 
sharing of injecting equipment and a relatable understanding of rushing. In Chapter 4, we learned 
more about the complex thought processes and other considerations related to injecting in public, 
including avoiding injecting in front of children and disposing syringes in a safe manner. Just as 
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the qualitative data informed the quantitative data, the reverse is also true. We were able to 
quantify the phenomena and patterns discussed in focus group sessions with survey data, such as 
the relationship between past year arrest and public injection. We also used the quantitative data 
to initially inform how to set up the facilitators guide and select photographs for discussion based 
on frequencies of place of injection drug use. We also used the survey data to compare 
demographic patterns in the focus group sessions (e.g. median age) to inform recruitment 
strategies. This ultimately resulted in adding a specialized focus group session for younger 
PWID. Lastly, the mixed methods approach allowed for the creation of a PWID-defined 
explanation of what public injection means. Given that public injection is the primary variable of 
interest in each of the chapters and the samples for the survey data and focus groups are similar, 
the integrity of of the definition is stronger and more meaningful versus a definition from a study 
at an international site. This definition may carry through other studies in the US related to 
public injection drug use since it is the first and only PWID-defined version.  
 
Second, the study is the largest and first exclusively public injection-related study in the US. 
Internationally, a plethora of research on the efficacy of SIFs and DCRs has been published. 
However, even the studies related to public injection drug use are limited. The majority of 
studies are quantitative in design and are primarily set up as feasibility studies prior to opening 
SIFs and DCRs. The few studies that are qualitative in nature are limited to specific areas of 
stigma, community perception, and policing. These studies do not explore the complex nature of 
calculated risks and tradeoffs of public injection drug use. Further, they are conducted in places 
with different drug policies, access to health services, and general policing patterns related to 
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drug use. Our study offers findings that both represent a sample of PWID in the largest city in 
the US and situations and experiences specific to US drug policies.  
 
Lastly, the study was designed and conducted by individuals who have extensive experience 
working with PWID or history of drug use in NYC. The survey was designed by experts in the 
field of harm reduction and public health research. The survey was tested and modified 
according to feedback from PWID who are current or past participants of SEPs. This improved 
the clarity and cultural competence of the survey itself. There was very little missing data due to 
interviewer-administered survey design and thorough training of the field interviews (16-20 
hours total). Further, surveys were conducted at sites where PWID already have a strong rapport 
with service staff and may have supported the recruitment of participants to the study. The focus 
group sessions were conducted by myself and a colleague who has worked in harm reduction and 
previously at a SIF in Australia. The focus group session participants were open to discussion 
and appeared to have little to no reticence to discuss their experiences or disagree with fellow 
participants or the researchers. The general tenor of all groups was very casual. This may be due 
in part to the setup of the facilitators guide, the familiarity and comfort of the researchers 
facilitating groups with PWID, and/or the familiarity of participants with each other. The 
benefits of having a research study on a new and sensitive research area designed and 
implemented with the support and guidance of PWID cannot be overlooked.  
 
	5.5	Limitations	
There are several limitations to this study. First, the study used observational data and was not 
under a randomized, controlled environment. Therefore, the associations described in this 
research cannot assert causal effects. While I adjusted for confounding factors that were 
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available in the IDUCS survey and informed by previous research, I cannot ascertain that they 
are comprehensive and account for all unmeasured confounding. While I cannot infer 
temporality, I used the qualitative data to understand the order of events to describe the 
associations.  
 
Second, there were multiple time periods in the IDUCS survey measures. In Chapter 2, the 
primary explanatory variable of place of injection drug use and receptive sharing of injecting 
equipment is a measure of reported behavior in the three months preceding the survey. However, 
general drug use is reported in the past 30 days. The implications of this limitation may be that 
drug use may not have been occurring the entire past three months, over representing the effect 
of drug use and its relationship to receptive sharing of injecting equipment (Chapter 2) or public 
injection drug use (Chapter 3).  
 
Third, our study is unable to determine whether the sharing of injecting equipment actually 
happened in a public place. While the focus group narratives described aspects of injecting in a 
public place that would promote receptive sharing, the measures do not indicate where the 
receptive sharing occurred. We attempted to identify other factors that may promote receptive 
sharing (i.e. unstable housing, past year arrest) to include in a multivariate model to account for 
factors identified in the focus group sessions, but the measures are still limited. Future studies on 
this topic should explicitly ask PWID about receptive sharing of injecting equipment by episode 
of injection by place of drug use.      
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Fourth, we were unable to distinguish what drugs were being injected, how often injection 
occurred, and the prevalence of poly-substance use using the IDUCS survey. The measures were 
limited to reporting whether a type of drug had been used in the past 30 days (yes versus no) and, 
if yes, how often; the most frequent option was ‘daily’ which included the majority of heroin and 
cocaine users. The measures also were unable to distinguished which drugs were being used at 
the same time, which is relevant to overdose risk. It is likely that more detailed measures of 
frequency or episodes of injection per day may be related to risk of receptive sharing of injecting 
equipment merely by increasing the likelihood of injections per day. Understanding how 
frequency of injection drug use is related to injection-related risk may be related to the likelihood 
of public injection drug use. Understanding the prevalence of poly-substance use may provide an 
enhanced understanding of overdose risk. Modifications to these measures to be more 
comprehensive in documenting drug use behavior may offer additional information to detect 
subtle differences between drug use type, frequency, and poly-substance use to better assess risk.  
 
Fifth, place of injection drug use is measured as whether participants had ever injected in any of 
the 10 categories of place in the three months preceding the survey. It is unknown how many 
times participants injected in which place or where they primarily inject. A participant may inject 
the majority of the time in their own home but injected a few times in public restrooms, and 
therefore would be categorized as a ‘public injector’. If my hypothesis that it is public injection 
that is associated with increased risk behavior, there may be additional sub-categories of public 
injectors that we were unable to determine with the availability of data and, thus, underestimate 
the associations between public injection and risk behavior. A modified measure to account for 
the distribution of where participants inject (e.g. mostly in public, sometimes in public, rarely in 
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public, never in public) would better explain the association between public injection and risk 
behavior. 
  
Sixth, the IDUCS survey data and the focus group sessions was a convenience sample and were 
conducted with PWID who are already engaged in harm reduction services in an urban setting. 
This may represent a sampling bias. The findings may not be generalizable to PWID who do not 
receive harm reduction services. There are several ways that the findings may be affected. First, 
participants who are engaged in harm reduction services have free access to sterile injecting 
equipment and educational resources. Therefore, the frequencies of reporting receptive sharing 
of injecting equipment may be lower compared to PWID who do not receive services at a harm 
reduction site. The level of knowledge of health risks of receptive sharing of injecting equipment 
may also be higher compared to PWID not connected to harm reduction services. Similarly, the 
findings may not be generalizable to PWID who are non-urban dwellers. We know from the 
emerging literature that new populations of injectors live in suburban or rural areas. Access to 
sterile injecting equipment may be more limited or consist of primarily syringe access via 
pharmacies. The places where PWID inject in suburban or rural areas may also be different.  
 
Lastly, the findings from the focus group sessions suggest that the concept of a SIF was 
acceptable to PWID but was not measured in any quantitative way. Acceptability and feasibility 
studies that involve a more in-depth explanation of SIFs, enrollment, hours of operation, services 
offered, and other details would be a more appropriate method to assess feasibility and 
acceptability of a SIF. Our findings support that there is initial interest and that PWID believed 
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that a SIF may address the barriers to applying safe injection practices, but does not measure 
potential projections of use.  
	
5.6	Future	Research	Directions	
Since this study is the first of its kind, future research is necessary to replicate in order to better 
understand the association between public injection and risk behavior in NYC.  In addition to 
addressing the aforementioned limitations, there are several ways to approach this research.  
First, a prospective study design to test the hypothesis that injecting in a public place is 
associated with sharing of injecting equipment would ideally include (a) a per-episode report of 
where an individual injected, whether or not they report receptive sharing of injecting equipment, 
and who they were with at the time of injection (b) PWID from a variety of geographic locations, 
(c) PWID engaged and not engaged in SEPs to reduce selection bias, and (d) accounts of other 
risky injection practices. Our study offers initial insight into themes associated with public 
injection drug use and risk behavior and future research may serve as pre-implementation 
research.  
 
Second, to conduct a feasibility and acceptability study of SIFs, a mixed methods approach 
involving PWID and other stakeholders is necessary. This should include an environment 
assessment of new cases of HIV and HCV, existing cases of HIV and HCV, prevalence of fatal 
and non-fatal overdose, and prevalence of public injection drug use. It should also include in-
depth interviews with key stakeholders to identify potential barriers to implementation and 
possible solutions. Logistics and planning of SIF operations should be informed by PWID who 
would use the services.  
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Third, we did not conduct a cost-benefit analysis. Our study suggests that public injection drug 
use is associated with risk behavior that may lead to costly health outcomes. A cost-benefit 
analysis may replicate the model used in San Francisco177 that identified cost-savings due to 
averting new cases of HIV due to injection drug use. A more robust version of a cost-benefit 
analysis would include averted HCV infections due to injection drug use and SSTIs cases in the 
ED.  
Lastly, the potential impact of a SIF on existing healthcare reform strategies is unknown. A SIF 
pilot in partnership with a hospital-based healthcare system in a targeted geographic area may 
offer insight into how a SIF may promote engagement and retention in services, reduce ED 
admissions, and save money. International studies offer models for measuring the impact of a 
SIF. The US may benefit from a pilot study to examine the impact on engagement and retention 
in support services among high risk PWID.   
 
In conclusion, this research offers an understanding of public injection drug use and the 
beginnings of developing a public health rationale to establish SIFs. This contribution to the 
literature may support both NYC and other cities in framing the issue of public injection drug use 
and implementing new interventions to curb the overdose and HIV/HCV epidemics. As I 
outlined in my policy recommendations, solutions include SIFs but also require systems-level 
transformation and reform in drug policy, policing, health care, and housing services. Applying 
an inter-disciplinary approach to improving these environments and systems for PWID will 
reduce public injection drug use, prevent risky injection practices and fatal overdose, and, in 
turn, improve population health.  
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Appendix B – IDUCS Survey Domains Overview 
 
IDUCS Survey Domains 
Socio-demographic and background information 
Program and location of interview, background characteristics, and health insurance 
Harm reduction program utilization  
Length of time at program and types of services used 
Housing Status 
Type and location of housing (past three months)  
Legal status 
History of arrest and probation/parole status 
General drug use 
Past 30-day drug use by type and frequency, drug treatment  
Type: methadone, alcohol, marijuana, cocaine, crack, heroin, methamphetamine, 
opioids (prescribed/not prescribed), synthetic marijuana b, downers, other 
Frequency: every day, a few times a week, once a week, less than once a week 
Injection drug use c 
Injection history, place of injection drug use, sharing of injecting equipment, and 
syringe access  
Overdose 
Overdose history and naloxone knowledge/use 
Medical history and medical service utilization 
Primary care provider assignment,a use of health services, HIV and hepatitis C testing 
and status, and other health status 
Mental Health 
Use of prescribed medications, experience of mental health symptoms, and coping 
Satisfaction and impact of SEPS d 
Satisfaction with SEPS and perceived changes in life domains: housing status, access to 
food, drug use, access and use of health care, relationships, education related to disease 
prevention, use of condoms, feelings of control, use of sterile injecting equipment.  
a Item included in IDUCS-P3 only  
b Synthetic cannabis is also known as ‘K2’ or ‘spice’ 
c Items asked only if participant reported history of injection drug use  
d  Participants reporting it was their first time at the SEPS were not asked items in this domain  
6/7/17	 	 159	
	
Appendix C – IDUCS Survey Instrument  
IDUHA Phase 3 - 2015 
Participant Survey 
  
Survey ID  |___|___| -|___|___|___|   
two-digit interviewer ID + three-digit 
sequential ID  ex: 3rd survey for interviewer 
ID 32 à 32-003 
 
Date: __ __ / __ __ / __ __ __ __ 
(mm/dd/yyyy) 
 
Time: _____:______ AM/PM 
 
Name of the interviewer:  
 
_____________________________
Agency: 
01 After Hours Project 
02 ACQC 
03 BOOM! Health 
04 CHASI 
05 Family Services Network 
(FSN) 
06 FROST'D at Harlem United 
07 Housing Works 
08 LESHRC 
09 NYHRE 
10 Positive Health Project 
(PHP) 
11 SACHR 
12 Streetwork  
13 VOCAL-NY 
14 Washington Heights 
CORNER Project 
 
Location of Site: ________________________________ (cross streets, borough)  
 
Where was this survey conducted?  
01 Office          02 Street/Walkabout/Backpack        03 Van/Tent/Fixed Unit    
04 SRO or Apartment  05 Other (Specify:_______________) 
 
DEMOGRAPHICS 
 
1. What is your age? _________      88 DK  99 NR 
2. How do you consider yourself: male, female, or transgender?  
  01 Male   02 Female                88 DK 
 03 Trans, Male to Female 04 Trans, Female to Male 99 NR 
3. What is your race or ethnicity? (Circle all responses stated) 
01 White 
02 Black or African American 
03 Hispanic / Latino 
04 Asian  
05 Other  
(Specify:___________________________) 
88 DK  99 NR 
4. What language do you speak most often? (Pick ONE)
01 English     
02 Spanish   
 
03 Other 
(Specify:_________________________)  
88 DK  99 NR 
 
5.  What is the highest level of education you have completed? 
 00 Less than high school 
 01 High school graduate or GED 
02 Some college, Associate’s Degree, or 
Technical Degree 
03 Bachelor’s Degree 
04 Any postgraduate studies 
88 DK  99 NR 
 
CODE 
 
Since we are not putting your name on this survey, we are going to make a unique code 
that we will use to keep track of your answers. The code will also help us if we do this 
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research study again in the future because we will be able to know who completes the 
survey more than once. To make the code, I need to ask you a few questions, okay? 
  
6. What is your . . .? 
 
   
 
 
 
 
INSURANCE 
 
7. Do you currently have medical insurance? If yes, What kind of insurance is it? (Circle all 
that apply)  
  00 No insurance (Skip to Q8) 
  01 Private insurance (What is the name of it?): ______________________ 
  02 Medicaid  
 03 Medicare 
 04 TRICARE/CHAMPVA    
 05 ADAP    88 DK  99 NR 
If person gives name of insurance or shows you insurance card and you don’t know where it fits, 
write it in here:___________________________________
 
  
__ __ __ __ __ __ 
Gender  
(M, F, or T) 
1st Letter 
First Name 
1st Letter 
Last Name 
Day of Birth Year of Birth 1st Letter Mother 
Maiden Name 
__ __ 
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If participant is on Medicaid, ask Q7A, Q7B, Q7C: 
 
7A. Do you know what type of Medicaid you have? What is the plan called?  
Straight Medicaid   
Affinity 
AmeriGroup 
Amida Care 
Health Insurance Plan of 
Greater New York 
HealthFirst 
Metro Plus 
MetroPlus Special Needs Plan 
Neighborhood Health Providers 
New York State Catholic Health 
Plan 
New York-Presbyterian 
Community Health Plan 
UnitedHealthcare 
VNS Choice SNP 
WellCare 
Other: ________________ 
88 DK  99 NR
7B. Is your Medicaid on or off? If it is on, is it restricted?  
01 On (active)        02 On, restricted       03 Pending     04 Undergoing recertification 
88 DK              99 NR       
 
7C. Have you been assigned to a Health Home? A Health Home is a centralized location 
that coordinates medical care for Medicaid patients who have several chronic medical 
conditions.  
  
00 No (Skip to Q8)      01 Yes (Continue to Q7D,E)   88 DK  99 NR  
 
If Yes to 7C, 7D. Have you already received services at your Health Home? 
00 No                    01 Yes                   88 DK                99 NR      
 
If Yes to 7C, 7E. Have you met with your Care Coordinator at your Health Home? 
00 No                    01 Yes                   88 DK                99 NR      
 
SEP AGENCY UTILIZATION 
 
Now I am going to ask you questions about your experience with [AGENCY].  
 
8. Please think about the first time you came to [AGENCY].  You could have come here to 
this site, or to other sites that are part of [AGENCY].  How long ago was the first time you 
came to [AGENCY]? <<Remember this!>>  
01 This is my first time (Skip to Q11) 
02 0-3 months  
03 4-6 months 
04 7-11 months 
05 1-2 years 
06 3-5 years  
07 6+ years 
88 DK  99 NR   
9. Now I am going to ask you about the services that you have received from [AGENCY] 
over the past 30 days. I am going to read through several services. I know that some of the 
services I list are not available at [AGENCY] – so only let me know of services that you 
have used at [AGENCY]. Please think about services you have used at [AGENCY] during 
the past 30 days. Okay? 
 
Ask in this format: “In the past 30 days, did you receive [service] from [AGENCY]?” (y/n) 
“Where did you receive that – from the office, a van, street outreach?”  
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In the past 30 days, have you received from 
[AGENCY]… 
Yes (Y) or 
No (N) 
Office/ 
Clinic 
(X) 
Street 
Outreac
h (X) 
Van/Tent 
/Fixed 
(X) 
SRO/ 
Apt 
(X) 
Other 
(X) 
A. Syringe exchange or safer injection  
supplies Y  /  N 
     
B.  Overdose prevention training and Narcan 
(aka naloxone) kit Y  /  N 
     
C. Shower, laundry, or clothes Y  /  N      
D. Drop-in space Y  /  N  -- -- -- -- 
E. Meet with a Case Manager or  Harm 
Reduction Counselor  Y  /  N 
     
F. Acupuncture/holistic health services Y  /  N      
G. Crisis Intervention, ex: help with 
becoming homeless, receiving a positive test 
result  
Y  /  N 
     
H. Care for a wound, such an abscess, or foot 
issue  Y  /  N 
     
I. Get tested for HIV Y  /  N      
J. Medical treatment for HIV Y  /  N      
K. Get tested for Hepatitis C Y  /  N      
L. Medical treatment for Hepatitis C Y  /  N      
M. General Medical Care Y  /  N      
There are just a few more services I would like to ask you about. Again, please just think about 
whether you have received these services from [AGENCY] in the past 30 days. 
N. Groups for support or education Y  /  N      
O. Suboxone  Y  /  N      
P. Help with housing placement Y  /  N      
Q. Help with insurance benefits Y  /  N      
R. Help with finding a job Y  /  N      
S. Peer Training Y  /  N      
T. Educational resources Y  /  N      
U. Meals (food and nutrition services) Y  /  N      
V. Other (specify): __________________ Y  /  N      
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10. Is there somebody at [AGENCY] that you consider to be your Case Manager or Harm 
Reduction Counselor?   
00 No        01 Yes    88 DK            99  NR 
 
Great, your answers have been really helpful so far. The questions are going to start to get 
a little bit more personal now. I want to remind you that this survey is completely 
confidential. Your name is not written on the survey, and no one can trace your answers 
back to you. We really appreciate your honesty. Your answers will help get the best 
information, so we can help the community and provide the best services. Okay? 
 
 
HOUSING 
 
11. In the past 3 months, where have you been staying? You might say that you have been 
sleeping in a park, a shelter, a friend’s apartment, your own home . . . Where have you 
been sleeping most often? (If respondent offers more than one response, PROBE: “If you had 
to pick the one place you slept the MOST OFTEN, where would it be?”) 
 
Circle ONE code that best matches their response  
Public place: street, park, subway, bus station, ATM lobby, building stairwell, roof, or basement   
02 Shelter for homeless people 
03 Jail or prison 
04  SRO (single room occupancy facility) or a welfare hotel or motel 
05 Drug treatment or a program  
06 Three-quarter housing  
07 Non-drug treatment setting: supportive housing or transitional housing 
08 Rooming with others: in someone else’s house, apartment, or room  
09  Your own place, apartment, or a house that is your home. (Clarify: Do you pay rent?  
 Do you have your own lease?)   
 10 Hospital, nursing home, or hospice 
11 Someplace else (Specify:_______________________________) 
  88 DK  99 NR 
 
12. Where is this? Do you know the zip code? If not, can you tell me the cross streets? 
 (Best answer is zip code. If can’t get zip code, get cross streets. If can’t, get  neighborhood) 
 
_________________________________________    88  DK      99 NR      
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LEGAL STATUS 
 
13. Have you been arrested or incarcerated in the past year?  
00 No (Skip to Q14)         01 Yes (Ask Q13A)        88 DK  99 NR  
If Yes to 13, 13A. Okay, how would you describe your status? Are you  
currently on probation, on parole, awaiting trial . . .? (Say options out loud!) 
 
01 On probation only 
02 On parole only 
03 On probation and parole 
04 Awaiting charge, trial, sentence 
05 Outstanding warrant 
06 Case pending 
00 None of the above  
       (Specify: ___________________) 
88 DK  99 NR
 
GENERAL DRUG USE 
 
Now I’m going to ask you about drug use. I am going to ask you whether you have used 
drugs, and then how often you use them. I know these are personal questions, so I really 
appreciate your being honest with me. 
Ask in this format: “In the past 30 days, did you use methadone?” (y/n) “How often did you use  
it?” (then you code their response as 1-4) 
 
14. In the past 30 days, did you use [item]?  
If Yes, ask Q14 
 
15.  How often did you use [drug]? 
1 = 
Every 
day 
2 = A few 
times a 
week 
3 = Once 
a week 
4 = Less 
than once 
a week 
A Methadone      00 No  01 Yes 1 2 3 4 
B Alcohol            00 No  01 Yes 1 2 3 4 
C Marijuana       00 No  01 Yes 1 2 3 4 
D Cocaine           00 No  01 Yes 1 2 3 4 
E Crack              00 No  01 Yes 1 2 3 4 
F Heroin             00 No  01 Yes 1 2 3 4 
G Methamphetamine: ice, tina, crank, crystal                           00 No  01 Yes 1 2 3 4 
 
H Other opiates, such as:   
Circle drugs used: Oxycontin, Vicodin, 
Percocet, Morphine, Other: _________ 
00 No  01 Yes 
If Yes, Was it prescribed to you by a doctor?  
00 No  01 Yes 
1 2 3 4 
I Synthetic marijuana (“K2,” “Spice”)                 
00 No  01 Yes 1 2 3 4 
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14. In the past 30 days, did you use [item]?  
If Yes, ask Q14 
 
15.  How often did you use [drug]? 
1 = 
Every 
day 
2 = A few 
times a 
week 
3 = Once 
a week 
4 = Less 
than once 
a week 
 
J Downers: Benzos: Valium, Ativan, Xanax                  
                         00 No  01 Yes 1 2 3 4 
 
K Any other drugs that we haven’t talked 
about, such as PCP, hallucinogens, ‘Club 
drugs’; BathSalts (cathinones))    
00 No  01 Yes   
If Yes, Which?:__________________ 
1 2 3 4 
 
16. Are you currently enrolled in a methadone program?   
00 No            01 Yes            88 DK             99 NR  
 
17. In the past 30 days, have you taken methadone that was not prescribed to you? Maybe 
that you bought in the street or a friend gave it to you? 
00 No            01 Yes            88 DK             99 NR Reduction 
 
18. Are you currently being prescribed Buprenorphine/“Bupe”/Suboxone/Subutex? 
00 No            01 Yes            88 DK             99 NR  
 
19. In the past 30 days, have you taken Buprenorphine/Bupe that was not prescribed to 
you? Maybe that you bought in the street or a friend gave it to you? 
00 No            01 Yes            88 DK             99 NR Reduction Evaluation Survey 
 
INJECTION DRUG USE 
 
20. Have you ever injected any drugs? (PROBE, if needed: This could be by mainlining, skin 
popping, or muscling.) <<Remember this!>>  
 
00 No (Skip to Q30 - Overdose)        01 Yes   88 DK  99 NR   
 
21. How old were you the first time you injected drugs?  
 
  _________   88 DK  99 NR 
 
22. During the past 3 months, have you injected any drugs?  
 
00 No (Skip to Q30 - Overdose)        01 Yes   88 DK  99 NR  
 
23. We are trying to understand where people are in the community when they inject 
drugs. I am going to mention some locations, and you can say “Yes” or “No.” So, please 
think about places that you have been when you injected in the past 3 months.  
   
In the past 3 months, did you inject in a . . . No Yes DK NR 
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Street or park 00 01 88 99 
A stairwell 00 01 88 99 
Abandoned building  00 01 88 99 
Public bathroom, like in a restaurant or train 
station 00 01 88 99 
Bus, Subway or Train 00 01 88 99 
Car or other vehicle 00 01 88 99 
Bathroom of a Syringe Exchange Program 00 01 88 99 
Shooting gallery 00 01 88 99 
Home of a friend, family member or partner’s  00 01 88 99 
Your own home? 00 01 88 99 
Any other place that we haven’t talked about? 
Where?_________________ 00 01 88 99 
 
If they mentioned more than one place in Q23:  
23A. You just mentioned several places where you have injected in the past 3 months. Of 
those, which location did you inject the most? 
 
  _______ (Write in item letter, e.g. street = A)  99 NR 
 
24. We are also trying to understand where people get their syringes. I am going to list 
some places. Please say “Yes” or “No” to if you got syringes there in the past 3 months.  
 
In the past 3 months, did you get your syringes from . . . No Yes DK NR 
Syringe Exchange Program  
Which one(s)? 1) __________________________ 
2) ______________________________________ 
3) ______________________________________ 
00 01 88 99 
A pharmacy or drug store 00 01 88 99 
A doctor’s office, clinic, or hospital 00 01 88 99 
From a friend, acquaintance, relative, or partner 00 01 88 99 
Purchased from someone on the street or in a shooting gallery 00 01 88 99 
Some other place that we haven’t talked about? 
Specify_________________________ 00 01 88 99 
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25. We know that sometimes people don’t have access to new, sterile syringes. In the past 3 
months, was there ever a time where you needed to inject but did not have a new, sterile 
syringe? If Yes, How recently was that? (Don’t read the time options out loud, just code based 
on what they say) 
 
No (Skip to Q26) 
Yes, within the past 24 hours   
Yes, within the past week    
Yes, within the past month    
Yes, between one and three months ago 
If Yes to 25, 25A. Think about the last time this happened. Where were you? Can  
you tell me the closest cross streets? 
 
                Cross streets:  _______________________________________________ 
                                             
If Yes to 25, 25B. What time of day was it?   ___________    AM/PM   
 
26. In the past 3 months, have you injected with a syringe that someone else had already  
used? 
 
 00 No  01 Yes (Ask Q26A)   88 DK  99 NR 
 
 If Yes to 26, 26A. How often would you say this happened? 
 
 01 All of the time 02 Most of the time 03 Some of the time  04 Rarely  
   
        88 DK  99 NR 
 
27. In the past 3 months, did you use a cooker that someone else had already used?   
  00 No  01 Yes (Ask Q27A)  88 DK  99 NR 
 
 If Yes to 27, 27A. How often would you say this happened? 
  
 01 All of the time 02 Most of the time 03 Some of the time  04 Rarely  
   
        88 DK  99 NR 
 
28. In the past 3 months, did you use a cotton that someone else had already used?   
  00 No  01 Yes (Ask Q28A)  88 DK  99 NR 
 
 If Yes to 28, 28A. How often would you say this happened? 
  
 01 All of the time 02 Most of the time 03 Some of the time  04 Rarely  
   
        88 DK  99 NR 
 
29. In the past 3 months, did you use water to inject that someone else had already used?   
 
  00 No  01 Yes (Ask Q29A)  88 DK  99 NR 
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 If Yes to 29, 29A. How often would you say this happened? 
 
 01 All of the time 02 Most of the time 03 Some of the time  04 Rarely  
   
        88 DK  99 NR 
OVERDOSE 
 
These next questions are about drug overdose.   
 
30. In your life, have you ever used drugs so strong they caused you to overdose?   
00 No   01 Yes (Ask Q30A)     88 DK  99 NR  
  
If Yes to 30, 30A. Have you overdosed within the past year?  
00  No    01 Yes   88 DK   99NR 
 
31. In the past year, have you witnessed someone else having an overdose? 
 00  No  01 Yes   88 DK  99 NR  
 
32. Do you know what Narcan or naloxone is? 
 
00 No     01 Yes               99 NR 
 
Narcan is used to prevent overdose. It comes in a blue bag and can be injected or sprayed 
up the nose. 
 
33. Do you know where to get a Narcan kit? 
 
00 No     01 Yes               99 NR 
 
34. If you needed a Narcan kit, do you think it would be easy or difficult to get one? Would 
you say Somewhat or Very?  
 
01 Very Easy   02 Somewhat Easy 03 Not Sure   
04 Somewhat Difficult 05 Very Difficult 99 NR 
35. Have you ever used Narcan on somebody you thought was having an overdose from 
opiates, like heroin?  
 
00 No     01 Yes              88 DK        99 NR 
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MEDICAL HISTORY AND MEDICAL SERVICE UTILIZATION 
 
Thank you for all of your responses so far, we are making great progress. Now we are 
going to talk about your health.  
 
36. Do you have a Primary Care Provider? That is, a doctor that you go to if you need 
something that isn't an emergency?  
 
00 No     01 Yes              88 DK        99 NR 
 
If yes to 36, 36A. Have you visited your Primary Care Physician in the past year? 
 
00 No     01 Yes              88 DK        99 NR 
 
 
I am going to list off some medical services – please let me know if you have used these 
services in the past year. 
 
Ask whether they have received each type of service. If Yes, ask Q38: how many times in the past 
year they used this service. 
37. In the past year, have you  No Yes DK NR If Yes to 37, 38. How many times in the past year? 
Been admitted to an Emergency 
Room 00 01 88 99 # of times _______ 
Stayed in the hospital overnight 00 01 88 99 # of nights _______ 
Ridden in an ambulance 00 01 88 99 # of times _______ 
Stayed in residential drug treatment 00 01 88 99 # of times _______ 
Went to short-term Detox 00 01 88 99 # of times _______ 
Been hospitalized for psychiatric 
reasons  00 01 88 99 # of times _______ 
Gone to the emergency room for 
something that wasn’t an 
emergency? 
00 01 88 99 # of times _______ 
 
39. Have you ever been tested for Hepatitis C?     
00 No (Skip to Q40)  01 Yes (Ask Q39A,B)                88 DK 99 NR 
 
If Yes to 39, 39A. When was your most recent Hepatitis C test? 
   00 Within the past 6 months   
   01 Within the past year 
   02 More than a year ago 88 DK  99 NR 
 
If Yes to 39, 39B. What was the result of your most recent Hepatitis C test?      
   00 Negative (non-reactive) (Skip to Q40)   
   01 Positive (reactive) (Ask 39C)     
   02 Undetermined    88 DK    99 NR   
 
   If Positive, ask Q39C,D,E:  
    39C. Have you discussed Hepatitis C treatment options with  
     your doctor?   
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     00 No  01 Yes  88 DK  99 NR 
    39D. How informed do you feel about your Hepatitis C  
     treatment options?  
      
    00 Not at all   01 A little  02 Somewhat     03 Well informed 
    88 DK  99 NR 
   39E. Are you currently in treatment or have you completed  
    treatment for Hepatitis C?   
     00 No  01 Yes  88 DK  99 NR 
 
   If No to Q39E, 39F. What is the main reason you haven’t started  
      treatment?  
 
    ________________________________________________ 
 
Now I am going to list some medical conditions that are common in the community. Please 
let me know whether you have ever been diagnosed with each condition. 
 
40. Has a doctor ever told you that you have . . . (Circle ALL that apply) 
 No Yes DK NR 
Asthma 00 01 88 99 
Diabetes 00 01 88 99 
Heart Disease 00 01 88 99 
Hypertension / High blood pressure 00 01 88 99 
Liver Disease (Hep C, cirrhosis) 00 01 88 99 
Kidney Disease 00 01 88 99 
Cancer 00 01 88 99 
 
41. Have you ever been tested for HIV?     
00 No (Skip to Q42)  01 Yes (Ask Q41A,B)                88 DK 99 NR 
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If Yes to 41, 41A. When was your most recent HIV test? 
   00 Within the past 6 months   
   01 Within the past year 
   02 More than a year ago 88 DK  99 NR 
 
If Yes to 41, 41B. Have you ever been diagnosed with HIV or AIDS?      
   00 No (Skip to Q42)   01 Yes  (Go to Q41C)     
       88 DK    99 NR   
  
41C. How long ago were you diagnosed with HIV? 
 00 Within the past 6 months    
 01 7-11 months ago 
 02 1-5 years ago   88 DK 
03 More than 5 years ago  99 NR 
 
41D. Are you currently taking antiretroviral medications for your HIV? 
 
  00 No (Skip to 41F)   88 DK 
01 Yes (Ask 41E)   99 NR 
     
 
41E. How often do you take your antiretroviral medications? Would you say that 
you…(read answer choices) 
 
01 Often miss doses     88 DK 
02 Take it most days but sometimes miss doses 99 NR 
03 Take it every day 
 
 
41F. Do you currently receive benefits or are enrolled as a client in HASA? (PROBE: HASA 
is the NYC HIV/AIDS Services Administration) 
 
00 No  01 Yes  88 DK  99 NR 
 
If Yes to Q41F, 41G. Do you currently receive HASA rental assistance? 
00 No  01 Yes  88 DK  99 NR 
 
MENTAL HEALTH 
 
We are getting close to the end of the survey, thanks for sticking with me. These questions 
are about your mental health, and what you do to help yourself feel better.  
 
42. In the past 3 months, has a doctor prescribed medication to you for psychological or 
emotional problems?  
00  No    01 Yes          88 DK  99 NR           
 
43. In the past 3 months, have you experienced… 
Ask each item. If the participant responds “Sometimes” or “Often”, ask Q44 about coping 
 Never Sometimes Often If Sometimes or Often, 
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44. Are you using drugs and / or 
alcohol to cope with this? 
Serious depression 00 01 02 
00 No                
01 Alcohol    
02 Drugs   
03 Alcohol & Drugs 
04 Prescription drugs 
Serious anxiety or tension 00 01 02 
00 No                
01 Alcohol    
02 Drugs   
03 Alcohol & Drugs 
04 Prescription drugs 
Hallucinations (hearing or 
seeing things that others 
thought were imaginary) 
00 01 02 
00 No                
01 Alcohol    
02 Drugs   
03 Alcohol & Drugs 
04 Prescription drugs 
Trouble understanding, 
concentrating, or 
remembering 
00 01 02 
00 No                
01 Alcohol    
02 Drugs   
03 Alcohol & Drugs 
04 Prescription drugs 
Trouble controlling violent 
behavior 00 01 02 
00 No                
01 Alcohol    
02 Drugs   
03 Alcohol & Drugs 
04 Prescription drugs 
 
If Sometimes/Often to any of 43A-E, 45. In the past 3 months, have you gotten prescription  
medications from a friend or off the street to deal with these feelings?   
 
00  No    01 Yes   88 DK  99 NR 
 
46. Since you enrolled at [AGENCY], have you gone to the agency for a health or emotional 
issue that in the past you would have otherwise gone to the emergency room for?  
 
00 No    01 Yes               88 DK        99 NR 
 
47. In general, how would you rate your overall health?  Would you say it is… 
 
 01 Poor   02 Fair   03 Good 
 04 Very Good  05 Excellent  88 DK  99 NR 
 
 
 
IMPACT OF AGENCY 
 
(IF IT IS THE PARTICIPANT’S FIRST TIME AT THE AGENCY (Q8), SKIP TO Q50.) 
 
These are the last set of questions. I am going to be asking you about your experiences since 
you came to [AGENCY]. Please be as honest as you can. Your answers will help us to 
improve the services for the community.  
48. You told me you first came to [AGENCY] _____ months/years ago (response from 
Q8).  I would like to know how your life has changed since then. I am going to ask you 
about different parts of your life – please tell me whether they are Much Better, Somewhat 
Better, Somewhat Worse, or Much Worse since you first came to [AGENCY]. If there has 
been no change, you can say, “No Change.”  
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How has your [item] changed? Much better 
Somewhat 
better 
No 
Change 
Somewhat 
worse 
Much 
worse 
 
Housing situation 05 04 03 02 01 88 DK 99 NR 
Access to food 05 04 03 02 01 88 DK 99 NR 
Drug use 05 04 03 02 01 88 DK 99 NR 
Feeling like you have access to 
health care 05 04 03 02 01 
88 DK 
99 NR 
Use of health care 05 04 03 02 01 88 DK 99 NR 
Relationship with 
friends/family 05 04 03 02 01 
88 DK 
99 NR 
Understanding of how diseases 
are prevented 05 04 03 02 01 
88 DK 
99 NR 
Use of condoms or other safer 
sex supplies 05 04 03 02 01 
88 DK 
99 NR 
Feeling that you have control 
over your life 05 04 03 02 01 
88 DK 
99 NR 
If participant has ever injected drugs (Q20)  
[If IDU] Use of new, sterile 
syringes 05 04 03 02 01 
77 INAP 
88 DK 
99 NR 
[If IDU] Use of safer injection 
supplies  05 04 03 02 01 
77 INAP 
88 DK 
99 NR 
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49. Overall, how satisfied are you with the services and care you have received at 
[AGENCY]? Are you… (Read each option out loud) 
 
01 Very satisfied   
02 Somewhat satisfied  
03 Neither satisfied nor dissatisfied 
04 Somewhat dissatisfied  
05 Very dissatisfied 
88 DK  99 NA
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50. If you could add one service that is not currently available at [AGENCY], what would it 
be?  
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
51. Do you have any other comments that you would like to share with me about 
[AGENCY]? 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
This is the end of the survey, thank you so for your time and your help. We all really 
appreciate it. 
 
52. Interviewer comments (relevant to research team or to data integrity) 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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Appendix D – IDUCS Field Interviewer Training Topics 
 
Appendix A. Overview of field interviewer training session topics 
 
Training Topic 
 
Overview of contents 
Harm reduction history  
(30 min) 
• Development of the harm reduction movement and 
community organizing 
• Review of research on syringe exchange 
• US drug policy 
• Racial disparities and inequity  
Harm reduction programs  
(30 min) 
• Overview of IDUHA and programs in NYC 
• Services offered 
• Low-threshold model of services and site locations 
• Role of peer educators 
Study overview  
(30 min) 
• Purpose of study 
• Timeline and logistics for field interviewers 
Returning field interviewers 
(30 min) 
• Field interviewers invited to return to share their 
highlights and lessons learned from their experience 
Working with drug users (30 
min) 
• Overview of why people use drugs 
• Experiences with providers 
• Language and interaction 
• Boundary setting and safety 
Peer interaction (100 min) • Advice from peer educators about appropriate dress, 
appearance, first impressions 
• Building rapport with participants  
• Role plays of how to approach participants, 
engagement, addressing challenging situations 
Question & answer  
(30 min) 
• Questions from field interviewers on any of the topics 
Review of the study findings  
(30 min) 
• Findings from the previous study wave 
Survey research methods 
(60 min) 
• 3 functions of the interviewer 
o Locate, 
o Motivate 
o Probe 
• Reliability and validity 
• Survey design – what to read out loud, skip patterns, 
how to field code responses, probing techniques 
Informed consent 
(30 min) 
• Overview of informed consent and how to obtain it 
QXQ of survey 
(120 min) 
• Review of survey instrument question by question 
(QXQ) 
• Importance of completion 
• How to address skipping questions or no response 
Survey practice 
(105 min) 
• Interactive group session where each field interviewer 
answered questions regarding skip patterns, case 
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scenarios of how to code responses, practice asking 
questions 
Prep for site visit 
(15 min) 
• Overview of what field interviewers should expect for 
their day onsite  
• Distribution of surveys for administration with friends 
to practice at home 
Site visit  
(180 min) 
• Field interviewers spent a minimum of 3 hours with the 
program site liaison to become familiar with 
surroundings 
Site visit report back  
(60 min) 
• Field interviewers shared their experiences from the 
site visit 
• Discussion of space challenges, personnel and safety at 
sites 
Survey administration report 
back 
(60 min) 
• Field interviewers described their experience delivering 
the survey to their friend 
• Practice of specific questions related to injection 
history and gender identity 
Challenges & Boundaries 
(90 min) 
• How to address challenges before, during or after 
interviews 
• Handing difficult interviews and strategies to re-engage 
• Role play of challenging interviewees 
Study materials 
(45 min) 
• Overview of contents of field interviewer binder 
• Overview of procedures for obtaining consent  
• Material storage 
• Emergency contact information  
Scheduling & Survey Period 
Logistics  
(90 min) 
• Review of each site schedule 
• Review of contact information 
• Distribution of incentives 
• Quality control and storage of surveys 
Follow up phone sessions 
(varied) 
• Follow up calls with MEC assigned contact or study 
coordinator on a weekly basis to address unanswered 
questions 
Data Entry Training 
(360 minutes) 
• Review of survey instrument 
• Handling missing responses 
• Documentation of missing responses 
• Review of quality assurance log 
• Steps for data entry into database 
• Cross check procedures 
• Storage of entered surveys 
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Appendix E – Dissertation Variable Table by IDUCS Domain 
 
Original IDUCS survey variables by domain (response options) 
Socio-demographic and background information 
1. Age (continuous) 
2. (Male, Female, Trans Male to Female, Trans Female to Male) 
3. Race/Ethnicity (Black, white, Latinx, Other) 
4. Primary language (English, Spanish, Other) 
5. Health insurance (Public, Private, None) 
Housing Status 
6. Type and location of housing (past three months) (Street-homeless, unstably 
housed, stable) 
Legal status 
7. Past year arrest or incarceration (Yes/No) 
General drug use 
8. Past 30-day drug use by type of drug (Yes/No) a  
9. Currently enrolled in methadone drug treatment program (Yes/No) 
10. Currently enrolled in a buprenorphine drug treatment program (Yes/No) 
11. Taken non-prescribed methadone past 30 days (Yes/No) 
12. Taken non-prescribed buprenorphine past 30 days (Yes/No) 
a Type: methadone, alcohol, cocaine, crack, heroin, methamphetamine, opioids, 
downers 
 
Injection Drug Use 
13. Injection drug use in the past 30 days (Yes/No) 
14. Place(s) of injection drug use in the past 30 days (Yes/No) 
a. Street or park * 
b. A stairwell * 
c. Abandoned building* 
d. Public bathroom* 
e. Bus, Subway or Train* 
f. Car or vehicle* 
g. Bathroom of a syringe exchange program* 
h. Shooting gallery* 
i. Home of a friend or family member 
j. Your own home 
15. Syringe source – where did you get syringes in the past 3 months? (Yes/No) 
a. Syringe exchange 
b. Pharmacy  
c. Doctors office 
d. Friend or acquaintance 
e. Purchased from the street 
16. Receptive sharing of a syringe in the past 3 months (Yes/No) 
17. Receptive sharing of a cooker in the past 3 months (Yes/No) 
6/7/17	 	 179	
	
18. Receptive sharing of a cotton in the past 3 months (Yes/No) 
* Defined as places of public injection drug use for primary variable  
Overdose 
19. Ever overdose in your life (Yes/No) 
20. Past year overdose (Yes/No) 
21. Witness an overdose in the past year (Yes/No) 
 
Medical history and medical service utilization 
22. Have you been admitted to the emergency department (ED) in the past year? 
(Yes/No) 
23. Do you have a primary care provider (PCP)? (Yes/No) 
24. Hepatitis C status (Positive, Negative, Unknown) 
25. HIV status (Positive, Negative, Unknown) 
 
Mental Health 
26. Experienced depression in the past 3 months (Yes/No) 
27. Experienced anxiety in the past 3 months (Yes/No) 
28. Experienced hallucinations in the past 3 months (Yes/No) 
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Appendix F – Original IDUCS Variables – Table of Missing Variables 
 
Original IDUCS variables - Missing by Variable      
         
Domain Measure Question  
Variable 
Name Categories Code NR DK Missing 
Demographics Age What is your age? Age Continuous 0 0 0 
         
 Gender 
How do you consider 
yourself: male, female, or 
transgender? Gender Male 1 3 0 1 
    Female 2    
    Trans, M to F 3    
    Trans, F to M 4    
 Race/Ethnicity 
What is your race or 
ethnicity? RaceEth white 1 0 0 10 
    black/AA 2    
    Latino 3    
    Other 4    
 Language 
What language do you 
speak most often? Pick 
ONE Language English 1 0 0 1 
    Spanish 2    
    Other 3    
 Insurance 
Do you currently have 
medical insurance? HealthInsType No insurance 0 1 1 0 
    
Public 
(Medicaid, 
Medicare) 1    
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Private 
Insurance 2    
         
         
         
Housing Housing Status 
In the past three months, 
where have you been 
staying? You might say 
that you have been 
sleeping in a park, a 
shelter, a friend's 
apartment, your own 
home… where have you 
been sleeping MOST 
often? Sleep_cat Street-homeless 1 0 0 0 
    
Unstably 
housed 2    
    Stably housed 3    
Legal Arrest 
Have you been arrested or 
incarcerated in the past 
year?  Arrested No 0 1 0 0 
    Yes 1    
General Drug Use        
 Alcohol 
In the past 30 days, did 
you use ____? AlcoholYN No 0 0 0 0 
    Yes 1    
 Methadone 
In the past 30 days, did 
you use ____? MethadoneYN No 0 0 0 0 
    Yes 1    
 Cocaine 
In the past 30 days, did 
you use ____? CocaineYN No 0 0 0 0 
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    Yes 1    
 Crack 
In the past 30 days, did 
you use ____? CrackYN No 0 0 0 0 
    Yes 1    
 Heroin 
In the past 30 days, did 
you use ____? HeroinYN No 0 0 0 0 
    Yes 1    
 
Methamphetami
ne 
In the past 30 days, did 
you use ____? MethYN No 0 2 0 0 
    Yes 1    
 Other opiates 
In the past 30 days, did 
you use ____? OpiYN No 0 0 0 0 
    Yes 1    
 Downers 
In the past 30 days, did 
you use ____? DownYN No 0 0 0 0 
    Yes 1    
 
Methadone 
Program 
Are you currently 
enrolled in a methadone 
program? 
MethadonePro
gram No 0 0 1 0 
    Yes 1    
 
Non-prescribed 
methadone 
In the past 30 days, have 
you taken methadone that 
was not prescribed to 
you? Maybe that you 
bought it in the street or a 
friend gave it to you? 
MethadoneNo
nPresc No 0 0 0 0 
    Yes 1    
 Buprenorphine 
Are you currently being 
prescribed 
Buprenorphine/"Bupe"/S
uboxone/Subutex? Bupe No 0 0 0 0 
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    Yes 1    
 
Non-prescribed 
buprenorphine 
In the past 30 days, have 
you taken 
Buprenorphine/"Bupe"/S
uboxone/Subutex that 
was not prescribed to 
you? Maybe that you 
bought in the street or a 
friend gave it to you? BupeNonPresc No 0 0 0 0 
    Yes 1    
Injection Drug 
Use  Current Injector 
During the past 3 months, 
have you injected any 
drugs?  Injected3MO No 0    
    Yes 1    
 
Place of 
Injection Drug 
Use 
We are trying to understand where people 
are in the community when they inject 
drugs. I am going to mention some 
locations, and you can say "Yes" or "No". 
So, please think about the places that you 
have been when you injected in the past 
three months. No 0    
    Yes 1    
  Street or park InjStreetPark No 0 2   
    Yes 1    
  A stairwell InjStairwell No 0 3   
    Yes 1    
  Abandoned building 
InjAbandonBl
dg No 0 5   
    Yes 1    
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Public Bathroom, like in 
a restaurant or train 
station InjPublicBath No 0 2   
    Yes 1    
  Bus, Subway or Train InjBusTrain No 0 2   
    Yes 1    
  Car or vehicle InjCar No 0 3   
    Yes 1    
  
Bathroom of a Syringe 
Exchange Program InjSEPBath No 0 2   
    Yes 1    
  Shooting gallery 
InjShootingGa
llery No 0 3   
    Yes 1    
  
Home of a friend, family 
member or partner 
InjFriendsPlac
e No 0 4   
    Yes 1    
  Your Own Home InjOwnPlace No 0    
    Yes 1    
 
Injected Most 
Often 
You mentioned several 
places where you have 
injected in the past 3 
months. Of those, which 
location did you inject the 
most? InjMostOften Categorical 
Inclu
ded 
item 
from 
the 
list 
above 10 0 107 
         
 Syringe Source In the past 3 months, did you get your syringes from…  
  
Syringe Exchange 
Program SyrSEP No 0 2 0 1 
    Yes 1    
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  Pharmacy or drug  SyrPharm No 0 2 0 2 
    Yes 1    
  Doctors office SyrDoc No 0 3 0 1 
    Yes 1    
  
Friend, acquaintance, 
relative or partner SyrFriend No 0 2 0 2 
    Yes 1    
  
Purchased from someone 
on the street or in a 
shooting gallery SyrStreet No 0 2 0 2 
    Yes 1    
 
Sharing of 
Injecting 
Equipment 
In the past 3 months, have 
you injected with a 
syringe that someone else 
had already used? Used Syringe No 0 9 0 1 
    Yes 1    
  
In the past 3 months, have 
you injected with a 
cooker that someone else 
had already used? UsedCooker No 0 5 2 1 
    Yes 1    
  
In the past 3 months, have 
you injected with a cotton 
filter that someone else 
had already used? UsedCotton No 0 5 1 1 
    Yes 1    
Overdose 
Lifetime 
overdose 
In your life, have you 
ever used drugs so strong 
they caused you to 
overdose? ODEver No 0 0 1 1 
    Yes 1    
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Have you overdosed in 
the past year? ODPastYear No 0 6 1 436 
    Yes 1    
  
In the past year, have you 
witnessed someone else 
having an overdose? ODWitness No 0 0 0 3 
    Yes 1    
Medical 
History 
Emergency 
Room 
In the past year, have you 
visited or received 
services in the emergency 
room?  ERYN No 0 3  2 
    Yes 1    
 
Primary Care 
Provider* 
Do you have someone 
you consider your 
primary care provider? 
PrimaryCareY
N No 0 3  426 
    Yes 1    
         
         
 
Hepatitis C 
Status 
What was the result of 
your more recent hepatitis 
C test? HCVpos Negative 0 0 0 0 
    Positive 1    
 HIV Status 
Have you ever been 
diagnosed with 
HIV/AIDS? HIVpos No 0 0 0 0 
    Yes 1    
Mental Health Depression 
In the past 3 months, have 
you experienced 
depression never, 
sometimes, or often? Depression Never 0 3 0 3 
    Sometimes 1    
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    Often 2    
 Anxiety 
In the past 3 months, have 
you experienced anxiety 
never, sometimes, or 
often? Anxiety Never 0 4 0 3 
    Sometimes 1    
    Often 2    
 Hallucinations 
In the past 3 months, have 
you experienced 
hallucinations (seeing or 
hearing things that others 
thought were not real) 
never, sometimes, or 
often? Hallucination  Never 0 6 0 4 
    Sometimes 1    
    Often 2    
         
 *Only asked in Phase 3       
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Appendix G – IDUCS Variables – Old and New Variables (Coding & Definitions) 
 
New Variables 
Domain Measure Question  
Variable 
Name Categories Code 
Original Age What is your age? Age Continuous  
      
New Categorical n/a AgeCat4 Under 30 1 
    30-39 2 
    40-49 3 
    50 and over 4 
      
Original  Gender 
How do you consider yourself: male, female, or 
transgender? Gender   
      
      
      
New GenderTotal  GenderRecode Male 1 
    Female 2 
      
Original Insurance Do you currently have medical insurance? HealthInsType No insurance 0 
    
Public 
(Medicaid, 
Medicare) 1 
    
Private 
Insurance 2 
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New 
Insurance 
Category  
HealthInsNPP
v No insurance 0 
    
Private 
Insurance 2 
    Medicaid 1 
    Medicare 1 
    
TRICARE/C
HAMPVA 1 
    ADAP 1 
      
General 
Drug Use      
 Any Opioid  AnyOpioid 
Heroin or 
Methadone 
or Opioid 1 
    
No Heroin or 
Methadone 
or Opioid 0 
      
General 
Drug Use 
Crack or 
Cocaine  CrackCocaine 
Crack or 
Cocaine 1 
    
No Crack No 
Cocaine 0 
      
      
Injection 
Drug Use 
Public 
Injector If injected in:  
Public 
Injector  1 
  Street or park  
No Public 
Injection 0 
  A stairwell    
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  Abandoned building   
  Public Bathroom, like in a restaurant or train station  
  Bus, Subway or Train   
  Car or vehicle    
  Bathroom of a Syringe Exchange Program  
  Shooting gallery    
      
      
 
Private 
Injector If only injected in either 
PrivateInject
or 1 
  Home of a friend, family member or partner 
Not only 
private 
injection  0 
  Your Own Home    
      
 
Count of 
Injection 
Places Count of injection categories 
CountInjPlace
s  Range 1-10 
      
 Count Reuse 
In the past 3 months, have you injected with a 
syringe that someone else had already used? CountReuse  Range 0-3 
      
 Any Reuse Reuse of syringe, cooker, or cotton AnyReuse Yes 1 
    No 0 
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Appendix H – IDUCS Group Comparisons (Wave 2 vs. Wave 3) 
Variable 
Exp 
(B) p-value 
Age (continuous) 1.001 0.916 
Variable 
Chi-
Square p-value 
Gender 0.021 0.99 
Race/Eth 4.739 0.192 
Language 12.86 0.002 
Arrested 0.278 0.622 
Sleep_cat 0.232 0.89 
Used Syringe 2.127 0.173 
Used Cooker 1.585 0.239 
Used Cotton 1.629 0.225 
InjStreetPark 0.01 0.999 
InjStairwell 4.168 0.048 
InjAbandonBldg 0.76 0.393 
InjPublicBath 0.428 0.28 
InjBusSubway 0.001 0.532 
InjCar 2.502 0.126 
InjSEPBath 0.497 0.501 
InjShootingGallery 0.102 0.412 
InjFriendsPlace 0.615 0.436 
InjOwnPlace 0.398 0.536 
Alcohol 0.528 0.256 
Methadone 5.723 0.12 
Cocaine 0.658 0.43 
Crack 0.016 0.934 
Heroin 0.022 927 
Methamphetamine 0.155 0.845 
Opioids 1.57 0.239 
Downers 0.921 0.351 
MethadoneProgram 10.548 0.005 
Bupe 0.01 1 
MethadoneNonPresc 5.541 0.021 
BupeNonPresc 0.332 0.642 
ERYN 0.605 0.441 
ODEver 7.968 0.005 
ODPastYear 0.627 0.443 
ODWitness 0.22 0.674 
Depression 0.584 0.747 
Anxiety 1.45 0.484 
Hallucinations  1.646 0.439 
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Appendix I – Focus Group Facilitator Guide  
 
Facilitators Guide for Public Injection & SIF Focus Groups 
 
Intro: Ground Rules and Purpose of the Study (~3 minutes) 
Survey 
Introduce facilitators 
Ground Rules 
 
Purpose of the research: As you may remember, the Injection Drug Users Health Alliance 
(IDUHA) conducted a survey among all 14 syringe exchange programs to better understand the 
needs of our community. In that survey, we asked specifically about where individuals were 
using drugs and broke it down by type of location. We are interested in learning from you, as a 
participant of [ORGANIZATION], what about a space makes it safe or unsafe for injection drug 
use.  
 
Part 1: Unique risks by location (~15 minutes) 
I’m interested in learning about what kinds of spaces people use drugs in, specifically inject 
drugs in, and what makes it safe and unsafe about injecting in different types of locations.  
 
When I say “safe for injection drug use”, what do you think of? What makes a space “safe”? 
What makes a space “unsafe”? 
What is an ideal location for injection drug use? 
 
I’m going to show you a series of photos of different spaces and I’d like to talk about what you 
see that is safe and/or unsafe about the space. 
 
[Photo of studio apartment, nobody inside] 
[Photo of subway platform] 
[Photo of syringe exchange program bathroom from organization] 
[Photo of room inside an apartment] 
[Photo of park/under bridge] 
[Photo of McDonald’s restroom] 
 
For each photo, ask the following questions: 
What do you see that is safe about this space for injection? 
What do you see that is unsafe about this space for injection? 
Under what circumstances would you inject in this location?  
When would it be the best option? 
What might they be thinking about while they were injecting in this location? 
Do you think the risk of overdose is higher or lower in this location compared to others? Please 
explain. 
  
Thanks for sharing so far. I’m going to share a scenario with out about someone who is trying to 
choose a location to inject.  
 
[Facilitator reads aloud the following vignette]  
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Dani has spent the majority of the morning trying to get money to buy a few bags to get straight. 
It’s 2pm and Dani could inject in the Burger King bathroom 5 blocks away, behind a tree in that 
park across the street, or go to their friends house 10-minute walk away.  
 
How would Dani decide where to inject?  Why?  
What may influence Dani’s decision? 
What do you think is the safest of the options?  
Why is it the most safe? Why? 
What location is the most unsafe? Why? 
  
Who were you picturing when you thought about Dani? 
Was Dani male, female or transgender?  
Does Dani’s gender make a difference in what location may be safer for injection drug use? If so, 
how or why? 
How old is Dani?  
Does Dani’s age make a difference in what location may be safer for injection drug use? If so, 
how or why? 
What is Dani’s race/ethnicity? 
Does Dani’s race/ethnicity make a difference in what location may be safer for injection drug 
use? If so, how or why? 
 
Part 2: Understanding perception of access to safe locations for use (~10 minutes) 
From the survey that I was talking about before, about one-third of the individuals who 
participated in the survey said that they had injected drugs in the last three months. Of those 
people, more than half said they had injected in a public place. But what makes a place 
“public”? 
 
What does a “public place” mean to you?  
What makes it “public”? 
What does a “private place” mean to you?  
What makes it “private”? 
 
Many people in our survey last summer reported that they injected in bathrooms of restaurants, 
syringe exchange programs, and bus stations.  
 
Do you consider a bathroom a “public” place? What makes it public or private? 
 
Let’s think about the different kinds of bathrooms where people inject. Why would someone use 
a bathroom for injection?  
What are some of the similarities between a syringe exchange program bathroom and another 
type of public restroom?  
What are some of the differences between a syringe exchange program bathroom and another 
type of public restroom?  
 
 
Part 3: Attitudes towards safer injection facilities (~15 minutes) 
Now I’m going to introduce you to a program that offers a space for individuals to inject drugs 
out in the open. This program is called “InSite” and is located in Vancouver, Canada. The 
program is a “supervised injection facility” where individuals can bring their own drugs and 
they can inject them inside the program.  
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[Show 2 minute video of introduction to InSite, including stalls/booths for injection] 
 
How did seeing this program make you feel? Initial reactions? 
What do you see?  
What is different about this compared to what you currently have? 
What do you like? What do you not like?  
 
How is that program similar to [ORGANIZATION]? 
How is that program different than [ORGANIZATION]? 
What would happen if stalls and medical staff were added to [ORGANIZATION] to allow 
individuals to inject onsite?  
 What would be safer? 
 What would be less safe? 
Is this something that you believe others at [ORGANIZATION] would use? Is this something 
that you would use if it were available? 
 
Part 4: Wrap Up (~5 minutes) 
 
Is there anything else that anyone wants to share at this time?  
Anything else that comes to mind? 
 
Thank you for all of your feedback! I’ll be returning in the Fall of this year (October 2015) to 
share the results of these focus groups with you. I may also want to check in with individuals 
between now and then to be sure that what I’m writing about is reflective of what you shared. If 
that is something you’d be open to, please share your name and contact information with me by 
filling out the form I’m passing around. If you aren’t interested in follow up later, that is ok – 
just don’t fill out a form. 
 
 
Remind participants that contact information for researchers provided on written consent form 
for follow up 
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Appendix J – Focus Group Screening Form for Eligibility 
 
  
Public Injection Focus Group Recruitment 
 
In-Person Drop-In Center Script for Convenience Sampling 
“Hi! We are hosting a focus group session at [TIME] today to discuss challenges around finding 
a location that is safe to prepare and inject drugs in. We’ll meet for about one-hour to discuss 
what people are seeing in the neighborhood in terms of where people can inject, what kinds of 
challenges people experience if they have to inject in a public place, and thoughts about how we 
as a community can address public injection. Since you would be sharing your expertise and 
experience with what you know about this topic, we’ll be offering a $10 gift card to [NAME] 
and refreshments during the group for your time. You may participate as little or as much as you 
like and can ask to leave the group if you’re uncomfortable with the subject matter or anyone 
else in the group.  
If you are interested in participating, please see me in the Drop-In Center between the hours of 
[TIME] to sign up for the session.” 
 
Individual Screening Script for Eligibility & Participation  
Note: Individuals will be screened for eligibility in a separated intake area to ensure 
confidentiality of responses. 
“Thank you for expressing interest in the session! There are a few questions I need to ask you to 
determine whether you are eligible to participate in the focus group.  
Are you over the age of 18 years old? 
Do you feel comfortable participating in a discussion that is in English? 
Have you injected any drugs in the past three months? 
Are you willing to stay for one hour for a short survey and discussion?” 
If the participant answers YES to all four (4) questions… 
“From what you have shared with me you are eligible to participate. Spots for the group are 
limited so it is important you show up at [TIME] for the session. Before we start the survey and 
focus group session, I will share more about the purpose of the research and what it means for 
you. At that time, you will still have an opportunity to decide if you would like to participate.” 
If participant answers NO to any of the four (4) questions… 
“From what you have shared with me, you are not eligible to participate in this particular 
research study. However, there are a number of research studies you may be eligible for that are 
posted in the drop-in center if you are looking for another opportunity. Thank you for taking the 
time to express your interest in the research!” 
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Appendix K – Focus Group Consent Form 
 
Consent Form to Volunteer in a Research Study 
 
 
TITLE OF RESEARCH STUDY 
 
 
Title: An Investigation of Public Injection Drug Use in New York City 
 
PRINCIPAL INVESTIGATOR NAME AND CONTACT INFORMATION 
 
 
Name: Nancy Sohler, Associate Medical Professor 
Address: City College of New York, Harris Hall 405B,  
    120 Convent Avenue, New York NY 10031 
Telephone Number:  212-650-7786 
E-mail: nsohler@med.cuny.edu 
 
WHAT IS A RESEARCH STUDY? 
 
 
A research study is when scientists try to answer a question about something that we don’t know 
enough about.  Participating may or may not help you or other people. 
 
People volunteer to be in a research study.  The decision about whether or not to take part is 
totally up to you.  You can also agree to take part now and change your mind later.  Whatever 
you decide is okay.  Your decision will not affect your relationship with the syringe exchange 
program where the research is taking place.  
 
I will explain this research study to you.  Feel free to ask as many questions as you want to 
before you decide you want to participate.  Any new information learned during the study that 
might make you change your mind about participating, will be given to you right away. 
 
 
 
WHY ARE YOU BEING ASKED TO TAKE PART IN THIS RESEARCH? 
 
 
You are being asked to take part in a research study about drug user health and location of 
injection drug use because you are a participant of a syringe exchange program in NYC. If you 
volunteer to take part in this study, you will be one of about 35 individuals to do so. 
 
 
WHAT IS THE PURPOSE OF THE RESEARCH STUDY? 
 
 
The purpose of the study is to learn about drug use practices, location of injection drug use and 
risks associated with injecting drugs in different places. We are also interested in hearing your 
feedback on supervised injection facilities, which is a type of program in several countries 
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outside of the United States. Lastly, we are interested in learning about individual health and 
housing status to identify city-wide needs and how it may relate to where individuals are 
injecting drugs.   
 
You may qualify to take part in this research study because you are a participant of one of a harm 
reduction program. 
 
 
 
Funds for doing this research are provided by the City University of New York (CUNY) 
Doctoral Student Research Grant. 
 
 
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT LAST? 
 
 
The research procedures will be conducted at an office-based site where one of the above 
programs provides syringe exchange services. You will complete an anonymous survey, which 
should take approximately 10 minutes. After everyone has completed the survey to the best of 
their ability, we will start the focus group session, which should last no longer than one hour (60 
minutes).  
 
 
DESCRIPTION OF WHAT’S INVOLVED 
 
 
If you agree to participate in this research study, the following information describes what may 
be involved.  Today, if you consent and are eligible, I will ask you a series of questions related to 
your drug use, your health, experience with law enforcement, history of overdose, and where you 
are injecting drugs in the survey. After the survey is completed, I will start an audio recording 
device that will record the focus group session. In the focus group, we will discuss what makes a 
space safe and unsafe for injection drug use, which may include you choosing to share your 
experience of injecting drugs in different spaces. The survey will take about 10 minutes, and the 
focus group will take about 50 minutes. After the focus group session, I will provide you with a 
$10.00 gift card in appreciation for your time.  
 
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS OF BEING IN THIS STUDY? 
 
 
There may be minimal risks involved in participating in this study.  There always exists the 
potential for loss of private information; however, there are procedures in place to minimize this 
risk. Your name will not be connected to any of the things you tell me. 
 
I will also be asking you questions that may bring up discomfort or difficult emotions, such as 
questions about witnessing or experiencing a drug overdose.  All questions are optional, and you 
do not have to answer any questions you do not choose to answer. 
 
 
ARE THERE ANY BENEFITS TO YOU BEING IN THIS STUDY? 
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You are not expected to get any direct benefit from participating in this research study. However, 
the information you tell me will help me share the experiences of injecting in different places 
with public health professionals and policy makers.  
 
 
COSTS OR PAYMENTS THAT MAY RESULT FROM PARTICIPATION: 
 
 
If you agree to take part in this research study, we will pay you for your time and effort.  After 
the survey, you will receive a $10.00 gift card for your time.  
 
 
VOLUNTARY PARTICIPATION AND ENDING PARTICIPATION 
 
 
Participation in this study is voluntary.  It is up to you to decide whether or not you participate.  
You will not lose any benefits or rights you would normally have if you choose not to volunteer.  
If you decide not to participate your relationship with the syringe exchange program will not be 
affected in any way. 
 
You can stop your participation at any time and not lose any rights or benefits to which you are 
entitled.   
 
 
OTHER POSSIBLE OPTIONS TO CONSIDER 
 
 
If you do not want to be in the study, you may choose not to participate  
 
 
WILL INFORMATION ABOUT ME BE CONFIDENTIAL? 
 
 
We will keep all research records that identify you confidential, to the extent allowed by law. 
 
Your information will be combined with information from other people taking part in the study.  
When we write about the study to share it with other researchers, we will write about the 
combined information gathered.  You will not be identified by name in these written materials.  
We may publish the results of this study.  However, we will keep your name and other 
identifying information private.   
 
We will make every effort to prevent anyone who is not on the research team from knowing that 
you gave me information, or what that information is. If someone says your name or refers to 
you by name during the focus group, it will not be included in the written transcription of the 
session.  
 
 
CONTACT PERSON(S) 
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Before you decide whether to take part in this study, please ask questions. If you have questions 
about the study later on, you can contact the researcher, Taeko Frost at (212) 923-7600 ext 123.  
If you have any questions about your rights as a volunteer in this research, contact the CUNY 
Institutional Review Board Research Integrity Officer at (212) 650-8234.  An IRB is a group that 
oversees the rights and welfare of people who are in research studies.  I will give you a copy of 
this consent form to take with you. 
 
 
 
 
SIGNATURE PAGE  
 
 
For Documentation of Capable Adult Consent: 
 
I have read this consent form and have had it read to me.  I have had the opportunity to ask 
questions and my questions have been answered.  I have been given a copy of this form.  I 
consent to participate in this study.  A signed and dated copy will be given to you. 
 
 
___________________________________   ___________________________ 
Initials of Participant       Date and Time 
_____________________________         
           
_____________________________  
 
 
 
 
Person Explaining Study and Obtaining Consent: 
 
 
___________________________________   ___________________________ 
Signature of person obtaining consent    Date and Time 
_____________________________         
           
_____________________________ ____________________________________ 
Printed name of person obtaining consent 
 
 
 
 
 
 
If the participant cannot read, a witness is required to observe the consent process and document 
below: 
My signature below documents that the information in the consent document and any other 
written information was accurately explained to, and apparently understood by, the participant 
and that consent was freely given by the participant. 
 
___________________________________   ___________________________ 
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Signature of witness to consent process    Date and Time 
_____________________________         
           
_____________________________ ____________________________________ 
Printed name of witness to consent process 
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Appendix L – Focus Group Survey Instrument 
 
Participant Survey 
PLEASE DO NOT WRITE YOUR NAME ANYWHERE ON THIS SURVEY 
 
DEMOGRAPHICS 
 
1. What is your age? _________       
2. How do you consider yourself: male, female, or transgender?  
  01 Male   02 Female                 
 03 Trans, Male to Female 04 Trans, Female to Male  
3. What is your race or ethnicity?  Please circle one
01 White 
02 Black or African American 
03 Hispanic / Latino 
04 Asian  
05 Other  
(Specify:___________________________
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HOUSING 
 
4. In the past 3 months, where have you been staying? Where have you been sleeping most 
often?  
 
Circle ONE code that best describes where you slept the most 
Public place: street, park, subway, bus station, ATM lobby, or building stairwell, roof, or 
basement   
02 Shelter for homeless people 
03 Jail or prison 
04  SRO (single room occupancy facility) or a welfare hotel or motel 
05 Drug treatment or a program  
06 Three-quarter housing  
07 Non-drug treatment setting: supportive housing or transitional housing 
08 Rooming with others: in someone else’s house, apartment, or room  
09  Your own place, apartment, or a house that is your home.  
 10 Hospital, nursing home, or hospice 
11 Someplace else (Specify:_______________ ________________) 
 
 
 
 
 
5. Have you been arrested or incarcerated in the past year?  
00 No   01 Yes   
 5A. If yes, were any of the arrests cited as public drug use? 
 
00 No   01 Yes            02 Unsure 
 
If you would like to write more about this, please do so below: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
GENERAL DRUG USE 
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7. In the past 30 days, did you use any of the below?  
 
8.  How often did you use [drug]? 
1 = 
Every 
day 
2 = A few 
times a 
week 
3 = Less 
than once 
a week 
4 = Less 
than once 
a month 
A Methadone      00 No  01 Yes 1 2 3 4 
B Alcohol            00 No  01 Yes 1 2 3 4 
C Marijuana       00 No  01 Yes 1 2 3 4 
D Cocaine           00 No  01 Yes 1 2 3 4 
E Crack              00 No  01 Yes 1 2 3 4 
F Heroin             00 No  01 Yes 1 2 3 4 
G Methamphetamine: ice, tina, crank, crystal                           00 No  01 Yes 1 2 3 4 
 
H Other opiates, such as:   
Circle drugs used: Oxycontin, Vicodin, 
Percocet, Morphine, etc 
00 No  01 Yes 
If Yes, Was it prescribed to you by a doctor?  
00 No  01 Yes 
1 2 3 4 
 
I Downers: Benzos: Valium, Ativan, Xanax                  
                         00 No  01 Yes 1 2 3 4 
 
Evaluation Survey 
LOCATION OF INJECTION DRUG USE 
 
9. Please think about places that you have been when you injected in the past 3 months.  
   
In the past 3 months, did you inject in a . . . No Yes DK NR 
Street or park 00 01 88 99 
A stairwell 00 01 88 99 
Abandoned building  00 01 88 99 
Public bathroom, like in a restaurant or train 
station 00 01 88 99 
Bus, Subway or Train 00 01 88 99 
Car or other vehicle 00 01 88 99 
Bathroom of a Syringe Exchange Program 00 01 88 99 
Shooting gallery 00 01 88 99 
Home of a friend, family member or partner’s  00 01 88 99 
Your own home? 00 01 88 99 
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Any other place that we haven’t talked about? 
Where?_________________ 00 01 88 99 
 
9A. Of all the places you injected in the past 3 months, which location did you inject the most? 
 
  _______ (Write in item letter, e.g. street = A)  
 
If you would like to write more about this, please do so below: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
 
10. In the past 3 months, have you… 
10A…. injected with a syringe that someone else had already used? 
 
  00 No  01 Yes   
 
10B… use a cooker that someone else had already used?   
  00 No  01 Yes   
 
10C. … did you use a cotton that someone else had already used?   
  00 No  01 Yes   
 
 
 
OVERDOSE 
 
11. In your life, have you ever used drugs so strong they caused you to overdose?   
00 No   01 Yes   
  
If Yes to 11, 11A. Have you overdosed within the past year?  
00  No    01 Yes   
 
12. In the past year, have you witnessed someone else having an overdose? 
 00  No  01 Yes     
 
 
HIV AND HEPATITIS C 
 
13. Have you ever been tested for Hepatitis C?     
00 No  01 Yes            
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If Yes to 13, 13A. What was the result of your most recent Hepatitis C test?      
   00 Negative (non-reactive)  
   01 Positive (reactive)  
   02 Undetermined     
    
14. Have you ever been tested for HIV?     
00 No  01 Yes  
 
  If Yes to 13, 13A. What was the result of your most recent HIV test?      
   00 Negative (non-reactive)  
   01 Positive (reactive)  
   02 Undetermined     
 
 
 
This is the end of the survey, thank you so for your time and your help. 
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